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Background and Purpose: Autism Spectrum Disorders (ASD) is a complex persistent 
neurodevelopmental disorder characterized by impairment in social interaction, 
communication difficulties and repetitive or stereotypic behaviors. In the past four 
decades, the prevalence of ASD has increased dramatically. The risk factors associated 
with ASD include genetic, environmental and possibly gene-environment interactions. 
Although the core features of ASD are well characterized, ASD presents heterogeneously 
with a wide spectrum of manifestations. These overlapping features or phenotypes are co-
morbidities that occur in ASD and span developmental, medical, behavioral and 
psychiatric conditions. These co-morbid features can include dysmorphology and growth 
abnormalities. It is postulated that children with significant dysmorphology are more 
likely to have an underlying genetic etiology and may have a higher load of genes 
controlling risk to ASD, including a higher copy number variant (CNV) burden and more 
single location variants. CNVs are alterations of the DNA resulting in structural variants, 
including deletion and duplication of genome sequence. ASD sub-phenotypes (such as 
dysmorphology) offer the potential of determining distinct genetic etiologies and 
enhancing genotype-phenotype correlations in ASD. In this study, we first characterized 
growth abnormalities in children with ASD in the Study to Explore Early Development 
(SEED) study. To investigate genotype-phenotype associations in ASD, we determined 
the association between genome-wide CNV burden with dysmorphology and abnormal 
growth in SEED children and tested for association between ASD-associated CNVs with 




Methods: The study population was drawn from the SEED Study, which was developed 
to identify risk factors for ASD in the prenatal and early post-natal period. To 
characterize abnormal growth patterns associated with ASD, we assessed growth 
abnormalities for all available anthropometric measures of growth (height, weight and 
head circumference), the bi-dimensional measure of body mass index (BMI), and a tri-
dimensional growth measure of growth phenotype assessing the symmetry of growth 
involving all three modalities in a single individual. We examined genotype-phenotype 
associations between genome-wide estimated CNV burden with dysmorphology and 
abnormal growth. Finally, we investigated the association of specific CNVs reportedly 
associated with ASD for possible association with dysmorphology and abnormal growth 
in children in the SEED study. 
 
Results: Assessment of growth abnormalities in SEED 1 study showed females with ASD 
had short stature and a combination of short stature, microcephaly and normal weight 
compared to typically developing or control females. We found genome-wide CNV 
burden was negatively associated with dysmorphology, and CNV burden in recognized 
ASD genes was negatively associated with tall stature and macrocephaly; these 
associations varied by sex. Investigation of association between CNVs associated with 
ASD and abnormal growth revealed a potential shared genetic risk for ASD and short 







Conclusions: These findings demonstrate the importance of taking into consideration the 
influence of sex in characterizing any association between growth abnormalities and/or 
dysmorphology and risk of ASD, as well as variability of reported genetic risk factors in 
ASD. There is potential shared genetic risk for ASD and growth abnormality that differs 
by sex, and this may lead to potential future clinical application in diagnosing of ASD 
that could be tailored to the child’s needs. 
 
Future directions: These results should be replicated in a different population, while 
expanding measurments of growth assessment to incorporate longitudinal change to 
better characterize growth abnormalities in ASD. Using a larger sample size and with 
parental genotyping information would enable CNV burden for de novo and rare CNVs 
to be considered. Whole exome sequencing would be a useful in excluding chromosomal 
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CHAPTER 1: INTRODUCTION   
 
 2 
The purpose of this thesis is to explore certain aspects related to the biological 
underpinnings of autism spectrum disorder (ASD) by examining alternative phenotypes 
related to ASD based on dysmorphological features, which may better inform etiologic 
discovery, prognosis, or early identification of this complex and heterogeneous 
neurodevelopmental disorder. In this work, we investigated overall dysmorphology and 
abnormal physical growth specifically as an ASD sub-phenotypes or subgroup. We 
examined the association between these phenotypes and ASD, and also examined the 
genetic risk for these phenotypes using estimated copy number variant (CNV), and their 
tested for their potential overlap with other genetic findings. Below, we describe what is 
currently known about ASD prevalence, potential causes, and outcomes, and how this 




Prevalence of Autism Spectrum Disorder 
 
ASD is a complex neurodevelopmental disorder characterized by impairment in social 
interaction, communication difficulties and delays and repetitive or stereotypic behaviors.  
Autism is diagnosed clinically, with the American Psychiatric Association's Diagnostic 
and Statistical Manual (DSM). In 2013, the field moved from using DSM-IV-R, which 
considered autism spectrum disorders as an umbrella grouping of several specific 
disorders including Asperger’s syndrome, Autistic disorder, and Pervasive Development 
Disorder – Not otherwise specified, to the DSM-5 criteria, which designated a single 
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diagnostic group, “Autism Spectrum Disorder”. The DSM-5 diagnostic criteria for ASD 
include abnormalities in two main categories: firstly, persistent deficits in social 
communication and social interaction across multiple contexts, and secondly, restricted, 
repetitive patterns of behaviors, activities or interests. The deficits in the category of 
communication and social interactions include poor non-verbal communicative 
behaviors, difficulty in developing and maintaining relationships, as well as a lack of 
reciprocity of socio-emotional interactions. Restricted and repetitive behaviors include 
stereotyped and repetitive motor movements, highly restricted, fixated interests with an 
abnormally high degree of intensity or focus, and unusual responses to sensory input, 
including both hypo- and hyper-reactivity. The degree of severity in ASD is taken into 
account for both these main areas of neurodevelopmental impairment, as well as the 
determination that the difficulties observed cannot be better explained by intellectual 
disability alone. In addition, these difficulties must be present early in development and 
impact current functioning in important areas, including socialization. In clinical practice, 
the deficits as laid out in DSM-5 manifest differently in different individuals, with their 
varying degrees of severity (American Psychiatric Association, 2013).  
 
Since the earliest epidemiologic studies in the late 1960s and early 1970s, the global 
prevalence of ASD has been increasing by over thirty-fold in the past five decades. The 
prevalence estimates from European studies were then one in 2,500 children, or 
approximately 0.04% (Gillberg & Wing, 1999). The prevalence increased to 
approximately 1-2% of all children by the turn of the 21
st
 century (Schieve et al., 2012; 
Blumberg et al., 2013; Wingate et al., 2014; Christensen et al., 2016). The most recent 
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report from the Centers for Disease Control and Prevention (CDC) surveillance program 
estimated in 2012, 1 in 68 (1.5%) 8-year-old children in the US had some form of ASD 
(CDC, 2016). In comparison, the childhood prevalence of intellectual disability is 
approximately 1-2% and has remained stable over time
 
(Leonard & Wen, 2002). The 
increasing prevalence of ASD makes understanding, managing and preventing this 
condition a major public health issue. ASD leads to an enormous emotional burden to the 
family and a substantial economic burden to the community. In 2011, the total societal 
cost for autism in the U.S. was $11.5 billion, and it is projected to increase to $300 billion 
by 2030
 
(Lavelle et al., 2014). 
 
Etiology of Autism Spectrum Disorder 
 
The exact etiologies and pathways leading to ASD are not well established. Research in 
autism has revealed associations with various risk factors (both environmental and 
genetic in origin), and raise the possibility of gene-environment interactions. These risk 
factors include increasing parental age, male gender, and medical conditions such as 
neurofibromatosis and tuberous sclerosis (Geschwind, 2011; Hallmayer et al., 2014; 
Harris, 2012; Risch et al., 2014; Sandin et al., 2014). Various non-inherited risk factors 
have been implicated with ASD, such as maternal peri-conceptual folic acid intake and 
SSRI (selective serotonin reuptake inhibitor) use in pregnancy (Schmidt et al., 2012; 
Suren et al., 2013; Kaplan et al., 2017; Mezzacappa et al., 2017). In addition, Caesarean 
section delivery, short inter-pregnancy interval, very low birth weight and maternal fever 
during pregnancy have all been associated with an increase risk of ASD (Atladottir et al., 
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2012; Yip et al., 2016; Durkin, DuBois & Maenner, 2015; Joseph et al., 2017). ASD has 
also been linked to environmental risk factors such as traffic-related air pollution and 
gestational pesticide exposure to organochlorine compounds (Volk et al., 2013; Shelton 
et al., 2014). The precise contribution of genes and environment is still debated. Early 
reports showed a high degree of heritability for ASD, with twin studies showing 
concordance as high as 0.77 in monozygotic compared to 0.31 in dizygotic male twins
 
(Folstein & Rutter, 1977; Bailey et al, 1995; Rosenberg et al, 2009), and the sibling 
recurrence risk has been estimated to be between 2-19%
 
(Chakrabarti & Fombonne, 
2001; Lauritsen, Pederson & Mortensen, 2005; Ozonoff et al., 2011). In addition, first-
degree relatives of individuals with ASD are more likely to display sub-threshold traits of 
autistic phenotypes, suggesting autistic traits occur within a spectrum and may be 
strongly correlated with genetic factors
 
(Constantino, 2014; Robinson et al., 2014). 
However, more recent heritability studies have estimated only 50% heritability 
(Hallmayer et. al. 2011), although other studies continue to find higher estimates as well 
(Sandin et al., 2014; Colvert et al., 2015; Lyall et al., 2017).  
 
Autism Spectrum Disorder Phenotypes 
 
ASD is one of the most heterogeneous neurodevelopmental disorders, with a greater 
diagnostic complexity beyond the impairments described in DSM-5. While the diagnosis 
of ASD is based on the observation of atypical behaviors, the specific constructs in ASD 
remain unclear. The two behavioral dimensions specified in DSM-5 represent the core 
defining features of ASD, with intellectual and language ability adding another 
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dimension to ASD heterogeneity. In addition, the characterization of ASD sub-groups, 
defined by the presence of known medical, developmental, neurologic, genetic, or other 
psychiatric disorders, furthers our understanding of the heterogeneity in ASD (Levy et 
al., 2010). Some examples of conditions that co-occur with ASD are epilepsy, 
dysmorphology, gastrointestinal abnormalities and sleep disturbance. The disorder is now 
widely accepted as a complex, pervasive, heterogeneous condition with multiple 
etiologies, sub-types, and developmental trajectories. Characterizing these co-occurring 
issues as ASD sub-groups or sub-phenotypes could improve our understanding of the 
nuances of autism biology and potentially unveil distinct associations with risk factors. 
The heterogeneity within ASD is postulated to be partly attributable to genetic risk 
factors (Miles, 2011). When ASD is classified as one homogenous category, the 
determination of true causal factors would be diluted, as different sub-groups of ASD 
may well have differing etiologies. Using ASD phenotypes as outcomes or sub-groups 
may enable delineation of possible distinct etiologies and therefore enhance power to 
detect associations with possible etiologic factors, including genes. The over-arching 
objective of this study is thus to investigate whether consideration of dysmorphology and 
growth, as ASD sub-phenotypes, can reduce heterogeneity and increase elucidation of 
ASD risk factors, particularly genetic risk factors. 
 
Genetics of Autism Spectrum Disorder  
 
Given the generally high estimated heritability for ASD, genetic studies in ASD have 
been a major focus of the field.  There are notable autistic features among individuals 
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with known chromosomal abnormalities and syndromes such as Fragile X, Rett syndrome 
and Down syndrome (Hall, Lightbody & Reiss, 2008; DiGiuseppi et al., 2010).
 
In about 
10% of ASD cases, genetic, neurologic and metabolic conditions have been identified as 
either leading to, or associated with, ASD-like characteristics (Kielinen et al., 2004; 
Cohen et al., 2005; Bolton, 2009).  
 
More recently, studies investigating genetic risk factors in ASD have found associations 
with both inherited and de novo mutations (Geschwind, 2011; Robinson et al., 2014). 
Inherited genetic risk factors include both common and rare variants, and may involve 
single base pair changes, small insertions or deletions, or copy number variants (CNVs).  
Common single base pair variants are called single nucleotide polymorphisms (SNPs), 
while rare variants are simply termed “single nucleotide variants” (SNVs). CNVs are “a 
segment of DNA ≥ 1 kilobase in size that differs in copy number compared with a 
representative reference genome”. Alterations in CNVs resulting in structural variants, 
including deletion and duplication of genome sequence (DiGiuseppi et al., 2016).
 
Some 
studies have attributed at least 20% of ASD liability to common SNP variants (Robinson 
et al., 2014; Gaugler et al., 2014), although few particular SNPs have been convincingly 
implicated as controlling risk, likely due to underpowered genome wide association 
studies in ASD (Pinto et al., 2010; Gaugler et al., 2014; Iossifov et al. 2014; Bralten et al., 
2017). The majority of findings in ASD genetics have been for rare variants, including 
CNVs (Prasad et al., 2012; Griswold et al., 2012; Malhotra & Sebat, 2012; Leppa et al., 
2016).  Many of these CNVs are de novo, meaning they occurred spontaneously in an 
individual, rather than being inherited from his/her parents. These are by definition rare 
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individually, but several studies have found numerous de novo rare variants across at 
least 400 different genes that may represent approximately 30% of genetic liability to 
ASD
 
(Iossifov et al., 2014). The majority of specific genetic findings now thought to 
contribute significantly to ASD are variants that are rare, de novo and likely to disrupt 
normal gene function (Pinto et al., 2010; Grayton et al., 2012; Shishido, Aleksic & Ozaki, 
2014; Iossifov et al. 2014).  Many common and rare, inherited and de novo, variant 
associations in ASD have involved CNVs, as discussed further below. 
 
Copy Number Variants in Autism Spectrum Disorder 
 
Recent studies have found CNVs are a genetic risk factor of considerable importance in 
ASD.  Studies of CNVs in ASD have shown both single location associations between 
specific CNVs and ASD, as well as an increased CNV burden by size or count across the 
entire genome. Pinto et al. in 2010 reported a higher global burden of rare CNVs in 
individuals with ASD, as well as a higher burden of ASD and intellectual disability (ID) 
genes and enrichment of CNV deletions in ASD compared to controls (Pinto et al., 2010). 
Others also see higher CNV burden in terms of CNV size (in kilobase) as well as counts 
of several CNVs, particularly for deletion CNVs and for rare CNVs
 
(Vulto-van Silfhout 
et al., 2013). ASD cases have also been reported to have an increased CNV burden over 
the whole genome for de novo CNV deletions and duplications
 
(Luo et al., 2012; 
Ericksson et al, 2015). Leppa et al. in 2016 found multiplex families (i.e. those with 
multiple individuals affected with ASD) there is a higher burden of large, rare, inherited 
mutations, while in simplex families (i.e. those with only one affected child), there is a 
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higher burden of large, rare, de novo mutations (Leppa et al., 2016).  Unpublished data 
from the SEED study – the sample upon which this dissertation is based, shows greater 
CNV burden by size in children with ASD compared to typically developing controls, 
with odds of ASD being 37% larger than controls in children whose cumulative CNV 
length was more than 1 standard deviation above the mean. This effect size was stronger 
for large CNVs (>400kb), particularly when considering CBVs overlapping with 
previously implicated as influencing risk to ASD.  
 
In addition to increased genome-wide burden, location-specific CNVs have also been 
reported to be associated with ASD. The most consistent of these include duplications at 
7q11.23, and duplication or deletion at 16p11.2 (Weiss et al., 2008; Merla et al., 2010; 
Sanders et al., 2011; Green Snyder et al., 2016). Weiss et al. identified 16p11.2 as a 
novel, recurrent microdeletion and a reciprocal microduplication CNV region that 
accounted for approximately 1% of all ASD cases (Weiss et al., 2008). ASD affects 15-
25% of carriers of such 16p11.2 deletions (Moreno-De-Luca et al., 2015). 
Complementary sub-phenotypes have been observed in individuals with copy number 
changes at 16p11.2, which has been associated with ASD, abnormal head size and weight 
abnormalities. Individuals with 16p11.2 deletions are more likely to have ASD, 
overweight and macrocephaly, and those with 16p11.2 duplications have increased risk 
of ASD and schizophrenia, underweight and microcephaly (Shinawi et al., 2010; 
Jacquemont et al., 2011; Qureshi et al., 2014; Maillard et al., 2014; Stein, 2015). While 
deletions in16p11.2 has been associated with a shift of IQ and social responsiveness, 
16p11.2 duplications have a wider variability in presentation (Moreno-De-Luca et al., 
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2015; Green Snyder et al., 2016). Other regions such as chr. 7q11.23 and 1q21.1 have 
also been implicated with ASD and abnormal head size (Merla et al., 2010; Sanders et al., 
2011). 
 
The Simons Foundation Autism Research Initiative (SFARI) maintains the searchable 
SFARI Gene database, from which all curated genetic associations in ASD can be pulled. 
SFARI gene designation gives confidence in identifying CNVs associated with ASD at 





Studies showing association between CNVs and the development and function of cells 
and neurons suggest potential biological pathways for ASD.  Enrichment analyses of 
CNV findings in ASD have implicated neuronal signaling, cell projection and motility, 
microtubule cytoskeleton, chromatin remodeling and kinase activity, and neuronal 
degeneration and regulation (Pinto et al., 2010; 2014). These links give insight into how 
genetic risk factors may affect and disrupt biological pathways fundamental for normal 
development. Another important finding from recent studies is the integrated networks 
found for autism and related disorders (such as intellectual impairment and 
neuropsychiatric conditions like schizophrenia) (Torres, Barbosa & Maciel, 2015). 
Recurrent CNVs have been associated with ASD, however they are often not specific to 
ASD, and also occur in other neurodevelopmental conditions such as intellectual 
impairment, suggesting a pleiotropic effect for certain causal genes. CNVs may also play 




To further understand ASD genetics, in this study we assess genotype-phenotype 
associations between overall CNV burden and the ASD sub-phenotypes of 
dysmorphology and abnormal growth, and consider the association between  
dysmorphology (and growth abnormalities) with ASD-associated CNVs previously 
reported in literature. 
  
Dysmorphology and Autism Spectrum Disorder  
 
David W. Smith first proposed the term dysmorphology in 1966, referring to “the study 
of abnormalities of structural development regardless of severity, timing, or etiology”
 
(Smith, 1966). Today, dysmorphology is understood to be the study of structural defects 
either genetic or idiopathic in origin that result in the development of physical 
abnormalities during the fetal or embryogenic stages of development. These include 
congenital malformations such as dysplastic ears, as well as abnormal anthropometric 
findings such as macrocephaly (enlarged head circumference) or short stature. 
Dysmorphic features can be categorized into measurement abnormalities or descriptive 
traits. Both are features at the extremes of expectation, with observations that are 
markedly higher or lower compared to age-specific population means for measurement 
abnormalities (for example macrocephaly), and physical features at the extreme range of 
variability for descriptive traits (for example clinodactyly) (Zahnleiter et al., 2013). 
Individually, dysmorphic features occur in approximately ≤4% of the general population 
(Aase 1990; Merks et al. 2003). Multiple dysmorphic features may indicate abnormal 
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development. In general, the presence of multiple dysmorphic features rarely occurs 
without co-existing genetic conditions or teratogenic exposure. Dysmorphology involves 
recognition and identification of patterns of structural malformations to elucidate 
etiologies and potential developmental trajectories plus outcomes of specific conditions.  
 
Various studies indicate the proportion of children with autism who have physical signs 
of some alteration in early development range between 5-30% (Ozgen et al., 2010; 
Angkutsiri et al., 2011). Children with ASD are more likely to have major congenital 
anomalies compared to the general population (Wier et al., 2016). Children with ASD 
and dysmorphic features also have a greater probability of a structural cranial 
abnormality or a known genetic syndrome (Ozgen et al., 2011).
 
In 2011, Angkutsiri et al. 
described clinical heterogeneity of physical features in ASD, and reported significantly 
more children with ASD were classified as dysmorphic compared to typically developing 
children (Angkutsiri et al., 2011). Various studies have described correlations between 
morphological abnormalities and ASD (Schendel et al., 2009; Miles et al. 2000; 2005; 
Ozgen et al., 2011; 2013; Wier et al., 2016;). A child with dysmorphology has a higher 
likelihood of carrying detectable genetic aberrations. By focusing on this ASD sub-
phenotype, it is possible there may be a greater likelihood of finding an association 
between specific ASD sub-phenotypes and identify underlying genetic mutations.  
 
The clinical diagnosis of dysmorphology is based on qualitative observations, for which 
there is wide variability amongst clinicians and no specified gold standard. There is no 
general consensus of a recognized rigorous method to classify dysmorphology for 
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research purposes. There have been previous studies that developed scales to assess 
dysmorphism among children with ASD. One of the most prominent recent scales was 
one pioneered by Miles et al., who developed a dysmorphology scale for use by clinicians 
without extensive dysmorphology training (Miles et al., 2008). However, it is likely this 
scale would have a high degree inconsistency due to the varying skill levels of the user. 
The SEED Dysmorphology Group also found that this algorithm had shortcomings in 
consistently identifying dysmorphism in children with ASD. To develop a better scale for 
quantifying these essentially qualitative observations, the SEED Dysmorphology Group 
led by Dr. Stuart Shapira developed a custom dysmorphology measure to identify and 
summarize dysmorphic features and classify dysmorphism among SEED participants.
 
Shapira’s study found children with ASD have significantly higher prevalence of 
dysmorphology compared to controls (Shapira et al., 2014). Children with multiple 
dysmorphic features were also more likely to have an underlying genetic condition or 
exposures to teratogens affecting normal developmental processes (Christensen et al., 
2013). In this dissertation, we extend this work on dysmorphology to examine whether 
the specific subtype of dysmorphism (or abnormal growth) might be associated with ASD 
itself, and whether genetic findings for either dysmorphism specifically can further 
inform ASD genetic investigations. 
 
Copy Number Variants in Dysmorphology 
 
There is a dearth of studies testing for associations between CNVs and dysmorphology. 
This could be due to the absence of a recognized gold standard for dysmorphology 
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classification, as well as the perceived lack of utility of dysmorphism as a clinical entity 
itself. Instead, dysmorphism, and various permutations (indicating dysmorphic features of 
some type, including congenital malformations) are often used in tandem with more 
clinically useful or relevant phenotypes such as intellectual disability, autistic features 
and neurological conditions such as epilepsy. A recent study on CNV-phenotype 
association using Winter-Baraitser Dysmorphology Database/London Dysmorphology 
Database reported rare, de novo and familial CNVs associated with cranial and forehead 
abnormalities (Qiao et al., 2014). Most studies in this area have examined associations 
between CNVs and intellectual disability (ID) with/without structural congenital 
malformations. A study in 2013 using the De Vries score, a composite measure of ID, 
growth retardation, ≥2 dysmorphic features and congenital anomalies, found an 
association between de novo and familial CNVs with De Vries score >3 (Vulto-van 
Silfhout et al., 2013). Cooper et al. in 2011 reported large CNVs (>400kb) were more 
prevalent in children with severe developmental phenotypes associated with multiple 
congenital anomalies (Cooper et al., 2011). Table 1 is a summary of recently published 
literature on CNV burden and dysmorphology. 
 
Copy Number Variants, Dysmorphology and Autism Spectrum Disorder 
 
Previous research assessing the intersection between CNVs for dysmorphology and ASD 
have focused on CNV associations among ASD individuals with comorbidities such as 
dysmorphic features, congenital anomalies and intellectual impairment. Eriksson et al. 
analyzed a population-based cohort of 162 children with ASD, and reported rare CNVs 
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were detected in 8.6%, with a higher likelihood found in children who also had 
dysmorphic features or congenital malformations (Ericksson et al., 2015). Dysmorphic 
features have also been identified in patients with ASD in targeted interrogation of CNVs 
of specific candidate genes (Nava et al., 2014). Al-Mamari found clinically significant 
CNVs were detected in 27% of individuals with ASD using chromosomal microarray 
analysis of 100 ASD patients from a highly consanguineous population, and that patients 
with dysmorphic features and congenital anomalies were statistically more likely to carry 
CNVs (Al-Mamari et al., 2015). 
 
The association between dysmorphism and ASD could potentially be developed into a 
diagnostic clinical tool for early intervention through laboratory-based and clinical 
methods (utilizing a reliable dysmorphism algorithm or measure). Understanding 
dysmorphic phenotypes may lead to more focused and potentially earlier provision of 
intervention in sub-groups of ASD children with abnormal growth, which could lead to 
better outcomes (Dawson, 2008; Boyd et al., 2010).
 
 
Growth Abnormalities in Children 
 
Growth in children is influenced by both genetic and environmental factors. The 
anthropometric growth measurements used in assessing growth in children include 
height, weight and head circumference. Multiple factors influence these different aspects 
of growth, with different effects at different stages of growth. As an example, height is a 
complex phenotype with multiple genetic factors influencing it. In addition, there are bi-
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dimensional aspects of growth based on two growth measures, the most frequently used 
is the Body Mass Index (BMI). Finally, the three types of growth (height, weight, head 
circumference) may be combined to check for growth symmetry, whereby any deviation 
from symmetry would indicate disproportionate growth.  
 
For growth measurements to be interpretable across children, specific growth measures 
are typically plotted on age and sex standardized growth percentile curves based on large, 
population based samples. The CDC growth chart, which has separate charts for boys and 
girls, and accommodations for prematurity, is a commonly used reference (Kuczmarski, 
Ogden & Guo, 2002). 
 
Population-based values for each growth modality typically exhibit a Gaussian 
distribution. Extremes of these distributions are declared “growth abnormalities”, 
although different cut-offs are used for different measures of growth. Thresholds for 
extremes of growth are often set at growth percentiles or based on extremes of standard 
deviations from the mean. For example, abnormally large head circumference, termed 
macrocephaly, is often recognized clinically as head circumference greater or equal to the 
97
th
 percentile for sex and age, and abnormally small head circumference (microcephaly) 
is less than the 3
rd
 percentile for sex and age. For height, abnormally tall stature is defined 
by height greater or equal to 3 standard deviations above the mean based on percentiles 
for sex and age, and abnormally short stature as less than the 10
th
 percentile for sex and 
age. For weight, overweight is defined by weight greater or equal to the 97
th
 percentile 
for sex and age, and underweight as weight less than the 10
th
 percentile for sex and age. 
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The somewhat arbitrary nature of these cut-offs makes it challenging to compare growth 
measurements to each other, and to use the measures for association analyses in genetic 
studies. One way to standardize assessment of these extremes of growth measures is to 





 percentile (decile) of the growth modality. This may be more useful for 
comparing different aspects of growth, as well as assessing the composite of all growth 
modalities. In this dissertation, we explored results based on definitions of growth 
abnormalities using both a clinically-derived threshold of extremes, as well as a simple 
decile definition. 
 
Growth Abnormalities and Autism Spectrum Disorder  
 
Children with ASD have been recognized to have abnormalities in several parameters of 
growth. These abnormalities include accelerated overgrowth of the head in the first year 
of life, leading to macrocephaly in some younger children with ASD (Courchesne, 
Campbell & Solso, 2011). Leo Kanner was the first to make observe some autistic 
children had macrocephaly (Kanner, 1943). The distribution of head circumference in 
ASD was quite wide, and ASD children have larger head circumference relative to height 
by the age of 9-10 years (Lainhart et al., 2016). 
 
Post-mortem studies of autistic brains 





In addition to abnormal head growth, children with ASD have also been reported to have 
both abnormal weight and height. Curtin et al. (2005) reported adolescents with ASD 
have an increased prevalence of being overweight (Curtin et al., 2005).  
 
In 2007, van Daalen et al. postulated ASD is associated with a general growth 
dysregulation, with increased rate of macrocephaly (11.3%) in the first year of life and 
accelerated growth of body length, or height (van Daalen et al., 2007). A study of 
physical growth in 429 children with autism in China (Xiong et. al., 2009) reported ASD 
children had above-average height, weight and BMI, with 17% of those aged between 2 
to 5 years being overweight, rising to 21.8% among 6-11 year-olds
 
(Xiong et al., 2009).  
 
A measure of growth in ASD where there is a paucity of data is the simultaneous 
consideration of the all three growth measures: head circumference, height, and weight, 
which we term ‘trivariate growth phenotype’.  Consideration of trivariate growth allows 
assessment of symmetry, whether children are small on all three measures, normal on all 
three, or large on all three. Deviations from symmetry, where one or more modalities of 
growth are not in proportion to the other, suggest a potentially pathological process, or an 
intrinsic cause of growth abnormality, for example endocrinopathies or specific 
syndromes.  
 




Macrocephaly and Microcephaly: Several studies have assessed ASD, growth 
abnormalities and potential genetic factors. One example is the association between 
autism, macrocephaly and the PTEN gene, which has a number of genetic mutations 
found to be associated with ASD with macrocephaly (Conti et al., 2012; Klein et al., 
2013). PTEN (phosphatase and tensin homolog on chromosome 10q23.31) is a tumor 
suppressor and has been implicated in tumor syndromes including Cowden syndrome, 
and is often mutated in neoplasms affecting the central nervous system, the intestines, as 
well as specific conditions such as small-cell lung cancer and endometrial cancer (Conti 
et al., 2012). Klein et al. in 2013 confirmed the association of PTEN mutations and 
extreme macrocephaly (>3 s.d.), identified mutations in 22% of patients with ASD, and 
suggested different phenotypic groups based on patterns of growth, including general 
overgrowth and disproportionate or relative macrocephaly (Klein et al., 2013). Children 
with ASD who have concurrent macrocephaly and detected to be carriers of PTEN may 
be screened for malignancies later in life, as this association has been linked to tumor 
syndromes.  
 
Weight and BMI: The phenomenon of “mirror phenotypes”, 
macrocephaly/microcephaly and high BMI/low BMI, have been associated with 
differential expression of the 16p11.2 CNV region, which is associated with ASD. As 
noted in the CNV section above, this region is one of the most commonly reported ASD-
associated CNVs, and is estimated to contain CNVs in up to 1% of all ASD cases. 
Deletions in this chromosomal region have been associated with risk to ASD, as well as 
obesity and macrocephaly, while reciprocal duplications have been associated with 
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underweight and microcephaly, as well as schizophrenia (Qureshi et al., 2014; Maillard et 
al., 2015; Kummer et al., 2015). It has been suggested chromatin modification in the 
differentially expressed 16p11.2 region (for example in lymphoblastoid cell lines) may be 
one possible mechanism for this “mirror phenotype” observation; this is an interesting 
finding as chromatin remodeling is one of the network of clusters of CNVs implicated in 
ASD
 
(Loviglio et al., 2017).  
 
Tall and Short Stature: Height is a polygenic trait known to be highly heritable, with 
over 700 common variants identified thus far. A study by Dauber et al. (2011) found 
short stature is associated with an increased burden of CNVs over the genome for both 
combined counts of CNVs and their length (p<0.002) in low-frequency  (<5%) and rare 
(<1%) CNV deletions. No significant association for tall stature was found (Dauber et al., 
2011). In 2013, Zahnleiter et al. showed that rare CNVs are a common cause of short 
stature, with patients with short stature having significantly larger CNVs statistically and 
55% of these CNVs enriched with known syndromes associated with short stature. 
Somewhere you must provide a review of CNVs.  How they are estimated from chip 
data.  Why it is necessary to sum counts or size of estimated CNVs.  Define your use of 
‘genome-wide’ only considering the autosomes.  Define deletions and duplications 
clearly (n.b. duplications may/may not be perfectly contiguous).  Give some sense of 
prevalence of CNVS, overall and common vs. rare variants.  Clearly state you cannot 
identify de novo CNVs because you don’t have genotypes on parents.  The stuff on page 
8 is not adequate. 
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OVERVIEW OF DISSERTATION 
 
Study Population: SEED 1 
 
This study will use data from the Study to Explore Early Development (SEED) Phase I, a 
multisite research collaboration under the auspices of the centers for Autism and 
Developmental Disabilities Research and Epidemiology (CADDRE) Network and funded 
by the CDC. The SEED 1 network consisted of study sites in six states: California, 
Colorado, Georgia, Maryland, North Carolina and Pennsylvania, a data coordinating 
center (DCC) in Michigan, and a central laboratory and bio-sample repository (CLBR) in 
Maryland. The SEED Study is an ASD case-control study with population-based 
ascertainment of cases and controls, with the objective of characterizing ASD cases 
between 2-5 years of age and identifying risk factors. Children aged 2-5 years were 
recruited into one of three groups: i) children with ASD (ASD group); ii) children with 
other developmental disabilities (DD group); and iii) children born in the same birth 
years and same zip codes from the general population (POP group). There were three 
criteria for eligibility of children into the study: i) born in the study catchment area during 
the period between September 1
st
, 2003 to August 31
st
 2006, ii) reside in the area at the 
time of first contact, and iii) live with a knowledgeable caregiver who was able to 
communicate orally in English or Spanish competently and provide informed consent. 
The enrolled children also had to be between the ages of 30 and 68 months of age at the 
completion of the in-person clinical developmental assessment. ASD and DD subjects 
were recruited from clinical and educational service providers from the study areas, and 
population-based children were recruited through state vital statistics. Upon screening 
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and clinical evaluation, children were given a final classification of ASD, non-ASD DD, 
typically developing population control (POP), or ambiguous phenotype. 
 
Data collection included biosampling (blood, saliva, hair), phenotypic data from 
caregiver interviews and questionnaires, and in-person developmental assessments and 
physical examination including dysmorphology measures. For all eligible children, a 
brief screening interview, the Social Communication Questionnaire (SCQ; Rutter et al. 
(2003)), was administered to the primary caregiver to identify children who required 
clinical diagnostic assessment to determine final ASD status. For SEED, a positive screen 
was defined as an SCQ score ≥11. Final classification was assigned using a SEED-
specific research algorithm based on Autism Diagnostic Observation Schedule (ADOS) 
and Autism Diagnostic Interview-Revised (ADI-R) and clinical judgment (Wiggins et al., 
2015). Regardless of ascertainment source, any eligible children with a previous ASD 
diagnosis, who were receiving special education services, and who had a positive screen, 
were assigned to the ASD workflow. This determined which instruments were 
administered and the type of diagnostic evaluation the child received during the data 
collection phase. Tools for ASD assessment included the ADOS and ADI-R (Falkmer et 
al., 2013; Lord et al., 2000). Based on previous diagnosis and SCQ screening, DD and 
POP children with negative SCQ screens were assigned to the DD or POP workflow, 
respectively. If a clinician suspects ASD during the clinical evaluation of a child in the 
DD or POP workflow, the child would be moved into the ASD workflow (Schendel et al., 
2012; DiGiuseppe et al., 2016). Blood and saliva biosamples shipped to the SEED 






Each paper of this dissertation is a cross-sectional analysis embedded within the case-
control study design of SEED 1. Although ascertainment was based on ASD status, Aim 
1 treats ASD as the independent variable, and three measures of growth abnormalities as 
dependent outcomes. Aims 2 and 3 focus on dysmorphology and abnormal growth 
specifically as outcomes, and CNV burden and candidate regions as independent 
variables.  In all three aims, the dependent and independent variables were assessed at 




Specific Aim 1:  
To estimate the association between ASD and abnormal growth measures in children of 
preschool age. 
H1: Children with ASD have abnormal growth and abnormal measures of growth 
compared to typically developing children. 
 
Specific Aim 2:  
a. To estimate the association between genome-wide (specifically, autosome-wide) CNV 
burden and dysmorphology among preschool children in the SEED Study. 
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b. To assess the association between CNVs recognized to be associated with ASD and 
dysmorphology. 
H2.a: Children with dysmorphic features will have greater burden of CNVs across the 
genome than children without such features. 
H2.b: ASD-associated CNVs will show an association with dysmorphology.  
 
Specific Aim 3:  
a. To estimate the association between genome-wide (specifically, autosome-wide) CNV 
burden and growth abnormalities among preschool children in the SEED Study. 
b. To assess association between CNVs recognized to be associated with ASD and 
growth abnormalities. 
H3.a: Children with growth abnormalities will have greater burden of CNVs across the 
genome than children without such features. 
H3.b: CNVs recognized to be associated with ASD will show association with growth 
abnormalities. 
 





ASD is a condition of considerable public health significance, with increasing prevalence 
reported over the past few decades. Comprehensive characterization of ASD phenotypes 
(such as abnormal growth) is a valuable contribution to improving in our understanding 
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of the heterogeneity and complexity of ASD. Exploration of genotype-phenotype 
associations may allow clear elucidation of the link between genetic risk factors and 
specific ASD phenotypes, and this could improve discovery of potential risk factors for 
ASD. These findings may open avenues leading towards increasing awareness of ASD 
sub-phenotypes, improving early detection of these sub-phenotypes and potentially 
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Intellectual disability (ID), 
ASD, Dyslexia, Multiple 
Congenital Anomalies 
(MCA).  
1,227 individuals with 
neurological deficits and 337 
controls. 
 
 Large CNV burden correlated 
positively with severity of childhood 
disability: ID and MCA most 
severely affected. 
 Greater burden of rare, de novo 
CNVs in ASD and ID. 
 Increased frequency of large CNVs 
(>1Mb) in ID compared to ASD. 
 Increased burden of large CNVs in 





ID with or without MCA. 
15,767 children with ID & 
MCA and 8,329 unaffected 
adult controls. 
 Large CNVs (>400kb) more 
prevalent in more severe 
developmental phenotypes 
associated with multiple congenital 
anomalies.  
 Greater enrichment of CNVs in 
individuals with craniofacial 
anomalies and cardiovascular defects 






ID and MCA. 
– 2312 children with ID 
and MCA. 
 Multiple, large CNVs associated 
with increasing clinical severity. 
 Total number of CNVs distinguishes 






Congenital malformations not 
ascribed to a specific 
syndrome  
95 fetuses 
– 68: isolated malfor-
mations 
– 27: multiple malfor-
mations 
 Rare, deletion CNVs (>100kb), 
mostly inherited but also de novo 
was associated 
with congenital malformations, 



















ID/ MCA  
5,531 well-phenotyped 
patients 5,531 with ID/MCA. 
*De Vries score (to assess 
phenotype severity): 
Intellectual disability (ID), 
Growth retardation, ≥2 
dysmorphic features and 
congenital anomalies 
 Increased frequency of de novo 
CNVs in those with MCA and 
dysmorphism.  
 Patients with severe phenotypes, 
including organ malformations and 
abnormal head circumference, had 
more de novo CNVs, whereas patient 
groups with milder phenotypes, such 
as facial dysmorphisms, were 
enriched for both de novo and 
inherited CNVs. 
 Multiple CNVs were associated with 
a more severe phenotype than single 
CNV. 
 De novo and familial CNVs 
associated with greater severity 
score.  
 CNV deletions were more likely to 
result in severe phenotypes than 
CNV duplications.  





DD/ID with congenital 
anomalies 
342 DD/ID cases 
 Congenital anomalies, especially 
heart defects, as well as primary 
microcephaly, short stature and 
failure to thrive were more frequent 
in children with pathogenic CNVs 
compared with children with 




ID with phenotypic 
abnormalities  
78 ID subjects with 
phenotypic abnormalities 
classified using the Winter-
Baraitser Dysmorphology 
Database (WBDD)  
 CNV/phenotype correlation analysis 
showed rare, de novo and familial 
CNVs were associated with cranial 
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Autism spectrum disorder (ASD) has a heterogeneous presentation with multiple 
subtypes, and is frequently found with co-morbid conditions ranging from 
neurodevelopmental to physical abnormalities. Greater understanding of autism and its 
sub-phenotypes may improve identification of risk factors, allow better prognostication, 
and potentially allow earlier, targeted, interventions. Here we investigate phenotypes of 
somatic growth, specifically for the anthropometric measures of head circumference, 
stature, weight, and body mass index (BMI) in a sample of ASD children compared to 
typically developing children from Phase 1 of the SEED Study. In addition, we assessed 
the combination of height, weight and head circumference simultaneously, which we 
term trivariate growth phenotype, to examine differences in growth symmetry in children 
with ASD compared to typically developing children. 
 
Methods: 
Our study sample is comprised of 913 children aged 2 to 5 years from the Study to 
Explore Early Development (SEED) Phase 1, with 532 ASD and 381 typically 
developing children (POP). We excluded children with known chromosomal 
abnormalities and genetic syndromes. We selected two different thresholds to 
dichotomously classify growth abnormality, one using clinician derived thresholds, and 
another using top and bottom deciles. Dichotomous growth phenotypes were derived for 
macrocephaly, microcephaly, tall and short stature, overweight and underweight plus 
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high and low BMI. These were compared between ASD cases and controls using logistic 
regression of growth abnormality on ASD adjusting for self-reported race and stratifying 
by sex. We also compared the frequency of ASD and POP children with each possible 
combination of trivariate growth phenotype using Fisher’s exact test. 
 
Results: 
Using clinical definitions for growth abnormalities, children with ASD had higher odds 
of short stature compared to typically developing POP children, adjusted for race 
(aOR=1.92, 95% CI: 1.06, 3.49; p=0.03). This odds ratio was attenuated using decile-
defined short stature (aOR=1.47, C.I. 0.91, 2.37; p=0.10).  Furthermore, this association 
was higher among girls (aOR = 5.56, C.I. 1.94, 15.97; p=0.001, using clinical definitions; 
aOR=3.52, C.I. 1.6, 7.76; p=0.002, using top deciles). Decile-defined tall stature was also 
decreased in ASD girls (aOR = 0.47, C.I. 0.22, 0.97; p=0.04). High BMI, based on the 
top decile from reference data, was again associated with ASD status (aOR=1.44, CI: 
1.04, 2.00; p=0.03).  
 
ASD children also had a higher frequency of the trivariate growth combination of 
microcephaly, short stature and normal weight (clinical definitions: Fisher’s p=0.01; 
decile definitions: Fisher’s p=<0.01). This association was strongest and statistically 
significant among girls, regardless of the definition used, but was not statistically 




Our study showed sex-specific differences in growth abnormalities among young 
children with ASD. ASD girls were found to have greater odds of short stature compared 
to control girls, and to have a higher prevalence of the combined growth phenotype 
involving microcephaly and short stature, but normal weight. This study illustrates the 
importance of considering how sex may influence the presentation of growth 
abnormalities among ASD childrene and how crucial it is to include girls in all future 
ASD research. 
 
Keywords: autism spectrum disorder, abnormal growth, macrocephaly, microcephaly, 











Autism spectrum disorder (ASD) is a neurodevelopmental condition with impairments in 
socialization, communication and restricted, repetitive behaviors and stereotypies 
(American Psychiatric Association, 2013). Although the specific causes of ASD are not 
yet established, ASD has been associated with multiple risk factors encompassing both 
genetic and environmental factors. The prevalence of autism is currently approximately 1 
in 68 children in the United States (CDC, 2016). It has a greater prevalence in boys 
compared to girls, with 3-5 times more boys affected (Werling & Geschwind, 2013; 
Loomes et al., 2017). Although there are common core features of ASD, considerable 
heterogeneity has been observed. Autistic individuals often have a wide variability of 
clinical features as well as differences in the degree of severity and developmental 
trajectories. Girls with ASD have been reported to have more severe presentations with 
co-existing conditions such as intellectual disabilities (Werling & Geschwind, 2013). 
Studying these autism phenotypes can improve our biological understanding of ASD, 
particularly if different risk factor constellations are reflected in different phenotype 
presentations.  This may be particularly helpful in parsing out different genetic risk 
factors. In addition, characterization of specific autistic phenotypes may aid in early 
diagnosis and prediction of outcomes (Walsh et al., 2011). For example, epilepsy, a co-
morbidity observed in 8-20% of all children with ASD (Berg, Plioplys & Tuchman, 
2011; Christensen et al., 2016), can inform treatment and prognosis for those with both 
conditions. Growth abnormalities, including macrocephaly, (i.e. the presence of a large 
head) have also been associated with ASD, and identification of children with 
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overlapping growth abnormalities and ASD may help guide identification and early 
intervention. 
 
Growth in early life is affected by both genetic and environmental factors, with different 
factors having varying influences at specific stages of development. Normal growth in 
children consists of 3 phases: prenatal, childhood and pubertal and relies on three uni-
dimensional growth parameters (height, weight and head circumference). These measures 
are considered individually, and also as bi-dimensional traits such as Body Mass Index 
(BMI), which incorporates both weight and height. Finally, the three modalities of 
growth may be combined to symmetry of overall growth in an individual. In this paper, 
we term a three-dimensional measure of ‘Trivariate Growth Phenotype’ (TGP) based on 
symmetry or asymmetry of head circumference, height, and weight. To allow 
comparability of anthropometric measurements, specific growth measures are typically 
standardized to age and sex specific population-based growth percentile curves 
(Kuczmarski et al., 2000; Wells, 2007; WHO, 2006).  
 
Growth “abnormalities” consider the extremes of growth, with different cut-offs used for 
different measures of growth. For example, abnormally large head circumference 
(macrocephaly) is often recognized clinically as head circumference >= the 97
th
 sex and 
age-specific percentile, while microcephaly defined as head circumference <= the 3
rd
 
percentile. For height, tall stature is defined by height >= 3 standard deviations above the 
mean for sex and age, but short stature defined as height less < the 10
th
 percentile for sex 
and age. For weight, overweight is defined by weight >= the 97
th
 percentile for sex and 
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age, and underweight as weight < the 10
th
 percentile for sex and age. The arbitrary nature 
of these cut-offs, in terms of comparability to each other, makes it challenging to directly 
compare all three growth measurements.  In this work, in addition to these clinical 
thresholds, we have also used the top and bottom 10% of the population to define 
abnormality for comparison of results across all growth parameters.  
 
Growth Abnormalities and Autism Spectrum Disorder  
 
Children with ASD have been recognized to have abnormalities in several parameters of 
physical growth. In fact, Kanner first made the observation that 5 of the 11 autistic 
children in his original clinical sample had abnormally large heads (i.e. macrocephaly) 
(Kanner, 1943).
 
Accelerated overgrowth of the head early in development, leading to 
macrocephaly, has been frequently observed in more recent literature
 
(Lainhart et al., 
1997; Fombonne et al., 1999; Miles et al., 2000; Courchesne et al., 2001; Courchesne et 
al., 2003; Redcay & Courchesne, 2005; Lainhart et al. 2006). Approximately 15-20% of 
children with autism have been reported to have macrocephaly, with some variability in 
these estimates (Fombonne et al., 1999; Lainhart et al., 2006; Dementieva et al., 2005;). 
Enlarged head circumference has been found to be associated with increased total brain 
volumes in some neuroimaging studies (Hazlett et al., 2005, Tate et al., 2007), and post-
mortem studies of autistic brains have shown increased gray and white matter volume in 
addition to enlarged head circumference (Redcay & Courchesne, 2005). A recent 
systematic review and meta-analysis lead by Sacco in 2015 based on 27 studies of brain 
size in autism, concluded 15.7% of autistic individuals have macrocephaly (Sacco, 
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Gabriele & Persico, 2015). Publications assessing macrocephaly stratified by sex have 
reported a higher prevalence of macrocephaly in ASD boys compared to ASD girls 
(Amaral et al., 2017). In the majority of studies on abnormal growth in ASD, however, 
girls are poorly represented due to the lower prevalence of ASD in girls compared to 
boys.  
 
In addition to abnormal head growth, children with ASD have also been reported to have 
abnormal weight and height. Autism has been associated with obesity in numerous 
studies (Ahearn et al., 2001; Evans et al., 2012; Curtin et al. 2005; Rimmer et al. 2010; 
Xiong et al., 2009; Broder-Fingert et al., 2014; Zuckerman & Fombonne, 2014; Must et 
al., 2017), including research in large databases such as the National Survey of Children's 
Health (Chen et al., 2009; Curtin et al., 2010). Excessive weight among people with ASD 
trends with increasing age, especially among adolescents with ASD (Hill, Zuckerman & 
Fombonne, 2015, Bicer & Alsaffar, 2013).  Higher rates of obesity have also been 
observed among ASD boys (Must et al., 2017). 
 
Some studies have described what is termed abnormal ‘early generalized overgrowth’ in 
children with ASD.  Growth trajectories among children with ASD have revealed an 
enlarged head circumference, taller stature and higher weight among autistic boys 
compared to typically developing controls in the first year of life (Chawarska et al., 
2011).  It was postulated children with autism show a general growth dysregulation 
instead of simply overgrowth, as certain growth modalities were found to be asymmetric 
(Curtin, 2005 et al.; van Daalen et al., 2007).  Rarely are combinations across all three 
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measures of physical growth considered in studies of growth and ASD.  Here, we use the 
term the ‘trivariate growth phenotype’ to capture the simultaneous combination of head 
circumference, height, and weight per child, allowing consideration of growth symmetry 
and estimation of whether some particular asymmetric combinations are more prevalent 
among ASD cases. Asymmetric growth, where one or more modalities of growth are not 
in proportion to the other, may suggest a more specific pathological process, as seen in 
for example endocrinopathies or other recognized syndromes.  
 
Here, we estimate the association between abnormal growth and ASD among 2-5 year 
old children who participated in the SEED 1 study, a national ASD case-control study 
supported by the CDC. We considered head circumference, height, weight, BMI, and the 
trivariate combination of the first three. Characterization of specific growth differences in 
cases and controls, can inform ASD phenotyping that may enable improved risk factor 
discovery, as well as better prediction of outcomes and perhaps targeted early 









The Study to Explore Early Development (SEED), phase I, is a national multi-site case 
control study funded by the CDC. Children between ages 2-5 years old were recruited 
and evaluated at one of six sites: California, Colorado, Georgia, Maryland, North 
Carolina and Pennsylvania. Potential cases, born between 2003 and 2006 were recruited 
through partnerships with developmental disability service providers, including 
healthcare and educational systems. Population-based control children born in the same 
years from the same catchment areas were recruited through vital statistics.  After phone-
based screening and in-person evaluations, children were classified as ASD, other non-
ASD developmental disabilities, and children without developmental disabilities from the 
general population (POP) (Schendel et al., 2012). Eligibility included birth in the study 
catchment area during the period between September 1
st
, 2003 to August 31
st
 2006, 
current residence in the area at the time of first contact, and child living with a 
knowledgeable caregiver who was able to communicate orally in English or Spanish 
competently and gave informed consent for participation. The enrolled children also had 
to be between the ages of 30 and 68 months of age at the completion of the in-person 
clinical developmental assessment.  
 
There were 3,899 children recruited into the SEED 1 study. Only ASD and POP children 
were considered in these analyses. There were 1,130 children who underwent 
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dysmorphology assessment. Children with complete dysmorphology assessment 
information were obtained after filtering out those with a high proportion of dysmorphic 
features categorized as ‘not scored’ (80 or more, out of a possible 397), either because the 
assessment was not completed by assessor or due to poor photograph quality. We 
restricted the sample to complete-case analyses, where data were available for growth 
abnormalities measures, sex, maternal education and race (N=958). We then excluded all 
children with chromosomal abnormalities and recognized genetic syndromes (N=45), 
where data were derived from parent report during the original clinic visit, recorded on 
the Dysmorphology Exam Form, and verified by the Clinical Geneticist in the SEED 




For all eligible children, a brief screening interview, the Social Communication 
Questionnaire (SCQ; Rutter et al. (2003)), was administered to the primary caregiver to 
identify children who required clinical diagnostic assessment to determine final ASD 
status. For SEED, a positive screen was defined as an SCQ score ≥11. Tools for ASD 
assessment included the Autism Diagnostic Observation Schedule (ADOS) and Autism 
Diagnostic Interview-Revised (ADI-R) (Falkmer et al., 2013; Lord et al., 2000). Final 
classification was assigned using a SEED-specific research algorithm based on ADOS, 
ADI-R and clinical judgment (Wiggins et al., 2015). Regardless of ascertainment source, 
any eligible children with a previous ASD diagnosis, who were receiving special 
education services, and who had a positive screen, were assigned to the ASD workflow. 
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This determined which instruments were administered and the type of diagnostic 
evaluation the child received during data collection. Based on previous diagnosis and 
SCQ screening, POP children with negative SCQ screens were assigned to the POP 
workflow. If a clinician suspects ASD during the clinical evaluation of a child in the POP 
workflow, the child would be moved into the ASD workflow (Schendel et al., 2012; 




SEED participants underwent anthropometric measurements and had standardized 
photographs taken of specific regions of the body. The specific growth measures of 
interest here were collected using a standardized procedure by trained clinic staff using 
standardized supplies including the tape measure for head circumference, the stadiometer 
and the weighing scale. For head circumference, a non-stretchable, plasticized measuring 
tape was used to measure head circumference for maximum circumference of the head. 
The tape was placed just above the eyebrows, above the ears and around the most 
protuberant part of the back of the head (occiput), pulled snugly to compress hair and 
read to the nearest 0.1cm, after which the measurement was recorded on the 
Dysmorphology Review Form (DRF) and repeated, so repeated measurements were 
within 0.2cm from each other. For height measurement, an accurate and appropriate 
stadiometer was used: a vertical board with an attached metric rule and a horizontal 
headpiece was brought into direct contact with the most superior (top) part of the head, 
and read to the closest 0.1cm. Height measurement was performed for all children with 
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hair accessories removed and without shoes. The child was measured standing with heels, 
buttocks, shoulders and head touching a flat upright surface. The arms were held on the 
side, with shoulders relaxed and legs straight, and heels close together. The child was 
asked to look straight ahead and the perpendicular headpiece lowered to the crown of the 
head snugly to compress the hair. The measurer’s eyes were parallel with the headpiece. 
The measurement was repeated, with agreement to within 1cm, and recorded on a growth 
chart appropriate for the child’s age and sex. The raw measurement and percentile growth 
from the percentile chart was then transferred to the DRF form. The stadiometer position 
was standardized, so there were no attachments to the wall and no underlying carpet. The 
stadiometer was also calibrated monthly using the SEED Equipment Checklist and 
Equipment Calibration Forms. For the measurement of weight, a safe and accurate scale 
with a wide enough platform to support the child being weighed was used. The scale was 
required to be calibrated with standard weights, able to be zeroed, and was not on a 
carpeted surface. The child stood on the weighing platform without assistance and 
wearing only light undergarments or gown. The reading was recorded, and repeated until 
agreement within 0.1kg.  
 
Clinical geneticists in the SEED Dysmorphology Group assessed these measures and 
photographs using the customized DRF tool. The SEED Dysmorphology Group 
developed the DRF to quantify the intrinsically qualitative observations used to classify 
dysmorphology. This tool consisted of clinical observations of 397 specific physical 
features in seven body regions divided into: Head/Hair/Face/Neck, Ears, Eyes/Eyebrows, 
Nose/Philtrum, Mouth/Lips/Teeth, Hands/Feet, and Growth/Skin. The clinical geneticists 
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were blinded to the child’s case status (ASD vs POP) and were each assigned a particular 
body region for consistency in rating individual regions. The DRF had specified cut-offs 
for defining abnormal growth, generally aligned with CDC guidelines.  
 
For these analyses, raw values of head circumference, height, and weight were converted 
to z-scores and percentiles using the 2000 CDC Head Circumference-for-Age Growth 
Charts for girls and boys ages 2–20, the Stature for-Age Growth Charts for girls and boys 
ages 2–20, the Weight-for-Age Growth Charts for girls and boys ages 2–20 and the BMI- 
for-Age Growth Charts for girls and boys ages 2–20.  
 
Dichotomous abnormal growth outcomes were defined for each child for: large and small 
head circumference (i.e. macrocephaly and microcephaly), tall stature, short stature, 
overweight, and underweight. Two alternative threshold strategies were used to define 
growth abnormalities. First, abnormalities were defined based on the SEED 
Dysmorphology Group thresholds, empirically derived through examination of SEED 
data, literature, and existing clinical thresholds.  These cut-offs are implicit in the 
definitions in the DRF, and capture extreme dysmorphology. As a second strategy, 
children were also classified simply by being in the top or bottom decline for head 
circumference, height, and weight. This includes less extreme features, but allows 
comparability across all three growth modalities. The bi-dimensional measure for weight 
and height: body mass index (BMI), was measured using the formula (BMI= Weight 
(kilograms)/ Height
2 
(meters)).  A trivariate growth phenotype was derived as the 
simultaneous combination of dichotomous growth classification across the three 
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measures of head circumference, stature and weight. This resulted in 27 trivariate groups. 
Children with the same category of growth across all three (e.g., macrocephaly, tall 
stature, overweight) were considered as having symmetric growth. All others were 





Participant self-identified race and sex, as well as parental race/ethnicity and maternal 
education were obtained from the Caregiver Interview (CGI), a computer-assisted 
telephone interview with mothers or other knowledgeable caregivers. This tool was used 
to acquire information about the child, family and caregiver, and quality assurance 
measures were used to ascertain their reliability (Schendel et al., 2012). Maternal and 
paternal race were used in an algorithm to determine child race/ethnicity as coded in the 
variable 'DR_DRF_DysmRace' in the dysmorphology analysis. Maternal education was 




We characterized the analytic sample using counts and percentages for ASD and typically 
developing (POP) children. We compared percentile means in growth modalities for both 




Odds ratios comparing the odds of each growth abnormality between children with ASD 
and POP children were estimated using the logistic command in STATA (MP12.1), 
modeling the log probability of each specific growth abnormality as a function of ASD 
status, adjusted for race. Overall, and sex-stratified models were run; models based on 
abnormalities defined by the DRF as well as by decile were also run separately. 
Frequencies of trivariate growth patterns were estimated in STATA, with Fisher’s exact 
test used to examine differences between ASD and POP children. For all abnormality 
analyses – univariate, divariate, and trivariate – both nominal and multiple test-corrected 














Of the 2595 SEED 1 case (n=1,306) and POP (n=1,289) children, 1,130 had complete 
dysmorphology information, and of these, 913 were available for this analysis (see 
Figure 1). Table 1 shows the sample characteristics of 532 children classified with ASD 
and 381 POP children. The study population included the following demographic 
breakdown: by ancestry 55% Non-Hispanic White, 22% African-American, 19% 
Hispanic and 4% other; by sex 70% boys and 30% girls; and by ASD status 44% ASD 
and 56% non-ASD, including 36% POP and 20% DD subjects. The higher percentage in 
boys overall is due to greater numbers of boys compared to girls in the ASD group, 
reflecting the higher preponderance of ASD in males.  There were more males in the 
ASD group than POP group, as expected given the established sex bias in ASD. Maternal 
education and maternal self-reported race were not statistically significantly different 
between groups. 
 
Mean Differences in Growth Percentiles 
 
Distributions of reference-standardized percentiles among SEED children for head 
circumference, stature, weight and BMI for ASD and POP children are illustrated in 
Figures 2 (overall) and 3 (sex-stratified).  There is generally an inflation of higher 
percentiles among the SEED sample.  Comparison of mean percentile values between 
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groups for each growth modality are shown in Table 2, and stratified by sex in Table 3. 
Mean estimates in ASD children were larger for head circumference and BMI, and lower 
for weight and height, than in POP children, although neither of these differences reached 
statistical significance.  ASD versus POP means were not statistically significantly 
different for boys or girls for head circumference, BMI or weight. ASD girls did show 
statistically significantly shorter mean height than seen in control (POP) girls (p=0.04).   
 
Differences in Growth Abnormalities 
 
 
The counts and proportions of ASD and POP children with each of the 8 growth 
abnormalities considered are shown in Tables 4 and 5.  Results are shown using the 
clinically-informed SEED DRF thresholds, as well as using top and bottom deciles.    
In general, DRF-defined macrocephaly and tall stature were rarely observed (5.1%, 1.6%, 
respectively). Using the reference-based decile cut-offs, more than the expected 10% 
were observed in the top reference decile for microcephaly, tall stature, overweight, and 
high BMI.  Sex-stratified results were only possible for decile-defined abnormalities, 
because DRF-defined frequencies were too low. There were 640 males (67.6% with 
ASD) and 273 females (36.2% with ASD). Using decile cut-offs, the numbers of females 
with growth abnormalities were quite low, for example only 10 females were identified 
with low BMI (n=6 and n=4 for POP and ASD, respectively). Overall, there were a 
higher percentage of ASD males with high BMI compared to POP males (24.5% vs. 
18.4%). For height in females, a higher percentage of ASD females were found to have 
short stature compared to POP females (19.2% vs. 6.3%). A smaller proportion of ASD 
females were tall compared to POP females (11% vs. 20.7%). Within the male ASD 
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subgroup, the growth abnormality with the highest number of males identified was high 
BMI, and the growth abnormality with the lowest number of males identified was low 
BMI. For the female ASD subgroup, the growth abnormality with the highest number of 
females identified was microcephaly, and the growth abnormality with the lowest number 
of females identified was low BMI. 
 
Results from logistic regression analyses estimating the association between each growth 
abnormality (defined by DRF) with ASD status, adjusted for race, are shown in Table 6.  
The unadjusted odds ratio for short stature among children with ASD was 1.90 (C.I.: 
1.05, 3.45; p=0.03) compared to POP children. Adjusting for race, the estimated odds 
ratio remained consistent at 1.92 (CI: 1.06, 3.49; p=0.03). However, this association did 
not survive correction for multiple testing. When using decile-defined abnormalities, the 
association with short stature was attenuated and not statistically significant (aOR=1.47, 
C.I. 0.91, 2.37; p=0.10; Table 8).  However, high BMI showed increased odds among 
ASD cases (aOR=1.44, C.I. 1.04-2.0, p=0.03), although this did not survive multiple 
testing correction. 
 
Similar analyses stratified by sex showed higher odds of DRF-defined short stature 
(Table 7) among girls with ASD compared to POP girls (aOR = 5.56, C.I. 1.94, 15.97; 
p=0.001). This was also observed using the decile definition of short stature (aOR=3.52, 
C.I. 1.6, 7.76; p=0.002, Table 9). Decile-defined tall stature was also observed to be 




Trivariate Growth Phenotypes 
 
Frequencies of ASD and POP children with each of the 27 possible combinations of 3 
growth modalities are show in Tables 10 and 11, reflecting both DRF-defined and 
decile-defined abnormalities, respectively.  As expected, most children for both groups 
had normal head circumference, normal height and normal stature.  Tests of overall 
differences in symmetry between ASD and POP children were not statistically significant 
using either abnormality definition. 
 
Using the DRF cut-offs for growth abnormalities, there were 12 cells in which no 
children were observed.  Only one pattern of DRF-defined trivariate growth showed a 
statistically significant difference between ASD and POP: the combination of 
microcephaly, short stature and normal weight, although this association did not survive 
correction for multiple testing. This may be driven by girls, where 7% of 99 ASD girls 
(compared to 1.1% of 174 POP girls) had this combination (p=0.01), yet only 2.7% of 
433 ASD boys and 0.9% of 207 POP boys had this combination (p=0.24).  Using decile-
defined thresholds, two patterns of trivariate growth showed statistically significant 
differences between ASD and POP: the combination of microcephaly, short stature and 
normal weight, as seen with DRF definitions, and also the combination of microcephaly, 
normal stature and overweight, although neither remained significant after correction for 
multiple testing. The association with microcephaly, short stature, normal weight 
phenotype and ASD was again statistically significant in girls (10.1% ASD vs 3.4% POP 





Abnormal growth in various forms, i.e. macrocephaly, has been recognized as a sub-
phenotype in autism spectrum disorder (ASD), a complex and heterogeneous group of 
neurological developmental disabilities where both genetic and environmental risk 
factors contribute to the etiology. Considering sub-groups of ASD such as growth 
abnormalities holds some potential for improving not only our understanding of autism 
spectrum disorder by providing a clearer picture of the complexities of clinical 
presentations of autism, but may also point towards important etiological risk factors, 
specifically genetic risk factors, as well as possibly being useful in screening for ASD 
and its phenotypes, and managing therapeutic strategies.  
 
In this work, we found increased prevalence of short stature among ASD children ages 2-
5, compared to population-based controls, and this association was stronger among girls. 
ASD children also had a higher frequency of the trivariate growth combination of 
microcephaly, short stature and normal weight (based on clinical definitions: Fisher’s 
p=0.01, Decile definitions: Fisher’s p=<0.01). This association was strongest and 
statistically significant among girls, regardless of the abnormality definition used, but 
was not statistically significant among boys.  We also observed a greater proportion of 
ASD cases above the 90
th
 percentile for BMI.  Notably, we did not observe statistically 
significant associations between head circumference and ASD, although ASD children 
had a slightly higher mean head circumference than POP children, and higher frequencies 




Previous studies of height and stature abnormalities in ASD cases have shown 
inconsistent results. Some studies found short stature and microcephaly among ASD 
children, but included some children with syndromic diagnosis, for example Smith-
Lemli-Opitz, where short stature is a recognized feature (Goldenberg et al., 2003). Most 
studies have found increased, rather than decreased, height among ASD children, 
particularly in boys, and often corresponding to increased head circumference 
(Davidovitch et al., 1996; Dissanayake et al., 2006).  The observation of an isolated 
association between short stature and ASD in girls has not been as widely reported. A 
study by Lainhart et al. (2006) reported a higher percentage of short stature in females 
compared to males with ASD (26.7% vs. 7%), although the sub-sample of subjects with 
short stature (n=13) was modest (Lainhart et al., 2006). The paucity of such reports may 
be due to the greater preponderance of ASD among boys, making it much more difficult 
to obtain cohorts of autistic girls with growth abnormalities. In fact, a number of studies 
concerning growth in ASD children, excluded girls due to inadequate sample sizes (Suren 
et al., 2013).  
 
Our findings also showed the combination of microcephaly, short stature and normal 
weight was associated with ASD.  Interestingly, no POP children were found to have this 
particular combination of growth abnormalities, and this association appears to be driven 
by growth abnormalities in girls only.  This particular combination of growth pattern is 
unusual. Clinically, children are frequently observed to have short stature and 
microcephaly following a prolonged period of failure to thrive, which is typically 
accompanied with these children being underweight. Microcephaly with short stature and 
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the absence of decreased body weight represents a deviation in expected patterns of 
growth, even in children with failure to thrive.  Previous studies have observed 
associations between ASD and combinations of head circumference, weight, and height, 
particularly for symmetric overgrowth (Torrey et al., 2004; Dissanayake et al., 2006; 
Mraz et al., 2007; Fukumoto et al., 2008, Zwaigenbaum et al., 2014). A recent 
population-based longitudinal study of 376 children culled from the Norwegian Mother 
and Child Cohort assessed these three modalities of growth in autistic children (Suren et 
al., 2013) and reported symmetric overgrowth in ASD boys, but a trend towards 
undergrowth in ASD girls compared to control children.  However, these investigators 
remarked there was an inadequate number of ASD girls in their study to support 
meaningful inferences. These authors found the growth acceleration among boys became 
apparent from 6 months of age onwards, and ASD girls had decreased head 
circumference and weight compared to control girls. They postulated their findings 
among girls with autism were driven by concurrent epilepsy, other forms of intellectual 
disability or genetic disorders, but that these comorbidities did not impact findings on 
head growth trajectory among boys. In our study, we excluded all children with 
chromosomal abnormalities and recognized genetic syndromes, but not those with 
reported epilepsy, and we had a reasonable, but modest, number of girls with ASD.  
Another longitudinal study in 347 ASD children found a child’s age and sex influenced 
growth abnormalities (Campbell et al., 2014). ASD boys were symmetrically larger 
across the three modalities. These changes were attributed to early, generalized 
overgrowth starting around 6 months of age. Girls with ASD did not show abnormal 




Previous studies of weight abnormalities in autism have also shown variable results. The 
prevalence of overweight and obesity in children with autism have been reported to be 
higher than in control children (de Vinck-Baroody et al., 2013; Egan et al., 2013; Evans 
et al., 2012; Hyman et al., 2012; Rimmer et al., 2010; Cheung et al., 2016; Phillips et al., 
2014). Two studies comparing ASD children directly to control children found higher 
rates of obesity, approaching statistical significance (Curtin et al., 2010; Evans et al., 
2012). However, these were relatively small studies (Curtin et al., 2005; Egan et al., 
2013; Evans et al., 2012; Ho et al., 1997), relied on parent-reported weight instead of 
direct measurements (Chen et al., 2010; Curtin et al., 2005), and used unconventional 
definitions of obesity (Ho et al., 1997).  Our finding of increased high BMI among 
children with ASD compared to control children may also reflect other co-morbidities 
such as sleep disorders (Broder-Fingert et al., 2014; Hill et al., 2015) and poorer 
psychosocial functioning (Hill et al., 2015) in the ASD group. 
 
We did not see statistically significant differences in head circumference between ASD 
and POP children, although ASD children had slightly higher means and slightly greater 
prevalence of both macrocephaly and microcephaly. This is different from many previous 
studies suggesting macrocephaly is associated with ASD (Courchesne et al., 2003; 
Fombonne et al., 1999; Lainhart et al., 2003; Lainhart et al., 1997; Barnard-Brak et al., 
2011, Chaste et al., 2013); although more recent research has also shown inconsistencies 
in this association (Suren et al., 2013; Dinstein et al., 2017).  This may reflect study 
selection and design, such as cross-sectional versus longitudinal data, or inclusion of 
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children with co-morbidities (including chromosomal abnormalities or genetic 
syndromes). Our finding of no statistically significant differences in head circumference 
and ASD may be due to our exclusion of children with chromosomal abnormalities and 
recognized genetic syndromes from our analysis, or our use of DRF and population-
reference definitions for abnormal growth. Recent cross-sectional studies comparing head 
circumference in ASD children and controls often have found no significant difference 
(Raznahan et al., 2013; Dinstein et al., 2017).  
 
When considering growth abnormalities, we used two alternative definitions, one based 
on a clinically-informed algorithm implemented in the SEED study (DRF), and another 
based simply on population reference deciles. The DRF definitions captured children at 
the extreme ends of specific growth modality distributions, while decile definitions were 
more inclusive. Further, the DRF thresholds were not consistent across the three 
modalities, while the decile definitions allowed standardized comparison across 
modalities. For example, the threshold for tall stature under the DRF is height three 
standard deviations above the mean (≥99.9th percentile), while that for short stature is 
height 1.25 standard deviations below the mean (<10th percentile). Comparing these 
stringent and more liberal definitions allowed consistent patterns to emerge. For example, 
results for short stature were consistent among analyses using both definitions, but 
stronger when based on the more stringent DRF definitions. 
 
In our study, we excluded children with chromosomal abnormalities and recognized 
genetic syndromes. ASD is a complex condition for which no specific etiology has been 
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determined, although genetic, environmental and gene-by-environment risk factors have 
been suggested (Iossifov et al., 2014; Krum et al., 2015; Karimi et al., 2017). We 
therefore wanted to exclude growth abnormalities likely caused by single chromosomal 
disorders or recognized genetic syndromes with Mendelian inheritance. In addition, 
increased prevalence of chromosomal abnormalities and recognized genetic syndromes in 
ASD children compared to control children may affect the distribution of growth 
abnormalities between ASD and POP children because these chromosomal defects and 
genetic syndromes increase likelihood of growth abnormalities and thus may confound 
any association between ASD and abnormal growth. 
 
Previous studies reporting rapid acceleration of growth early in life, particularly in 
autistic boys, suggested this may be an indicator of abnormal neural development and 
somatic growth dysregulation (Hazlett et al. 2005), potentially mediated via 
neurotrophins (a group of proteins involved in neurodevelopment, including neurotrophic 
factor and insulin-like growth factor, and neuropeptides such as vasoactive intestinal 
polypeptide [VIP] and calcitonin gene-related protein [CGRP] (Akshoomoff et al., 2002; 
Courchesne et al., 2001)). Although previous hypotheses have considered effects of 
neurotrophins on somatic overgrowth, and here we observed undergrowth among ASD 
girls, it is still possible that neurotrophin-mediated mechanisms are acting in opposing 
directions. It is also possible co-occurring plasma growth hormone dysregulation and 
pituitary-hypothalamic dysfunction may play a role. This has been previously observed in 




Whether growth abnormalities represent a true neurobiological sub-type of autism is not 
yet established. While some have postulated growth abnormalities (e.g. macrocephaly) 
may be endophenotype-specific etiopathogenic factors (Sacco et al., 2007), others 
suggest a more general tendency towards growth dysregulation (Fombonne et al., 1999; 
Lainhart et al., 2006; Van Daalen et al., 2007). Here, the preponderance of growth 
abnormalities in girls suggests a potential association with sex-specific risk for autism. 
Sex-specific findings in previous growth studies of ASD have been observed (Campbell 
et al., 2014; Suren et al., 2013; Campbell et al., 2014; Must et al., 2017). Campbell et al. 
(2014) suggested generalized somatic overgrowth, seen only in autistic boys, is part of 
the sexual dimorphism for autism. The observation in a longitudinal study of overgrowth 
in autistic boys, and microcephaly and underweight among autistic girls, gave rise to the 
hypothesis that growth trajectories in autism are sex-specific (Suren et al., 2013). There 
may be differences in growth regulation and hence growth abnormalities based on sex 
and the child’s age (Campbell et al., 2014; Suren et al., 2013). Our study further 
contributes to the hypothesis of growth abnormalities are sexual dimorphisms in autism. 
We describe a distinctive pattern of abnormal growth in autistic girls, specifically short 
stature in ASD girls, and the combination of short stature, microcephaly and normal 
weight. Compared to the overgrowth seen in austic boys, girls with autism appear to 
present with the opposite growth abnormality phenotype of undergrowth, at least for 
short stature with microcephaly. Other studies have reported sex-specific differences in 
physical brain changes in ASD. A recent study showed autistic boys have small callosal 
regions projecting to the orbitofrontal cortex, and autistic girls have smaller callosal 
region projecting to the anterior frontal cortex (Nordahl et al., 2015). In addition, 
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comparing autistic males and females, there are substantial differences in the overall 
pattern of changes in gray and white matter volume across the brain (Lai et al., 2013). 
These differences in brain regions may be part of the neurodevelopmental basis for the 
differences in ASD phenotypes between the sexes. 
 
One of the complexities of studying sex-specific effects in autism is that sex has 
sometimes been treated as a covariate rather than simply doing a stratified analysis. In 
addition, to reduce variability and to better characterize autistic core symptoms or 
phenotypes, many studies have restricted all analyses to boys. For example, there is an 
8:1 male bias in brain volumetric studies and a 15:1 bias in functional neuroimaging 
studies (Lai et al., 2015).  Studies of autistic females, even if it may be limited by smaller 
samples, are therefore important to identify possible sex-specific risk factors. Sex gives a 
unique perspective to understand the underlying etiologies in autism, and should become 
as a core principle in autism research to further explore the heterogeneity of this 
neurodevelopmental condition (Rutter et al., 2003; Lai et al., 2015; Loomes et al., 2017; 
Ecker et al., 2017). Understanding sexual dimorphism in ASD could also potentially lead 
to new and targeted treatment strategies. 
 
In Chapter 4, we explore the association between CNV burden with growth abnormalities 
in the SEED Study, and examine the potential association of growth abnormalities  with 
autism-associated CNVs. Lai et al. (2015) suggested early growth trajectories in autism 
may show differential trajectories, where ASD females should be considered different, 




Study Limitations and Strengths 
 
This is a cross-sectional study, and children were only assessed once between the ages of 
2 and 5 years. Unfortunately, we were unable to draw a more comprehensive 
characterization of developmental changes pertaining to physical growth as in a 
longitudinal study design. Growth in children is a developmental process with sensitive 
periods and trajectories of change over age. As described earlier, growth trajectories (and 
their deviations) are time-sensitive, with abnormal growth changes occurring often from 
6 months and starting to decline in severity after 2 years of age. Thus, whenever a growth 
measure is performed, it is integral to not just the results of any one analysis, but also the 
interpretation of these results. Absence of any evidence of overgrowth in autistic boys 
may reflect this limitation in our study design. 
 
Also, despite this being a reasonably-sized study of children with ASD, for certain 
growth abnormalities examined here, e.g. tall stature based on the DRF cut-offs and low 
BMI using the decile cut-offs (stratifying by sex), we had limited statistical power due to 
the small numbers of children with abnormalities. This was also an issue with the 
assessment of certain patterns of trivariate growth phenotype, where the stringent DRF 
cut-off, resulted in a number of empty cells for both ASD and control children, (e.g. the 
combination of macrocephaly, overweight and short stature). Using the less stringent 
decile thresholds, each cell was populated by at least one individual, although there were 
some cells without representation for one or another group, (e.g. the combination of 
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macrocephaly, underweight and normal height in ASD children). Thus, this study may be 
underpowered to test certain patterns of trivariate growth phenotype associated with 
ASD. 
 
An important limitation is the possibility there may be undiagnosed chromosomal 
abnormalities and recognized genetic syndromes left among our study sample. The 
exclusion of these children was based only on parental report; children did not undergo 
genetic evaluation. These children with undetected genetic syndromes could influence the 
effect estimate assessed as these conditions are also associated with ASD and may be the 
cause of growth abnormalities. This important issue could be addressed in future work. 
 
Despite the limitations described above, this study also has many strengths. The study 
ascertainment was population-based, and involved individuals from six sites across the 
United States, with various racial groups reflecting the racial composition of the source 
populations (Schendel et al., 2012). Large numbers of individuals with ASD were 
assessed, including 99 ASD girls. Including girls in ASD studies can be challenging due 
to lower prevalence in females, and stratified analysis by sex can become more difficult. 
Stratification was not attempted in several studies of autism and growth due to sample 
size issues.  Some studies do not even include autistic girls in their final analysis. 
Inclusion of autistic girls in ASD studies is increasingly recognized as quite valuable, and 
may give rare insights into potential risk factors. Growth abnormality in autistic 
phenotypes is also an important area to further explore, especially in terms of the variable 
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sex-specific presentations, and whether this may potentially be associated with in terms 
of etiology, management and prognosis.  
 
SEED also provided rigorously obtained exposure and outcome data. All SEED sites 
conducted a uniform assessment of ASD based on a standard protocol across sites 
delivered and adjudicated by research-reliable professionals, within ongoing quality 
control (QC) throughout the data collection phase. Physical measurements were taken 
using standardized growth measurements across all sites, with frequent QC. These 
provided data on multiple growth modalities. Previous studies often concentrated on just 
one aspect of growth abnormality, for example, macrocephaly, in ASD children.  
 
This study adds to the literature in ASD research, increasing our understanding of the 
autism phenotypes related to somatic growth, and highlighting the importance of studying 
growth in ASD girls.  These findings will hopefully contribute to our understanding of 
ASD, and with future studies, offer hope for early detection, intervention and potentially 
prevention. These autistic sub-phenotypes may help parse out risk factors, particularly 
genetic risk factors leading to autism and particular autistic sub-phenotypes. Identifying 
these individuals may improve detection of these genetic risk factors, by examining the 
confluence of genetic abnormalities leading to both autism and specific sub-phenotypes. 
 
For future work, it would be useful to expand this study to a longitudinal analysis, to 
further understand developmental trajectories for somatic growth. Another avenue to be 
explored is considering assessing other ASD co-morbidities (e.g. intellectual impairment) 
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as a covariate for certain growth abnormalities, and potentially other covariates. Finally, 
for future projects in this area, the design of the study could be improved by obtaining 
parental growth measurements, and genetic analyses incorporating whole exome 
sequencing and whole genome sequencing on these subjects. Sequencing information 
would have helped to eliminate undiagnosed chromosomal abnormalities from our study 
population, to better delineate growth phenotypes associated with ASD as opposed to 
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Table 1: Baseline characteristics of study sample 
  
Baseline Characteristics POP ASD P-value 












Mother’s Highest Education 
Less Than High School 
High School 













































Table 2: Percentile means overall (ASD and POP) for head circumference, weight, 




ASD (N=532) POP (N=381) 
Mean % 95% CI SE Mean % 95% CI SE 
HC  44.81 42.06, 47.55 1.39 42.00 38.94, 45.06 1.55 
Weight 55.91 53.33, 59.27 1.51 56.30 53.35, 58.46 1.30 
Height  56.08 53.48, 58.69 1.32 59.34 56.43, 62.26 1.48 
BMI 59.84 57.30, 62.37 1.29 58.04 55.1, 60.91 1.46 
HC: Head Circumference   
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ASD (N=433) POP (N=207) P-
value Mean 
% 
95% CI SE Mean 
% 
95% CI SE 
HC  45.30 42.31,48.28 1.52 43.29 39.20,47.37 2.08 0.44 
Weight 55.81 52.97, 58.65 1.44 56.73 52.72,60.74 2.04 0.71 
Height 57.39 54.57,60.21 1.43 57.66 53.70,61.61 2.01 0.91 




ASD (N=99) POP (N=174) P-
value Mean 
% 
95% CI SE Mean 
% 
95% CI SE 
HC  42.66 35.81,49.51 3.49 40.46 35.86,45.06 2.34 0.59 
Weight 56.33 50.51,62.15 2.96 55.78 51.38,60.19 2.24 0.88 
Height 50.35 43.79,56.91 3.34 61.37 57.08,65.66 2.18 0.04 























Total 381 (100) 532 (100) 913 (100) 381 (100) 532 (100) 913 (100) 
Macrocephaly 19 (5.0) 30 (5.6) 54 (5.1) 35 (9.2) 61 (11.5) 96 (10.5) 
Microcephaly 30 (7.9) 44 (8.3) 95 (8.9) 72 (18.9) 102 (19.2) 174 (19.1) 
Tall Stature 5 (1.3) 8 (1.5) 17 (1.6) 69 (18.1) 84 (15.8) 153 (16.7) 
Short Stature 16 (4.2) 41 (7.7) 80 (7.5) 28 (7.4) 56 (10.5) 84 (9.2) 
Overweight 29 (7.6) 50 (9.4) 94 (8.8) 60 (15.7) 82 (15.4) 142 (15.5) 
Underweight 19 (5.0) 31 (5.8) 65 (6.1) 37 (9.7) 57 (10.7) 94 (10.3) 
High BMI 41 (10.8) 76 (14.3) 143 (13.4) 70 (18.4) 128 (24.1) 198 (21.7) 
Low BMI 25 (6.6) 32 (6.0) 70 (6.6) 21 (5.5) 27 (5.1) 48 (5.2) 
DRF: Dysmorphology Review Form. Thresholds based on these vary (refer to Figure 2) 
Decile: Decile Percentile Curve thresholds at ≥90
th
 percentile for upper limit of growth 
(overgrowth) and <10
th




Table 5: Growth abnormalities (count, (percent)) in ASD and POP using Decile 




































































Table 6: Odds Ratios of growth abnormalities in ASD children compared to POP children 
using the DRF thresholds (unadjusted and adjusted for race) 
 
ORs are compared to POP 
 Bolded: p-value <0.05 before correcting for multiple testing   





















Macrocephaly 1.14 0.63,2.05 0.66 1.10 0.61,1.99 0.74 
Microcephaly 1.05 0.65,1.71 0.83 1.13 0.69,1.84 0.62 
Tall Stature 1.15 0.37,3.53 0.81 1.12 0.36,3.48 0.83 
Short Stature 1.90 1.05, 3.45 0.03 1.92 1.06,3.49 0.03 
Overweight 1.26 0.78,2.03 0.34 1.26 0.78,2.04 0.33 
Underweight 1.18 0.65,2.12 0.58 1.19 0.66,2.15 0.55 
High BMI 1.38 0.92,2.07 0.11 1.41 0.94,2.12 0.09 
Low BMI 0.91 0.53,1.56 0.73 0.91 0.53,1.56 0.73 
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Table 7: Odds Ratios of growth abnormalities in ASD children compared to POP children 
using the DRF thresholds adjusted for race and stratified by sex 
 
ORs are compared to POP 
 Bolded: p-value <0.05 before correcting for multiple testing   



















Macrocephaly 1.17 0.53,2.60 0.68 1.28 0.45,3.36 0.67 
Microcephaly 0.92 0.49,1.72 0.81 1.98 0.86,4.54 0.10 
Tall Stature 0.88 0.21,3.59 0.86 1.83 0.25,13.34 0.54 
Short Stature 1.20 0.58,2.48 0.61 5.56* 1.94,15.97 0.001 
Overweight 1.59 0.85,2.98 0.14 0.56 0.20,1.62 0.29 
Underweight 1.20 0.56,2.56 0.62 1.20 0.41,3.49 0.73 
High BMI 1.68 0.97,2.54 2.90 1.15 0.56,2.37 0.69 
Low BMI 0.68 0.36,1.29 0.24 1.58 0.55,4.49 0.39 
 ASD, N= 433 
POP, N= 207 
 ASD, N= 99 




Table 8: Odds Ratios of growth abnormalities in ASD children compared to POP children 
using the Decile thresholds (unadjusted and adjusted for race) 
 
ORs are compared to POP 
Bolded: p-value <0.05 before correcting for multiple testing   
 * p-value <0.003 after correcting for multiple testing 
  
ASD, N= 532 


















Macrocephaly 1.28 0.82,1.98 0.27 1.25 0.80,1.94 0.32 
Microcephaly 1.01 0.72,1.42 0.91 1.04 0.74,1.46 0.80 
Tall Stature 0.84 0.59,1.20 0.35 0.84 0.59,1.20 0.35 
Short Stature 1.48 0.92,2.38 0.10 1.47 0.91,2.37 0.10 
Overweight 0.97 0.67,1.40 0.89 0.98 0.68,1.41 0.93 
Underweight 1.11 0.72,1.72 0.62 1.12 0.72,1.74 0.59 
High BMI 1.40 1.01,1.95 0.04 1.44 1.04,2.00 0.03 




Table 9: Odds Ratios of growth abnormalities in ASD children compared to POP children 
using the Decile thresholds adjusted for race and stratified by sex 
 
ORs are compared to POP 
Bolded: p-value <0.05 before correcting for multiple testing   
 * p-value <0.003 after correcting for multiple testing 
 
  

















Macrocephaly 1.12 0.64,1.98 0.68 1.76 0.83,3.74 0.14 
Microcephaly 1.05 0.68,1.62 0.82 1.22 0.67,2.22 0.51 
Tall Stature 1.09 0.69,1.71 0.71 0.47 0.22,0.97 0.04 
Short Stature 1.02 0.56,1.87 0.93 3.52* 1.60,7.76 0.002 
Overweight 0.86 0.55,1.33 0.51 1.21 0.61,2.41 0.58 
Underweight 1.38 0.77,2.48 0.27 0.77 0.34,1.78 0.55 
High BMI 1.48 0.97,2.24 0.06 1.28 0.69,2.37 0.42 
Low BMI 0.69 0.35,1.35 0.28 1.16 0.32,4.23 0.81 
 ASD, N= 433 
POP, N= 207 
 ASD, N= 99 




Table 10: Trivariate Growth Phenotype Frequencies in ASD and POP groups using the 
DRF thresholds for growth abnormalities 
 
 
Table 11: Trivariate Growth Phenotype Frequencies in ASD and POP groups using the 






Overweight Normal Weight Underweight 
Tall Normal 
Height 
Short Tall Normal 
Height 


























































































































Key for Tables 10 and 11 
Blue: counts and percentages of ASD children with the TGP combination described 
Red: counts and percentages of POP children with the TGP combination described 
Black Italic: Fisher’s p-value 
Bolded: significant for Fisher’s p<0.05  
Decile: Decile Percentile Curve cut-offs at ≥90
th
 percentile for upper limit of growth 
(overgrowth) and ≤10
th
 percentile for lower limit of growth (undergrowth) 






Overweight Normal Weight Underweight 
Tall Normal 
Height 
Short Tall Normal 
Height 



















































































































































Figure 2: Percentile distribution of a. Head Circumference b. Height c. Weight d. BMI  






Figure 3: Percentile distribution of a. Head Circumference b. Height c. Weight d. BMI  










Table I. Baseline Characteristics of Excluded Children with Chromosomal 
Abnormalities and Genetic Syndromes comparing POP vs. ASD 
 
 ASD Status Chi-
squared 
p-value 
Exclusion Criteria POP /No ASD (%) ASD (%) 
Chromosomal 
Abnormalities 
  0.045 
Present 0.8 2.5 
Absent 99.2 97.5 
Non-Chromosomal 
Genetic Syndromes 
  0.318 
Present 2.3 3.4 
Absent 97.7 96.6 
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Introduction:   
Autism Spectrum Disorder (ASD) is highly heterogeneous. Use of endophenotypes, or 
subgrouping of cases, may improve our ability to detect genes related to specific 
etiologies. Dysmorphism, physical malformations occurring in the embryonic and fetal 
period, indicates disruption in early development and has been associated with ASD. 
Investigating genetic susceptibilities in dysmorphism on its own and as a sub-phenotype 
of ASD may help identify genetic factors related to both. Copy number variants (CNVs) 
have been identified as a significant contributor to several neurodevelopmental 
conditions. Here we estimate genome-wide burden of CNVs comparing dysmorphic to 
non-dysmorphic children drawn from an ASD case-control study, which allows 
association estimates overall, and among ASD cases with and without dysmorphology. 
 
Methods:  
Children from the Study to Explore Early Development, phase 1 (SEED 1) were included 
in these analyses.  SEED is a national, multi-site case-control study of ASD where 2-5 
year old children born between 2003 to 2006 from six study states across the United 
States (including California, Colorado, Georgia, Maryland, North Carolina, and 
Pennsylvania) were recruited.  This analysis includes cases and controls who underwent 
dysmorphology assessment and had genome-wide genotype data. Using a custom tool for 
classifying children as dysmorphic resulted in n=45 dysmorphic children (based on 397 
physical features) and n=443 non-dysmorphic children. Single nucleotide polymorpohis 
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(SNP) genotyping was performed using the Illumina Human Omni1-Quad array, and 
PennCNV was used to call deletion and duplication CNVs. CNV burden over all 
autosomes was estimated as counts of CNVs per person, as well as the cumulative length 
of the genome identified as representing a CNV in each person. These were compared 
between dysmorphic vs. not dysmorphic children. CNVs subsets were also considered: 
large CNVs (>400 kb), only those overlapping genes, and only those overlapping 
previously implicated ASD gene regions. Comparisons were stratified by self-reported 
race/ethnicity, ASD status and sex. Associations between candidate CNV regions 
previously reported to be associated with ASD and dysmorphism were also estimated to 
further inform this sub-group of ASD.   
 
Results:  
Dysmorphic children in SEED 1 showed less CNV burden than non-dysmorphic children 
(ratio of cumulative length affected=0.76, p=0.02). This was true for large CNVs (ratio of 
length=0.49, p=0.01), duplication CNVs (ratio=0.65, p=0.01) and large duplication 
CNVs (ratio=0.48, p=0.02). Analysis of CNV burden restricted to genic regions showed 
similar results for overall, large and duplication CNVs. This decreased CNV burden 
among dysmorphic children remained when restricting the analysis to ASD cases, to non-
Hispanic black children, and among males, although none of these associations were 
statistically significant after correction for multiple testing.  None of the candidate ASD 
CNV regions revealed statistically significant associations with any measure of 
dysmorphism, but the individual CNVs observed were quite rare and, in the current study 





Our results show reduced CNV burden among children classified as dysmorphic in SEED 
1, even among ASD cases. This may be due to the exclusion of children with 
chromosomal abnormalities and recognized genetic syndromes from our analysis, to 
undetected single-gene insults among particants in the dysmorphic group and 
unrecognized genetic burden in the control group, or to actual protective effects. Further 
exploration of monogenic versus genome-wide genetic associations in this sample, via 
exome or full genome sequencing, may be necessary to fully characterize the potential 
utility of observable dysmorphism as a phenotype for ASD.  
 






Autism spectrum disorder (ASD) is a highly heterogeneous neurodevelopmental disorder 
with multiple subtypes, and is frequently found with co-morbid conditions ranging from 
psychiatric to physical abnormalities. Although ASD is understood to have both genetic 
and environmental risk factors, the genetic etiology is postulated to underlie 
heterogeneity within ASD
 
(Miles et al., 2011). Clustering all ASD cases based on 
diagnostic classification may combine many distinct genetically-driven sub-groups and 
thus undermine efforts to determine true causal factors. Greater understanding of 
observable autism phenotypes may improve identification of genetic risk factors, as well 
as allow better prognostication, and potentially allow earlier, targeted, interventions.  
Dysmorphism, physical malformations occurring in the embryonic and fetal period, has 
been associated with ASD and is known to be heritable itself. Dysmorphic features may 
therefore be a useful phenotype of ASD that could help identify a sub-group of ASD 
associated with particular genetic etiologies. 
 
The term ‘dysmorphology’ was first proposed by David W. Smith in 1966, and refers to 
“abnormalities of structural development regardless of severity, timing, or etiology” 
(Smith, 1966). Examples of dysmorphic features include dysplastic ears and abnormal 
growth measures such as macrocephaly (enlarged head circumference) or extremely short 
stature. Dysmorphism at any specific feature is typically defined as being at the extremes 
of expectation in a general population, with observations markedly higher (or lower) 
compared to age- and sex-specific population means (Aase, 1990; Merks et al., 2003).  
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Any single dysmorphic feature occurs in approximately 4% or less of the general 
population (Merks et al., 2003), although overall dysmorphism affects approximately 3% 
of all newborns in the United States (Centers for Disease Control and Prevention 2008).  
Multiple dysmorphic features may represent a general marker for departure from normal 
developmental processes. In general, multiple dysmorphic features rarely occur without 
co-existing genetic conditions or teratogenic exposure (Merlob et al. 1985).  
 
Various studies indicate the proportion of children diagnosed with ASD who have 
physical signs of dysmorphism range between 5-30% (Angkustsiri et al., 2011; Ozgen et 
al., 2010). Children with ASD are more likely to have major congenital anomalies 
compared to the general population (Weir et al., 2006). Children with ASD and 
dysmorphic features also have a greater probability of structural cranial abnormality or 
known genetic syndromes (Ozgen et al., 2011).
 
In 2011, Angkutsiri et al. described 
clinical heterogeneity of the physical features of ASD, whereby significantly more 
children with ASD were classified as dysmorphic compared to control children. 
Numerous studies have described correlations between morphological abnormalities and 
ASD (Weir et al., 2006; Miles & Hillman, 2000; Miles et al., 2005; Ozgen et al., 2011; 
Ozgen et a., 2013). Any child with dysmorphology has a higher likelihood of carrying 
some detectable genetic aberration. By focusing on this ASD sub-phenotype, it is 
postulated there may be a greater likelihood of finding an association between specific 




Rigorous research definitions of dysmorphism remain challenging. Previous studies have 
used a brief 16 abnormality tool – the ‘Minor Anomaly Scale’ (Waldrop, 1968) or the 
Miles dysmorphology classification system, based on 200 features used to categorize 5 
classes (Miles and Hillman, 2000) and later three groups: dysmorphic, equivocal and 
non-dysmorphic (Miles et al., 2005).  The Miles algorithm was further fine-tuned into the 
Miles Autism Dysmorphology Measure (ADM) (Miles et al., 2008), and showed 16% of 
ASD children were dysmorphic. However, this tool was developed only among children 
with ASD; no comparison was made with typically developing children. Further, the 
sample was clinic-based patients and mostly white. For these reasons, the Study to 
Explore Early Development (SEED) Dysmorphology Group developed a research-
reliable quantitative method to characterize and classify dysmorphology among a 
population-based sample with a mix of ethnicities. They developed a novel, standardized 
dysmorphology review protocol of over 300 potential dysmorphic features (Shapira et al., 
2014). This scale was developed with normal children, as well as children with ASD and 
generalized developmental delay (DD), involved young children aged 2-5 years of age 
and represented by three ethnic groups, non-Hispanic white (NHW), non-Hispanic black 
(NHB), and Hispanic.
 
Unpublished data from the SEED study, source of samples used 
here, found this tool classified 17% of ASD cases as dysmorphic in each ethnic group, 
compared to 5% among typically developing control children. This difference remained 
significant even after accounting for children with chromosomal abnormalities and 
recognized genetic syndromes. These findings suggest considering dysmorphology as an 
ASD sub-phenotype may improve risk factor detection in ASD, as genetic risk factors for 
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children with ASD or population based control children who are dysmorphic could be 
simultaneously assessed. 
 
Although some chromosomal abnormalities and recognized genetic syndromes have been 
associated with ASD (Hall, Lightbody & Reiss, 2008; DiGuiseppi et al., 2010), the 
majority of ASD children do not have any known syndrome. Some of the most consistent 
genetic findings for ASD to date are inherited and de novo copy number variants (CNVs) 
(Robinson et al., 2014). Studies of CNVs associated with ASD have identified specific 
CNVs and risk of ASD, as well as an overall association between the genome-wide CNV 
burden a person carries and ASD risk. In terms of specific CNVs, studies have implicated 
a number of genes and chromosomal regions, including most prominently regions on 
chromosomes 7q11.23, 15q11-13, 16p11.2, and 22q11.2 (Pinto et al., 2010; Sanders et 
al., 2011), which were identified from the Simon Simplex Collection such as 1q21.1 and 
3q29 (Pinto et al., 2010; Picinelli et al., 2016), as well as regions encompassing the 
SHANK2 (Pinto et al., 2010), SHANK3 (Gauthier et al., 2009), NRXN1 (Bucan et al., 
2009), CNTN4 (Roohi et al., 2009) and CNTNAP2 (Bakkaloglu et al., 2008) genes. These 
genes and regions are not exclusively associated with risk of ASD but are also associated 
with different neuropsychiatric phenotypes (i.e. as schizophrenia) or fall under a broad 
range of neurodevelopmental conditions (Malhotra and Sebat, 2012). In our analysis, we 
assessed the association between ten loci previously implicated with risk of ASD, 
including some of the chromosomal regions mentioned above, with dysmorphism in 
SEED children. Increased genome-wide CNV burden, or more precisely, autosome-wide 
burden (not including sex chromosomes), has been consistently shown as more common 
 
 105 
in ASD cases. Pinto et al. (2010) reported a higher count of rare CNVs among ASD 
cases, as well as increased counts of deletion CNVs. Others have shown a greater length 
of the genome affected by CNVs, as well as greater counts, among ASD cases, especially 
for deletions and for rare CNVs (Vulto-van Silfhout et al., 2013). This has been shown 
multiple times, with some suggestion that rare de novo CNVs are a driver (Sanders et al., 
2011) and both deletion and duplications influence risk to ASD (Luo et al., 2012).  
 
Here, we examine whether CNV burden, or CNVs in particular ASD candidate regions, 
are associated with dysmorphism, considering it as an ASD sub-phenotype. There is a 
dearth of studies testing for association between CNVs and dysmorphism exclusively. 
Most studies in this area have examined associations between CNVs and intellectual 
disability and/or ASD with congenital malformations or dysmorphic features as a 
supplementary condition, or one that is associated merely with differences in severity. 
Approaches using alternative phenotypes may enable delineation of possible distinct 
genetic etiologies. The over-arching objective of this study is to investigate one these 
features, specifically dysmorphology, and test for potential associations with genetic risk 













The Study to Explore Early Development (SEED), phase I, is a national multi-site case 
control study funded by the CDC. Children between ages 2-5 years old were recruited 
and evaluated at one of six sites: California, Colorado, Georgia, Maryland, North 
Carolina and Pennsylvania. Potential cases, born between 2003 and 2006 were recruited 
through partnerships with developmental disability service providers including healthcare 
and educational systems. Population-based comparison children born in the same years 
from the same catchment areas were recruited through vital statistics.  After phone-based 
screening and in-person evaluations, children were classified as ASD, other non-ASD 
developmental disabilities, and children without developmental disabilities from the 
general population (POP) (Schendel et al., 2012). Eligibility included birth in the study 
catchment area during the period between September 1
st
 2003 to August 31
st
 2006, 
current residence in the area at the time of first contact, and child living with a 
knowledgeable caregiver who was able to communicate orally in English or Spanish 
competently and gave informed consent for participation. The enrolled children also had 
to be between the ages of 30 and 68 months of age at the completion of the in-person 
clinical developmental assessment.  
 
Of the 3,899 children recruited into the SEED 1 study, 1,132 underwent genotyping. 
There were 541 children who had complete dysmorphology classification information 
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and who were also genotyped. Children with a high proportion of dysmorphic features 
categorized as not scored (80 or more, out of a possible 397), either because the 
assessment was not completed or due to poor photograph quality, were filtered out. Our 
analyses included all of SEED 1 children, except 21 children with non-ASD 
developmental delay, and 32 children with known chromosomal abnormalities and 
recognized genetic syndromes, resulting in 488 children in the final sample. The study 
flow chart describing how the final study population was obtained is shown in Figure 1.  
 
Dysmorphology Assessment and Review 
 
Children recruited into the SEED 1 Study were evaluated clinically, and this included a 
developmental assessment followed by a standardized evaluation for dysmorphology 
developed by the SEED Dysmorphology Group. This Group included clinical geneticists 
from each of the six SEED sites who also oversaw and trained personnel (dysmorphology 
aides) at each site to perform the standardized dysmorphology protocol. Unpublished data 
from the SEED Dysmorphology Workgroup describes the protocol in greater detail 
(Shapira, personal communication, SEED Dysmorphology Group unpublished 
manuscript). Briefly, the 6-part protocol consisted of: 1) in-person anthropometric 
measurements of the child and all available parents; 2) in-person standardized visual 
examination of the child, including under a Woods lamp; 3) acquiring a standard series of 
photographs of the child as well as supplementary photographs of any unusual physical 
findings; 4) obtaining bilateral hand scans; 5) completing a standardized Dysmorphology 
Examination Form (DEF) with the observations obtained from the dysmorphology 
assessment; and 6) carrying out a set of measurements from photographs and hand scans 
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and documenting those measurements on the DEF, and determining and recording 
percentiles for all measurements obtained after the in-person evaluation. Dysmorphology 
aides queried the caregivers about congenital abnormalities and reported genetic 
syndromes for the child (including birth defects, any previous diagnosis of malformation 
or developmental syndromes and any previous genetic evaluations or surgeries associated 
with congenital abnormalities). Quality control measures were instituted for 
anthropometric measurements and photographs taken of different body parts.  
 
The dysmorphology assessment reviewed a total of 397 potential dysmorphic features per 
child (37 considered major malformations, and 360 judged as minor), which were 
grouped into 7 body regions: 1) Ears (90 features); 2) Eyes and eyebrows (62 features); 
3) Growth and skin (16 features); 4) Head, hair, face and neck (68 features); 5) Hands 
and feet (83 features); 6) Mouth, lips, and teeth (26 features); 7) Nose and philtrum (52 
features). For each body region or system, one clinical geneticist was assigned to assess 
all children in the study for dysmorphic features in that region using information from the 
DEF and all photographs of that region. That clinician’s review, and classification of any 
noted dysmorphism was entered on a standardized Dysmorphology Review Form (DRF). 
The dysmorphology review included all data in the DEF and all photographs for that 
body region. Each physical feature was assessed on a Likert scale ranging from 1 to 4: 
0=normal or absent; 1=possible or questionable; 2=mild; 3=moderate; and 4=severe; 
denoting how the feature compared to what was expected in a general population. For 
features that included a quantitative measure, such as height, percentile ranges were also 
scored on the 4-point Likert scale. The clinical geneticist responsible for the 
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dysmorphology review of his or her specified body region was blinded to the child’s final 
classification of ASD or POP. The children were assessed sequentially by race, with the 
clinical geneticists reviewing all non-Hispanic White children followed by non-Hispanic 
Black children and Hispanic children.  
 
A feature was classified as ‘dysmorphic’ if it occurred in ≤5% of the POP group, because 
these children are considered a sample of the general population. To summarize overall 
dysmorphism per child, a race/ethnic specific Dysmorphology Score (DS) was calculated 
as DS = [#Dysmorphic Features/Total features assessed] x 100. Children who had 
missing data for more than 80 features were excluded from further analysis.  The 
distribution of DS for POP children in each race/ethnicity category was found to fit a log-
normal distribution.  The expected values based on a log-normal distribution were 
converted to a corresponding percentile score, and percentile scores >95th percentile 
were categorized as ‘dysmorphic’, scores ≤90th percentile were categorized as ‘not 
dysmorphic’, and scores >90th percentile and ≤95th percentile were considered 
‘equivocal’. For analyses presented here, the equivocal group was combined into the not 




For all eligible children, a brief screening interview, the Social Communication 
Questionnaire (Rutter et al., 2003), was administered to the primary caregiver to identify 
children who required clinical diagnostic assessment to determine final ASD status. For 
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SEED, a positive screen was defined as an SCQ score ≥11. Tools for ASD assessment 
included the Autism Diagnostic Observation Schedule (ADOS) and Autism Diagnostic 
Interview-Revised (ADI-R) (Falkmer et al., 2013; Lord et al., 2000). Final classification 
was assigned using a SEED-specific research algorithm based on ADOS, ADI-R and 
clinical judgment (Wiggins et al., 2015). Regardless of ascertainment source, any eligible 
children with a previous ASD diagnosis, who were receiving special education services, 
and who had a positive screen, were assigned to the ASD workflow. This determined 
which instruments were administered and the type of diagnostic evaluation the child 
received during data collection. Based on previous diagnosis and SCQ screening, DD and 
POP children with negative SCQ screens were assigned to the DD or POP workflow, 
respectively. If a clinician suspected ASD during the clinical evaluation of a child in the 
DD or POP workflow, the child would be moved into the ASD workflow (Schendel et al., 
2012; DiGiuseppe et al., 2016).  
 
Copy Number Variants (CNVs)  
 
Blood and buccal samples were collected by trained local staff and shipped to the SEED 
Biosample Repository at Johns Hopkins Bloomberg School of Public Health. These were 
used to isolate DNA via the QIAsymphony DNA Investigator and QIAsymphony DNA 
Midi kits (Qiagen) for buccal and blood, respectively. A total of 1,132 SEED 1 cases and 
controls were genotyped at 1 million single nucleotide polymorphisms (SNPs) on 
Illumina Human Omni1-Quad array. Genotyping and initial data cleaning was carried out 
at the Johns Hopkins University SNP Center. Quality control measures at the SNP and 
sample levels were performed. Samples were excluded if <98% of all markers were 
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called successfully, if estimated identity by descent (IBD) sharing suggested cryptic 
relatedness between subjects, if there were sex discrepancies, or if there was excess 
heterozygosity/homozygosity possibly due to genotyping error. SNPs were excluded for 
call rates <0.95, minor allele frequency (MAF) <0.01 and if there was evidence of 
deviation from expected genotype frequencies predicted by Hardy-Weinberg equilibrium 
(p<1.0x10
-8 
in controls).  
 
CNVs were called using a hidden Markov model implemented in PennCNV (Wang et al., 
2007). Hidden copy number state along each autosome was estimated using total signal 
intensity, allelic intensity ratio, SNP allele frequency, distance between neighboring 
SNPs, and genomic GC content (Diskin et al., 2008). Quality control (QC) filters were 
applied at both the CNV and sample levels. CNVs were filtered out if they contained < 
10 SNPs, were < 30 kb, or in centromere and telomere regions; samples were excluded if 
the standard deviation of the log R ratio (LRR) >0.3, the B-allele frequency (BAF) >0.01, 
or absolute value of a ‘wave’ factor (due to high GC content over the region) >0.05.  The 
overall data quality pipeline for calling CNVs is shown in Figure 2.  
 
Burden Metrics. It is important to remember that CNVs are estimated from SNP data, 
and they can vary in their beginning and ending positions, as well at the content of the 
genomic region they encompass.  Therefore, we considered summary measures of 
autosomal CNVs, both CNV counts across all autosomes, as well as their summed 
lengths in this study. CNV count was based on the total number of unique CNV sites 
(estimated by PennCNV) for each individual; and cumulative length was determined 
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summing the length of these unique CNVs in kilobases (kb) per individual.  Overall 
count and length burden metrics included both duplications and deletions, and CNVs 
occurring anywhere in an autosome (sex chromosomes were omitted). Measures were 
also calculated separately for duplications and deletions, and for only large CNVs (i.e. 
those spanning >400kb). Finally, subsets of autosomes were considered: only CNVs 
overlapping known genes, using hg19 gene boundaries (categorized as “genic CNVs”), 
and only CNVs overlapping genes reported to be associated with ASD, using the Simons 
Foundation Autism Research Initiative gene list (termed as “SFARI CNVs”). The UCSC 
genome database using “TxDb.Hsapiens.UCSC.hg19.knownGene”, “annotate”, and 
“org.Hs.eg.db” Bioconductor packages (Goldstein et al., 2016; Carlson et al., 2016) were 
used to establish known genes and their boundaries.  For the “SFARI CNVs”, SFARI 
gene 2.0_ENREF_22 was consulted, and a list of 757 autosomal candidate genes for 
ASD were used.  
 
CNV Candidate Regions. Malhotra and Sebat (2012) reviewed specific CNV regions 
associated with ASD, and identified the precise boundaries for each region compared to 
the catalog on CNVs available on SFARI (Malhotra & Sebat, 2012; 
https://gene.sfari.org). The largest interval between start and end of any CNV was used to 
best define the affected autosomal region. We focused on CNVs in 10 specific autosomal 
regions: chromosomes 1q21.1, 3q29, 7q11.23, 15q11.2, 15q11.2.13.1, 15q13.3, 16p11.2, 





Statistical Analysis  
 
We characterized the analytic sample using counts and percentages for children with 
dysmorphism and those without. CNV burden was assessed for both CNV counts and 
CNV lengths, with effect sizes estimated as the ratio of each measure between 
dysmorphic and non-dysmorphic SEED 1 children (both ASD cases and POP controls). 
Mean counts or lengths of CNVs were compared between dysmorphic and non-
dysmorphic groups using t-tests. These analyses were carried out overall, for deletions 
and duplications separately, and then restricting to CNVs to: 1) large CNVs, i.e. 
those>400 kb, 2) Genic CNVs, i.e. CNVs overlapping with known genes, and 3) SFARI 
Genic CNVs, i.e. those CNVs overlapping with genes associated with ASD.  Analyses 
were also stratified by self-identified race (Non-Hispanic White, Non-Hispanic Black and 
Hispanic), ASD classification, and sex. Finally, sensitivity analyses were performed to 
assess the effect of excluding or including children with chromosomal abnormalities and 
recognized genetic syndromes, and excluding and including children diagnosed with 
developmental delay. For ASD candidate region analyses, CNV counts between 
dysmorphic and non-dysmorphic children were compared via Fisher’s exact tests. All 






Characteristics of the Study Sample 
 
After restricting to SEED 1 participants with genotype and complete dysmorphology 
data, and further sample filtering for genotyping and CNV calling QC, there were 488 
children available for analyses; 45 classified as dysmorphic and 443 not dysmorphic. 
Baseline characteristics of this sample are shown in Table 1. Those classified as 
dysmorphic were more likely to be male and to have ASD. There was no statistical 
difference in self-identified race between these two groups. There were higher 
proportions of children with both chromosomal abnormalities and recognized genetic 
syndromes in the dysmorphic group as shown in Supplemental Table I, but these were 
excluded from our analysis. 
 
CNV Burden  
 
There were 10,394 CNVs detected in the whole sample, with a mean CNV count of 20 
CNVs per person among dysmorphic children and 21 per person among non-dysmorphic 
children (Supplemental Table I). The mean combined CNV length in dysmorphic 
children was 2.02 Mb per person, compared to 2.63 Mb per person in children who were 
not dysmorphic (Supplemental Table II). Both CNV counts and lengths were generally 
lower among dysmorphic children compared to non-dysmorphic children in SEED 
(Table 2).  Dysmorphic children had 76.6% less genome affected by CNVs than non-
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dysmorphic children (p=0.022), and this remained true when considering only CNVs 
overlapping gene boundaries (74%, p=0.034).  The ratio of length affected among 
dysmorphic versus non-dysmorphic children was even lower when considering only large 
CNVs (D/ND = 0.491, p=0.015) and only large gene-overlapping CNVs (D/ND = 0.519, 
p=0.029). When considering only duplications, there were fewer duplications CNVs and 
less length affected among dysmorphic children (D/NDcount = 0.834, p= 0.035; D/NDlength 
= 0.655, p = 0.011). This was consistent when only considering duplications overlapping 
with genes (D/NDcount = 0.766, p =0.035; D/NDlength = 0.583, p=0.008). Further 
restricting the CNVs to only large duplication CNVs also showed a smaller cummulative 
length among dysmorphic children (D/NDlength =0.483, p=0.022) (Supplemental Table II).  
However, none of these tests remained statistically significant after correcting for 
multiple testing. 
 
The SEED 1 samples with genotypic data and dysmorphism classification included 297 
non-Hispanic White children (NHW), 32 of whom were categorized as dysmorphic. 
There were also 88 non-Hispanic black (NHB) children, 6 with dysmorphism, and 103 
Hispanic children, of whom 8 were dysmorphic. The length-based effect sizes were 
generally in the same direction across all ethnic groups, with D/ND ratios < 1. However, 
none of these were statistically significant in the NHW group, despite it representing the 
largest subset of children (Table 3). In the NHB group, D/ND comparisons were 
nominally significant for all CNVs and for all large CNVs (D/NDlength = 0.557, p = 0.027; 
D/NDlength  = 0.132, p = 0.008). Similar patterns were observed for genic, and large genic 
CNV lengths (D/NDlength = 0.502, p = 0.034; D/NDlength = 0.15, p = 0.016).  Among 
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Hispanic children, deletions, and genic deletions, showed slightly lower genome burden 
among dysmorphic children, although this was not seen in other groups or the overall 
sample.  
 
The trend for less CNV burden among SEED 1 children with dysmorphism was 
consistent when stratifying by ASD status (Table 4). There were 267 children with ASD, 
34 of them categorized as dysmorphic, while only 8 of 212 POP children were 
dysmorphic. Results were also similar among 345 males, 38 of whom had some 
dysmorphism (Table 5). 
 
ASD Candidate CNVs Regions  
 
There were few observations of CNVs among ASD candidate regions in dysmorphic 
children compared to non-dysmorphic children (Table 6).  In the few regions where 
CNVs were observed, there was no statistically significant difference in CNV burden 
between dysmorphic and non-dysmorphic groups, and CNV counts were often more 







We explored the use of dysmorphism, observable physical abnormalities known to be 
associated with autism spectrum disorder (ASD), as an ASD sub-phenotype for genetic 
association studies, in hopes that shared genetic association between dysmorphism and 
ASD might further illuminate etiological mechanisms for ASD in this sub-group. In our 
sample of young children from the Study to Explore Early Development, Phase 1 (SEED 
1), a national case-control study of autism, we observed trends for decreased CNV 
burden among children with dysmorphism. Many specific associations with length of the 
genome affected by CNVs, including overall, large CNVs, CNVs in known genes, and 
duplications showed nominally statistically significant comparisons, although these did 
not reach significance after Bonferroni correction for multiple testing.  The reduced CNV 
burden results were consistent when considering only ASD cases or only boys.  Results 
were also generally consistent across ethnic groups, although nominal statistical 
significance was seen in non-Hispanic black children. None of the CNV burden analyses 
restricted to previously genes previously associated ASD (based on the SFARI ASD list) 
were associated with dysmorphism. 
 
Our analyses did not include the few (N=21) SEED 1 children with non-ASD 
developmental delay (DD) that had available genotyping and dysmorphology data. 
Sensitivity analyses including those DD children did not change the results 




Importantly, our analyses excluded 8 (13%) of the dysmorphic children and 6 (1%) of the 
non-dysmorphic children with chromosomal abnormalities and the 10 (16%) dysmorphic 
and 9 (2%) non-dysmorphic children with non-chromosomal genetic syndromes 
(Supplementary Table IV).  Had these children and the DD children with been included 
in our analyses, we would have observed excess burden in CNV length among 
dysmorphic children, across all analyses (Supplementary Table VId). It is likely that the 
combination of congenital abnormalities and recognized genetic syndromes with 
dysmorphic features is an indication of some underlying deviation from normal 
developmental processes resulting from either exposure to teratogens prenatally or other 
genetic causes. The excluded children thus appear to increase CNV burden when 
comparing dysmorphic to non-dysmorphic children.  
 
In this study, we endeavored to use the phenotype of dysmorphism, the study of physical 
malformations present early in life, classified using a newly developed tool established as 
part of the SEED Study, as sub-phenotype of ASD. As a condition with origins during the 
embryonic or fetal period, dysmorphism is understood to have both genetic and 
idiopathic risk factors, with environmental or an interaction between genes and 
environment likely to represent distinct idiopathic etiologies. In terms of sensitive time 
periods, dysmorphism and ASD likely share overlapping periods of vulnerability early in 





Across neurodevelopmental conditions such as ASD, some CNVs have emerged as a 
strong genetic risk factor. However, even the most recurrent CNVs are individually rare. 
Therefore, global CNV burden as an aggregate may be one way to assess the impact of 
CNVs on developmental conditions and potentially support the importance gene dosage 
in leading to these conditions (Walsh et al., 2008; Sebat et al., 2009). CNVs are present 
not only in those with disease, but also in healthy populations. A comparison with healthy 
controls is thus important to understand the contribution of CNVs to neurodevelopmental 
conditions (Rosenfeld & Patel, 2016). Studies of individuals with developmental 
conditions such as congenital anomalies (Geng et al., 2014; Stark et al., 2015), 
intellectual disability/developmental delay (ID/DD) (Girirajan et al., 2011; Cooper et al., 
2011; Di Grigorio et al., 2017) and ASD (Pinto et al., 2010; Sanders et al., 2011; Leppa et 
al., 2016) have all supported some role for CNVs in a subset of individuals with these 
conditions. However, previously published studies investigating the association between 
CNV burden and dysmorphism specifically are harder to find.  Dysmorphism is 
challenging to quantify, and no specific tool has been accepted as a gold standard.  
Further, it is considered an accompanying feature to other outcomes of primary clinical 
relevance. Published studies including dysmorphism often consider it only as a 
supplementary component of the phenotype, or a marker of increased severity, rather than 
as a primary phenotype.  
 
Our results revealed decreased burden among children with dysmorphism in SEED 1. 
While several other studies have seen associations with length of CNVs burden in 
dysmorphic children, particularly for large CNVs (Girirajan et al., 2011), the effect 
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direction has been towards greater length, not less. Previous studies also found increased 
burden of large CNVs in individuals with intellectual disability (ID) with multiple 
congenital anomalies (MCA) compared to ID alone, and Cooper et al. (2011) reported a 
higher prevalence of large CNVs (>400kb) in more severe developmental phenotypes 
associated with MCA. Individuals with ID, MCA and dysmorphism have been reported 
to have an increased frequency of de novo CNVs, particularly those with more severe 
phenotypes such as abnormal head circumference (Vulto-van Silfhout et al., 2013).  Our 
results are not consistent with these findings. One possible reason for our finding of 
smaller mean combined length of CNVs in dysmorphic children may be because we 
excluded children with the more severe phenotypes of congenital abnormalities and 
recognized genetic syndromes. Indeed, when they are included, our results are consistent 
with previous literature. In that literature, children with chromosomal abnormalities and 
genetic syndromes were included (Cooper et al., 2011; Girirajan et al., 2011; Qiao et al., 
2014). Thus, our study is asking a different question – what is the CNV burden 
comparison among those without any reported congenital abnormalities, major or minor?  
Another possible explanation for this finding of reduced CNV burden is that children 
categorized as ‘dysmorphic’ in SEED may represent a sub-group with a high incidence of 
single-gene insults or undiagnosed syndromes, or potentially those who have had 
teratogenic exposure in-utero that selectively affected a specific gene or region, but not 
aggregate measures of CNVs burden.  Alternatively, the group of children classified as 
‘non-dysmorphic’, because they did not have enough features across the multitude 
considered to be declared dysmorphic, may nonetheless have isolated dysmorphic 
features corresponding to otherwise undiagnosed genetic burden. If this were a generally 
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large proportion, it could explain our counter-intuitive results.  The observation that this 
reduced burden among dysmorphic children is strong in ASD cases would be consistent 
with these latter two hypotheses, if the single-gene insults among non-dysmorphic 
children or the isolated physical abnormalities among the non-dysmorphic children still 
contributed to ASD risk. Full genome sequencing, or even exome sequencing, could help 
to resolve this, but such data are not yet available for these SEED samples.  
 
Reduced CNV burden is rarely reported in neurodevelopmental conditions, which has 
generally been associated with increased CNV burden. Grozeva et al. (2013) reported that 
in adult patients with bipolar disorder, the rate of very large (>1Mb) and rare CNVs were 
significantly lower compared to controls, which they postulate may have resulted from 
increased rates of CNVs in some other phenotype in the controls not accounted for, such 
as diabetes. It is possible there were other phenotypes not accounted for in our analyses. 
Another interesting finding from our analysis is that comparing dysmorphic to non-
dysmorphic children, there was reduced genome affected by CNVs driven by large CNV 
duplications. CNV burden involving duplications is not as commonly reported as CNV 
burden involving deletions, although duplications are more difficult to estimate from SNP 
data.  One a plausible mechanism for how variability in CNV duplications could affect 
gene expression is if specific regulatory mechanisms (such as STOP codons) were 
duplicated in the CNV. A study by Martin et al. (2014) found total CNV rare duplications 
showed a negative correlation with positive symptoms of schizophrenia, and 
hypothesized this indicated CNV duplication burden may have a small protective effect 
against symptoms of schizophrenia. Extrapolating their results to our study, in our 
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analysis large CNV duplications appear to have a negative association with risk of 
dysmorphism in children, and CNV burden for large duplications may potentially have a 
small protective effect against risk of dysmorphology. Our results, like Martin et al.’s, did 
not survive correction for multiple testing. Our study population was small, and this may 
have impacted statistical power in our analysis. 
 
Our study sample was obtained from SEED 1, a case-control study of ASD, and thus was 
not truly representative of a population-based sample. This is important to consider in 
when interpreting our results of risk of dysmorphisms. Our sample was made up 54.7% 
children with ASD, who represent 75.6% of children found to be dysmorphic. This was 
by design, given our interest in dysmorphism as an ASD sub-phenotype, but does limit 
generalizability to dysmorphism per se. To improve generalizability of future studies, it 
would be of interest to perform the analysis in another sample that is more representative 
of the general population when testing for any role of CNV burden on risk of 
dysmorphology. 
 
We performed analysis restricted to self-identified race to manage potential confounding 
due to race/ethnic group. The majority of study participants were Non-Hispanic Whites, 
with only 6 (6.8%) of Non-Hispanic Blacks and 7 (6.8%) of Hispanics classified as 
dysmorphic. Previous studies have assessed the impact of race in general on CNV 
burden, with different populations harboring different average number of CNVs per 
sample, and admixed populations having a higher number of CNVs (Jakobsson et al., 
2008). Analysis on larger and more representative samples would provide clearer 
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understanding of the role of race in affecting CNV burden for dysmorphology. Of 
interest, although we used self-reported race instead of genetic ancestry for our analysis, 
correspondence between self-reported race and genetically predicted ancestry via 
Principal Components analysis is high (Ladd-Acosta, personal communication). 
 
Our results were also most prominent in boys. Unpublished analysis by the SEED 
Dysmorphology group on this same analytic population found (after excluding children 
with developmental delay (DD) from the SEED analyses), there were little differences in 
dysmorphism prevalence comparing males to females (Shapira, personal communication, 
SEED Dysmorphology Group unpublished manuscript). Our analysis showed 
dysmorphic males appear to drive the association between ASD and CNV burden, 
although these results need to be considered with caution as there were significantly 
fewer females in the study overall and only 7 (4.8%) of all female children assessed were 
categorized as dysmorphic. 
 
There were very few overlaps observed when assessing CNV association with 
dysmorphism in genes previously reported to be associated with ASD. These individual 
CNVs are rare, and it is possible that our study population was not large enough to detect 
these overlapping CNVs. As Kaminsky et al. (2011) observed, obtaining adequate 
evidence for the functional role of rare CNVs in disease causation requires very large 





Study Limitations and Strengths 
 
Our cross-sectional design, culled from a national case-control study may not be fully 
representative of the United States in terms of racial make-up (Schendel et al., 2012). 
Although the study recruitment included a population-based approach, ascertainment bias 
for selection into the study is still possible with families self-selecting for participation. In 
terms of limitations associated with the dysmorphology outcome, the young age of the 
children recruited (2-5 years) restricts the generalizability of our results to only major or 
minor dysmorphisms identified in early childhood, and we cannot consider 
morphological changes with age. Also, despite various quality control measures instituted 
to maintain the quality of the photographs used for dysmorphology assessment, there was 
variability in missing data for the dysmorphology data gathered attributed to poor photo 
quality in one recruitment site. However, unpublished data from the SEED study 
performed by the SEED Dysmorphology subgroup found the missing data had no 
significant effect on the observed results following sensitivity analyses and multiple 
imputations.  
 
An important limitation already discussed is undiagnosed chromosomal abnormalities 
and recognized genetic syndromes in our sample. The information we did have on such 
conditions was based solely on parental report, and no new genetic testing was available. 
Thus, it is likely that additional chromosomal abnormalities or genetic syndromes are 





We were also not able to stratify analyses on de novo versus inherited CNVs, yet de novo 
CNVs have been implicated in previous literature (Vulto-van Silfhout et al., 2013). 
Unfortunately, we did not have parental genotyping information and hence are not able to 
determine the impact of de novo CNVs. In addition, rare CNVs have also been associated 
with congenital malformations (Serra-Juhe et al., 2012). Although the SEED Study is one 
of the largest population-based samples of ASD in the US, for analysis of dysmorphism, 
we only had a subset of the full SEED 1 sample, and are underpowered for detecting rare 
CNVs.  
 
This study also has a number of strengths. The SEED Study is one of the largest ASD 
studies with population-based ascertainment. Previous studies have used clinic-based 
samples, and have often been smaller. Although this study was not fully representative of 
the United States in terms of racial/ethnic make-up, it included three major groups by 
design  (Schendel et al., 2012), and allowed for the potential effects of race to be 
considered in the analyses. Finally, the SEED Study involves varied geographical 
locations across the United States.  A major strength is the uniform developmental 
assessment of all study participants including research-reliable ASD classification, as 
well as a customized standardized dysmorphology assessment tool with quality assurance 
across sites.  Previous dysmorphology classification protocols were based on clinic 
patient populations, and on individuals who were primarily white (Miles et al. 2005; 




In summary, we found overall CNV burden, specifically overall large duplication CNV 
burden, is lower among children with dysmorphology in SEED, particularly among 
SEED ASD children. Although these results were not anticipated, and the estimated 
associations were no longer significant after correcting for multiple testing, we think our 
observations are worthy of further investigation. Autistic sub-phenotypes like 
dysmorphology may help parse out risk factors, particularly genetic risk factors leading 
to subsets of ASD.  Due to the relatively small sample sizes, these results still need to be 
considered as preliminary, and future work replicating these findings would be needed to 
further evaluate genotype-phenotype associations in ASD, a complex and heterogeneous 
disorder. In addition, genetic analyses incorporating full genome sequencing or at least  
whole exome sequencing on these subjects should enable improved detection of 
underlying genetic abnormalities. This information would have helped to more 
definitively exclude children with undiagnosed chromosomal abnormalities from our 
study population.  
 
The relevance of CNV burden in children with ASD, particularly those with 
dysmorphism or multiple congenital anomalies, is supported by the consensus statement 
issued by the American Academy of Pediatrics recommending the use of microarray 
analysis in these children, which has a much higher yield than those without (Miller et al., 
2010; Shen et al., 2010). Genotype-phenotype studies is an important area for research 
that could potentially lead to better understanding of the biologic basis of disease and the 
development of individualized management. Discovering the genetic basis of any 
condition, particularly in ASD with dysmorphism, will not only allow earlier screening 
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for and intervention of both ASD and any co-occurring medical conditions, and possibly 
also improved understanding of prognosis.  
 
This study was given approval by the IRB Committee of Johns Hopkins School of Public 
Health. Informed consent was obtained from all caregivers before clinical assessment as 
part of the SEED Study protocol. Diagnoses and assessments were performed at the six 
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Table 1: Characteristics of Children Classified as Dysmorphic and Not Dysmorphic in the 
SEED 1 Study 
 
Baseline Characteristics 
Total N= 488 
Dysmorphic 
N= 45 (9.2%) 
Not Dysmorphic 
N= 443 (90.8%) 
 
p-value 
Diagnosis ASD 34 (75.6%) 233 (52.6%) <0.001 
 Possible Case 3 (6.7%) 6 (1.4%) 
POP 8 (17.8%) 204 (46.0%) 
Sex Male 38 (84.4%) 307 (69.3%) 0.033 
 Female 7 (15.6%) 136 (30.7%) 
Race Non-Hispanic White 32 (71.1%) 265 (59.8%) 0.335 
 Non-Hispanic Black 6 (13.3%) 82 (18.5%) 




Table 2: CNV Burden for Counts and Lengths in Dysmorphic vs. Non-Dysmorphic 
Children 
 




N (D)= 45 










Overall 0.934 0.381 0.766 0.022 
Overall Genic  0.933 0.425 0.740 0.034 
Overall SFARI 1.017 0.911 1.014 0.935 
All Large CNVs 
Overall large 0.640 0.052 0.491 0.015 
Overall large Genic  0.654 0.083 0.519 0.029 
Overall large SFARI 1.737 0.471 1.080 0.909 
Deletions 
Overall Deletion 1.023 0.821 0.967 0.755 
Deletion Genic  1.080 0.384 1.046 0.709 
Deletion SFARI 1.113 0.618 1.029 0.904 
Duplications 
Overall Dup. 0.834 0.035 0.655 0.011 
Dup. Genic  0.766 0.035 0.583 0.008 
Dup. SFARI 0.883 0.574 0.989 0.971 
Bolded: significant t-test p<0.05 
D= Dysmorphic 









Table 3: CNV Burden for Lengths in Dysmorphic vs. Non-Dysmorphic Children 
stratified by Race/Ethnicity 
 
 Average CNV 































Overall 0.766 0.022 0.825 0.210 0.557 0.027 0.757 0.129 
Overall Genic  0.740 0.034 0.842 0.351 0.502 0.034 0.588 0.026 




Overall large 0.491 0.015 0.584 0.150 0.132 0.008 0.617 0.456 
Overall large 
Genic  
0.519 0.029 0.616 0.207 0.150 0.016 0.785 0.727 
Overall large 
SFARI 
1.080 0.909 0.311 0.174 -- -- 22.29 0.189 
Del. Overall 
Deletion 
0.967 0.755 1.014 0.909 1.161 0.640 0.635 0.012 
Deletion Genic  1.046 0.709 1.153 0.346 1.018 0.947 0.630 0.033 
Deletion SFARI 1.029 0.904 0.847 0.552 2.334 0.181 0.609 0.382 
Dup. Overall Dup. 0.655 0.011 0.721 0.134 0.313 0.002 0.863 0.666 
Dup. Genic  0.583 0.008 0.677 0.148 0.337 0.018 0.552 0.159 
Dup. SFARI 0.989 0.971 0.775 0.503 0.520 0.310 2.520 0.116 
Sample 
size 















Bolded: t-test p<0.05 
D: Dysmorphic  ND: Not Dysmorphic 





Table 4: CNV Burden for CNV Lengths in Dysmorphic vs. Non-Dysmorphic Children 
Stratified by ASD Status 
 
 Average CNV 
























0.766 0.022 0.693 0.027 0.839 0.402 
Overall Genic  
0.740 0.034 0.676 0.055 0.749 0.224 
Overall SFARI 
1.014 0.935 1.039 0.855 1.097 0.820 
All Large 
CNVs 
Overall large 0.491 0.015 0.359 0.012 0.752 0.698 
Overall large Genic  0.519 0.029 0.404 0.031 0.638 0.453 
Overall large 
SFARI 
1.080 0.909 1.147 0.849 -- -- 
Deletions 
Overall Deletion 0.967 0.755 1.014 0.911 0.752 0.059 
Deletion Genic  1.046 0.709 1.149 0.336 0.664 0.079 
Deletion SFARI 1.029 0.904 0.928 0.787 1.509 0.518 
Dup. Overall Dup. 0.655 0.011 0.530 0.009 0.893 0.735 
Dup. Genic  0.583 0.008 0.469 0.012 0.801 0.557 
















Bolded: t-test p<0.05 
ASD: Children with Autistic Spectrum Disorder   




Table 5: CNV Burden in Dysmorphic vs. Non-Dysmorphic Children Stratified by Sex 
 
























All CNVs Overall 0.766 0.022 0.771 0.047 0.787 0.253 
Overall Genic  0.740 0.034 0.768 0.097 0.707 0.193 
Overall SFARI 1.014 0.935 0.985 0.945 1.140 0.643 
All Large 
CNVs 
Overall large 0.491 0.015 0.496 0.028 0.540 0.277 
Overall large 
Genic  
0.519 0.029 0.524 0.054 0.605 0.358 
Overall large 
SFARI 
1.080 0.909 1.145 0.849 0 0.093 
Deletions Overall 
Deletion 
0.967 0.755 1.000 0.999 0.825 0.356 
Deletion Genic  1.046 0.709 1.094 0.514 0.874 0.579 
Deletion 
SFARI 
1.029 0.904 0.959 0.885 1.402 0.401 
Dup. Overall Dup. 0.655 0.011 0.643 0.014 0.767 0.453 
Dup. Genic  0.583 0.008 0.595 0.019 0.628 0.310 

















Bolded: t-test p<0.05 
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Table 6: CNV Associations with Dysmorphism at ASD CNV Candidate regions 
Region 
All and large CNVs 
Deletions and large 
deletions CNVs 
Duplications and large 
duplications CNVs 






























1q21.1A 0 (0%) 11 (2.5%) 0.61 0 (0%) 3 (0.6%) 1.00 0 (0%) 8 (1.8%) 1.00 
1q21.1L 0 (0%) 4 (0.9%) 1.00 0 (0%) 0 (0%) -- 0 (0%) 4 (0.9%) 1.00 
3q29A 0 (0%) 4 (0.9%) 1.00 0 (0%) 0 (0%) -- 0 (0%) 4 (0.9%) 1.00 
3q29L 0 (0%) 0 (0%) -- 0 (0%) 0 (0%) -- 0 (0%) 0 (0%) -- 
7q11.23A 1 (2.2%) 9 (1.9%) 1.00 0 (0%) 2 (0.4%) 1.00 1 (2.2%) 7 (1.5%) 0.54 
7q11.23L 0 (0%) 0 (0%) -- 0 (0%) 0 (0%) -- 0 (0%) 0 (0%) -- 
15q11.2A 4 (8.9%) 58 (13.0%) 0.63 2 (4.4%) 35 (7.9%) 0.56 2 (4.4%) 23 (5.2%) 1.00 
15q11.2L 0 (0%) 2 (0.4%) 1.00 0 (0%) 0 (0%) -- 0 (0%) 2 (0.4%) 1.00 
15q11.2.13.1A 4 (8.9%) 55 (12.4%) 0.80 2 (4.4%) 33 (7.4%) 0.75 2 (4.4%) 22 (4.9%) 1.00 
15q11.2.13.1L 0 (0%) 0 (0%) -- 0 (0%) 0 (0%) -- 0 (0%) 0 (0%) -- 
15q13.3A 1 (2.2%) 7 (1.5%) 0.54 0 (0%) 0 (0%) -- 1 (2.2%) 7 (1.5%) 0.54 
15q13.3L 1 (2.2%) 4 (0.9%) 0.38 0 (0%) 0 (0%) -- 1 (2.2%) 4 (0.9%) 0.38 
16p11.2A 0 (0%) 2 (0.4%) 1.00 0 (0%) 1 (0.2%) 1.00 0 (0%) 1 (0.2%) 1.00 
16p11.2L 0 (0%) 2 (0.4%) 1.00 0 (0%) 1 (0.2%) 1.00 0 (0%) 1 (0.2%) 1.00 
16p13.11A 4 (8.9%) 55 (12.4%) 0.63 1 (2.2%) 10 (2.2%) 1.00 3 (6.7%) 45 (10.1%) 0.60 
16p13.11L 0 (0%) 2 (0.4%) 1.00 0 (0%) 0 (0%) -- 0 (0%) 2 (0.2%) 1.00 
17q12A 8 (17.8%) 65 (14.6%) 0.51 1 (2.2%) 4 (0.9%) 0.38 7 (15.5%) 61 (13.7%) 0.65 
17q12L 0 (0%) 2 (0.4%) 1.00 0 (0%) 0 (0%) -- 0 (0%) 2 (0.2%) 1.00 
22q11.21A 2 (4.4%) 18 (4.0%) 0.53 1 (2.2%) 2 (0.4%) 0.25 1 (2.2%) 16 (3.6%) 1.00 





































































S. Table I: CNV Count/Rate by Dysmorphic Status  






Rate, N= 45 
Non-
Dysmorphic 




Overall 10,394 20.022 21.428 0.934 0.381 
Overall Genic  5,082 9.777 10.478 0.933 0.425 
Overall SFARI 
 
619 1.288 1.266 1.017 0.911 
Overall large 360 0.488 0.763 0.640 0.052 
Overall large Genic  305 0.422 0.645 0.654 0.083 
Overall large SFARI 
 
20 0.066 0.038 1.737 0.471 
Deletion Total 5,545 11.600 11.338 1.023 0.821 
Deletion Genic  2,730 6.000 5.553 1.080 0.384 
Deletion SFARI 
 
364 0.822 0.738 1.113 0.618 
Deletions large 50 0.066 0.106 0.628 0.337 
Deletions large Genic 39 0.066 0.081 0.820 0.717 
Deletions large SFARI 
 
5 0 0.011 0 -- 
Overall Duplication 4849 8.422 10.090 0.834 0.035 
Duplication Genic  2352 3.777 4.925 0.766 0.035 
Duplication SFARI 
 
255 0.466 0.528 0.883 0.574 
Duplication large 310 0.422 0.656 0.642 0.083 




15 0.066 0.027 2.461 0.311 






S. Table II: Average CNV Length by Dysmorphic Status 
ALL Ave. CNV length (kb) 
CNV characteristics 
N=488 
Length in D 
n=45 





Overall 2,018.41 2,632.16 0.76 0.02 
Overall Genic  672.15 907.90 0.74 0.03 
Overall SFARI 
 
145.25 143.20 1.01 0.93 
Overall large 430.1 875.19 0.49 0.01 
Overall large Genic 









     
Deletion Total 908.19 938.60 0.96 0.75 
Deletion Genic  321.77 307.57 1.04 0.71 
Deletion SFARI 92.42 89.82 1.03 0.90 
Deletion large 54.21 98.12 0.55 0.22 
Deletion large Genic 36.12 40.94 0.88 0.83 
Deletion large SFARI 0 2.53 0 -- 
Overall Duplication 1,110.22 1,693.55 0.65 0.01 
Duplication Genic  350.38 600.32 0.58 0.01 
Duplication SFARI 
 
52.82 53.37 0.99 0.97 
Duplication large 375.91 777.07 0.48 0.02 
Duplication large Genic 









     
Bolded: t-test p<0.05 
D= Dysmorphic   
ND= Not Dysmorphic 
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S. Table III: CNV Burden for Lengths in Dysmorphic vs. Non-dysmorphic: Analysis 
With DD Children (+DD) and Without (-DD) 
 
N (+DD)= 509 
N (DD)=21 
Average CNV 
Length (kb) -DD 
Average CNV 
Length (kb) +DD 
N (D): 45 





All CNVs Overall 0.766 0.022 0.778 0.029 
Overall Genic  0.740 0.034 0.755 0.046 
Overall SFARI 1.014 0.935 1.027 0.870 
All Large CNVs Overall large 0.491 0.015 0.509 0.020 
Overall large Genic  0.519 0.029 0.539 0.039 
Overall large SFARI 1.080 0.909 1.119 0.869 
Deletions Overall Deletion 0.967 0.755 0.970 0.773 
Deletion Genic  1.046 0.709 1.053 0.665 
Deletion SFARI 1.029 0.904 1.042 0.860 
Duplications Duplication Overall 0.655 0.011 0.670 0.015 
Duplication Genic  0.583 0.008 0.599 0.012 
Duplication SFARI 0.989 0.971 1.002 0.993 
Bolded: t-test p<0.05 
D= Dysmorphic   
ND= Not Dysmorphic  
DD= Developmental delay 
+DD= Analysis With DD Children (+DD) 
-DD= Analysis Without DD Children (-DD) 
Note:  
CNV burden for lengths in dysmorphic vs. non-dysmorphic without DD children (-





S. Table IV: Proportion of Children with Congenital Abnormalities and Non-Genetic 







 = 541 























DD= Developmental delay 
N(All)
#
= 541 includes all children with chromosomal abnormalities, non-chromosomal 





S. Table V: CNV Burden and CNV Lengths in Dysmorphic Children vs. Not Dysmorphic 
Children: Analyses without (-CAGS) and with (+CAGS) Children with Chromosomal 
Abnormality and Non-Chromosomal Genetic Syndromes  
 
 Average CNV 











All CNVs Overall 0.766 0.022 1.722 0.125 
Overall Genic  0.740 0.034 1.716 0.150 
Overall SFARI 1.014 0.935 1.499 0.102 
All Large CNVs Overall large 0.491 0.015 3.022 0.103 
Overall large 
Genic  
0.519 0.029 2.756 0.122 
Overall large 
SFARI 
1.080 0.909 7.154 0.041 
Deletions Overall Deletion 0.967 0.755 1.329 0.228 
Deletion Genic  1.046 0.709 1.286 0.234 
Deletion SFARI 1.029 0.904 1.300 0.314 
Duplications Duplic. Overall 0.655 0.011 1.934 0.159 
Duplic. Genic  0.583 0.008 1.932 0.183 
Duplic. SFARI 0.989 0.971 1.822 0.106 






Bolded: t-test p<0.05 
CAGS= Chromosomal Abnormality and Non-Chromosomal Genetic Syndromes 
D= Dysmorphic 





S. Table VI: Overall CNV Burden for Length in Dysmorphic vs. Non-dysmorphic:  
Analyses Comparing Combinations of DD and CAGS Children  
 
Analysis of Overall CNV Burden 
for Length for D vs. ND using 
combinations 
 
a. Average CNV 
Length (kb) 




b. Average CNV 
Length (kb)  
D vs. ND, 
+DD, -CAGS 
(N=509) 
c. Average CNV 
Length (kb) 




















0.766 0.022 0.779 0.029 1.722 0.125 
Overall Genic  
0.740 0.034 0.755 0.046 1.716 0.150 
Overall SFARI 
1.014 0.935 1.027 0.876 1.499 0.102 
 
Analysis of Overall CNV Burden 
for Length using different 
combinations 
 
d. Average CNV 
Length (kb) 
D vs. ND, +DD, 
+CAGS 
(N=541) 
e. Average CNV 
Length (kb) 
Dysmorphic 
with CAGS vs. 
ND (no CAGS) 
+DD  
(N=481) 
f. Average CNV 
Length (kb) 
Non-dysmorphic 
with CAGS vs. 




















2.068 0.041 5.837 0.009 2.513 0.215 
Overall Genic  
2.063 0.052 5.886 0.013 2.532 0.192 
Overall SFARI 
1.687 0.036 3.631 0.016 2.037 0.118 
Bolded: t-test p<0.05 
D= Dysmorphic ND= Not Dysmorphic DD= Developmental delay 
+DD= Analysis With DD Children (+DD) -DD= Analysis Without DD Children (-DD) 
CAGS= Chromosomal Abnormality and Non-Chromosomal Genetic Syndromes 
+CAGS= Analysis With CAG Children (+CAG) 
-CAGS= Analysis Without CAG Children (-CAG) 
Analysis ‘a’ is the same analysis as for Table 2 




S. Table VII: List of Chromosomal Abnormalities and Non-Chromosomal Genetic 





47, XXY Klinefelter Syndrome 15q11.2q13 duplication 
Mosaic Down Syndrome 1q44 deletion 
Trisomy 21 (Down Syndrome) Trisomy 21 (Down Syndrome) 
 Chromosome 17p13.2 
 Deletion 15q13.2q1 
 Mosaic 45X/46XY 
 Partial Monosomy 21 
 Unbalanced Translocation 
 Williams Syndrome 
 
 
Non-Chromosomal Genetic Syndromes 
POP ASD 
Glucose-6-Phosphate deficiency Alopecia 
Hypothyroidism Cytomegalovirus (CMV) 
Neurofibromatosis Ehlers-Danlos Syndrome 
Retinoblastoma Fragile X Syndrome 
Rheumatoid Arthritis Hypothyroidism 
 Mitochondrial Disorders 
 Menke Syndrome 
 Proteus Syndrome 
 Rubinstein-Taybi Syndrome 
 Septo-optic Dysplasia 
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Autism Spectrum Disorder (ASD) is highly heterogeneous, with strong evidence of some 
genetic control. Use of endophenotypes, or sub-grouping of cases, may improve our 
ability to detect genes related to specific sub-groups of ASD. Abnormal growth for sex 
and age, including large or small head circumference (macro- or microcephaly), 
abnormally tall or short stature, overweight or underweight, or high/low BMI, is also 
highly heritable, and may be a related feature among some children with ASD.  
Investigating genetic susceptibilities for growth abnormalities and as a sub-phenotype of 
ASD may help identify genetic factors related to both. Copy number variants (CNVs) 
have been identified as a significant contributor to several neurodevelopmental conditions 
(including ASD) and to growth. Here we estimate burden of CNVs comparing children 
with abnormal to normal growth in an ASD case-control study.  We also examined 
whether particular CNVs in regions previously associated with ASD are also associated 
with abnormal growth in this ASD case-control study.  
 
Methods:  
Participants included 840 children aged 2-5 years (born between 2003 and 2006) from six 
sites across the United States enrolled into Phase 1 of the Study to Explore Early 
Development (SEED 1).  This analysis includes ASD cases and controls who had 
genome-wide genotype data from the Illumina Omni1 array and also had anthropometric 
measurements to determine physical growth, standardized to age and sex. CNVs were 
called using the PennCNV algorithm. CNV burden over all autosomes was estimated as 
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counts of CNVs per person, as well as the cumulative length of the genome affected by 
CNVs per person.  Burden was compared between SEED 1 children classified with a 
growth abnormality (large: >90
th
 percentile or small: <10
th
 percentile) and children in the 
normal range, for head circumference (HC), height, weight, and BMI. CNV types, 
duplications versus deletions, and CNV subsets were also considered: large CNVs (>400 
kb), only those overlapping known genes, and only those overlapping previously 
implicated ASD genes. All analyses were stratified by sex. Associations between 
candidate CNV regions previously reported to be associated with ASD and growth 
abnormalities were tested separately to assess for possible common genetic links between 
ASD and growth abnormalities. 
 
Results:  
The burden ratio for tall versus normal stature children was <1 for both CNV counts and 
lengths (Tall/Normcounts = 0.909, p = 0.029; Tall/Normlength = 0.833, p = 0.033), although 
this was not statistically significant after Bonferroni correction for multiple tests.  Similar 
patterns were observed when restricting to genic CNVs and CNVs encompassing 
recognized genes associated with ASD, as identified by SFARI (T/Ngenic = 0.83, p=0.06; 
T/NSFARI = 0.79, p=0.044), and among deletions overlapping SFARI genes (T/NSFARI = 
0.63, p=0.005). Results for tall stature among girls were similar, with burden ratios < 1. 
Deletions, and genic deletions, showed nominally statistically significant differences 
(T/Sdel = 0.76, p = 0.010; T/Sdelgenic = 0.78, p = 0.037).  Some signals were seen for short 
stature, although less of the genome was affected by deletion CNVs (S/N=0.78, p=0.008) 
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and large deletion CNVs (S/N=0.23, p=0.001), when both were restricted to genic 
regions.  
 
For HC, children with macrocephaly had less their genomes affected when considering 
CNVs that overlapped with SFARI regions: large SFARI CNVs (Mac/N=0.21, p=0.032), 
duplication SFARI CNVs (Mac/N=0.58, p=0.049) and large duplication SFARI CNVs 
(Mac/N=0.01, p=0.008).  Decreased CNV burden with macrocephaly was consistent in 
boys, although the estimated effect sizes were in the opposite direction for macrocephaly 
and microcephaly in girls, although sex-stratified results for HC were not statistically 
significant. 
 
Compared to children with normal BMI, children with high BMI had less of their genome 
affected by large duplication SFARI CNVs (H/N=0.21, p=0.049).  Girls, specifically, 
showed less CNV burden from deletions with high BMI (H/N ranged from 0.1 to 0.86 
when analyzing deletion CNV, with corresponding p-values ranging from 0.001 to 0.18), 
and also showed some evidence for decreased CNV burden among overweight girls, 
particularly for deletion CNVs.    
 
CNVs, particularly duplications, in the ASD candidate region 1q21.1 showed positive 
association with macrocephaly, especially in girls. ASD candidate region 15q11.2 was 
positively associated with short stature, again only in girls. Finally, 15q11.2 and 
15q11.2.13.1 showed negative associations with microcephaly, among both boys and 
girls, but only achieved nominal statistical significance among boys. None of these 
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remained significant after correction for multiple testing. No other regions or growth 




We observed nominally significant decreased CNV burden among children with tall 
stature in the SEED 1 sample, consistently for boys and girls. However, we also observed 
marked differences between sexes for overweight and high BMI, where only girls 
showed evidence for differential (decreased) CNV burden. Macrocephaly may also be 
associated with decreased CNV burden in these samples, although estimated effects were 
in the same direction for boys, but in the opposing direction among girls. Associations 
with specific CNVs in previously identified ASD candidate regions also showed sex-
specific results. Our study shows CNVs may contribute to genetic risk of abnormal 
growth, and there appears to be some potential for common pathways involving CNVs 
for ASD and abnormal physical growth differing by sex. Establishing potential genotype-
phenotype associations between ASD and growth abnormalities may improve risk factor 
identification in the subset of ASD individuals with growth abnormalities. 
 
Key Terms: macrocephaly, microcephaly, tall stature, short stature, overweight, 





Autism spectrum disorder (ASD) is a complex and highly heterogeneous 
neurodevelopmental disorder with multiple subtypes, and is frequently found with co-
morbid conditions ranging from psychiatric to physical abnormalities. Although ASD is 
understood to have both genetic and environmental risk factors, no single genetic 
etiology has been identified and it is likely quite heterogeneous
 
(Miles et al., 2011). 
Clustering all ASD cases based solely on diagnostic classification may combine many 
distinct genetically-driven sub-phenotypes, and thus undermine efforts to determine true 
causal factors. Better understanding of observable autism sub-phenotypes may improve 
identification of genetic risk factors, as well as allow better prognostication, and 
potentially allow earlier, targeted interventions.  Abnormal growth, particularly in early 
childhood, has been associated with ASD and is known to be heritable. Consideration of 
abnormal growth, in the context of ASD, may be a useful sub-phenotype that could help 
identify a sub-group of ASD associated with genetic etiologies. In this study, we aim to 
investigate association between copy number variant (CNV) burden and abnormalities of 
physical growth in ASD and compare cases to typically developing (control) children. 
We also tested for association between growth abnormalities and ASD by analyzing for 
association between CNVs previously implicated with ASD and growth abnormalities. 
By investigating growth abnormality as a sub-phenotype of ASD, we may be able to 
parse out distinct genetic etiologies.  
 
ASD is known to have multiple etiologies including genetic, environmental and 
epigenetic risk factors. Although all affected individuals share the core features of ASD, 
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ASD sub-phenotypes are frequently observed. These co-occurring conditions in ASD 
include medical, psychiatric, and behavioral conditions, e.g. cognitive impairment, 
gastrointestinal disturbance, and abnormalities of physical growth. As a complex disease 
with high heterogeneity, lumping all autism cases based strictly on diagnostic 
classification may hamper our ability to identify autism risk factors. Approaches utilizing 
sub-phenotypes of ASD may permit delineation of distinct genetic sub-groups. The over-
arching objective of this study is to investigate growth abnormalities that may identify a 
sub-phenotype of ASD, and test for potential associations with genetic risk factors.  
 
The exact etiologies and pathways leading to ASD are not well established, with both 
genetic and environmental risk factors reported, in addition to likely interactions between 
genes and between genes and the environment (Geschwind, 2011).  Although some 
chromosomal abnormalities and recognized syndromes have been associated with ASD 
(Hall, Lightbody & Reiss, 2008; DiGuiseppi et al., 2010), the majority of ASD children 
do not have any known syndrome. Genetic discovery in ASD has found associations with 
both inherited and de novo (newly occurring in a child resulting from a germline change 
in a parent) mutations (Robinson et al., 2015). These include common and rare single 
nucleotide variants (SNVs) as well as copy number variants (CNVs). Some of the most 
consistent ASD genetic findings to date are CNVs (Robinson et al., 2014).  Studies of 
CNVs in ASD have shown associations between specific CNVs and risk of ASD, as well 
as an overall association between the genome-wide CNV burden a person carries and risk 
of ASD. In terms of specific CNVs, studies have implicated a number of genes and 
chromosomal regions, including most prominently regions on chromosomes 7q11.23, 
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15q11-13, 16p11.2, and 22q11.2 (Pinto et al., 2010; Sanders et al., 2011), loci identified 
from the Simon Simplex Collection such as 1q21.1 and 3q29 (Pinto et al., 2010; Picinelli 
et al., 2016), as well as genomic regions encompassing the SHANK2 (Pinto et al., 2010), 
SHANK3 (Gauthier et al., 2009), NRXN1 (Bucan et al., 2009), CNTN4 (Roohi et al., 
2009) and CNTNAP2 (Bakkaloglu et al., 2008) genes. These genes and regions are not 
exclusively associated with ASD, but are associated with different neuropsychiatric 
phenotypes such as schizophrenia or fall under the more general term 
‘neurodevelopmental conditions’ (Malhotra and Sebat, 2012). In our analysis, we tested 
for the association between ten regions previously reported to be associated with ASD, 
including some of the regions mentioned above, with growth abnormalities in SEED 
children.  Increased genome-wide CNV burden, or more precisely, autosome-wide CNV 
burden (i.e. the sex chromosomes X and Y were excluded), has been consistently shown 
to be associated with ASD using several measures. Pinto et al. (2010) reported a higher 
count of rare CNVs among ASD cases, as well as increased deletion CNVs. Others have 
shown a greater length of the genome affected by CNVs, as well as greater counts, 
among ASD cases, especially for deletions and for rare CNVs (Vulto-van Silfhout et al., 
2013). This has been shown multiple times, with some suggestion that rare de novo 
CNVs are drive evidence of association (Sanders et al., 2011) and that both deletion and 
duplications are relevant (Luo et al., 2012).  
 
Various studies indicate the proportion of children diagnosed with ASD who have 
physical signs of growth anomalies range between 5-30% (Angkustsiri et al., 2011; 
Ozgen et al., 2010; Weir et al., 2006; Miles & Hillman, 2000; Miles et al., 2005; Ozgen et 
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al., 2011; Ozgen et al., 2013). Any child with dysmorphology, abnormal physical 
features, has a higher likelihood of carrying detectable genetic aberrations. Abnormal 
growth is a specific set of dysmorphic features, typically including abnormal head 
circumference, height, or weight for a child’s sex and age. Children with ASD have been 
recognized to have abnormalities in several modalities of physical growth. Amongst these 
abnormalities is accelerated overgrowth of the head early in development, leading to 
macrocephaly in young children with ASD
 
(Lainhart et al., 1997; Miles & Hillman, 2000; 
Courchesne et al., 2001; Redcay & Courchesne, 2005; Courchesne et al., 2003). 
Approximately 15-20% of children with autism have been reported to have macrocephaly 
in various studies, with some variability (Fombonne et al., 1999; Dementieva et al., 2005; 
Lainhart et al., 2006). The child’s age influences when growth abnormalities are seen. 
Macrocephaly is often not observed at birth, but by the first year of life it begins to be 
more frequently recognized (Courchesne, Carper & Akshoomoff, 2003; Hazlett et al., 
2005, Fukumoto et al., 2008, Mraz et al., 2007). 
 
In addition to abnormal head growth, children with ASD have also been reported to have 
abnormal growth for both weight and height. Recent studies on  
ASD children show an association between autism and obesity or being overweight 
(Curtin et al., 2005; Curtin et al., 2010; Rimmer et al., 2010; Evans et al., 2012; Broder-
Fingert, 2014; Zuckerman & Fombonne, 2015; Must et al., 2016). ASD children have 
also been reported to have tall stature and generalized overgrowth, especially in boys 




Multiple factors likely affect different aspects of physical growth. Growth in children is 
influenced by genetic, environmental and gene-by-environment interactions. Taking 
stature as an example, height is a complex phenotype influenced by many genetic factors 
(Marouli et al., 2017; Lettre, 2009). Genome-wide association studies have identified 
hundreds of common genetic variants influencing adult height, but together these only 
explain a small proportion of the estimated genetic variation. Variation in height due to 
genetic markers may reflect combined effects of genes (both common and rare variants), 
gene-by-gene or gene-by-environment interactions (Hirschhorn & Lettre, 2009; Lango et 
al., 2010). Genetic control of height may vary across the distribution of height in 
percentiles. While height is largely attributable to the combined effects of multiple genes, 
extreme height abnormalities  (e.g. short and tall stature), may be controlled by single 
rare variants which exert large effects (Hirschhorn & Lettre, 2009; Lango et al., 2010; 
Hemani et al., 2013). These rare variants may be individual SNPs or CNVs.  Some 
studies report up to 10% of children with idiopathic short stature carry pathogenic CNVs 
(Canton et al., 2014; Zahnleiter et al., 2013; van Duyvenvoorde et al., 2014). Rare, genic 
CNVs have also been implicated in short stature (Dauber et al., 2011; Zahnleiter et al., 
2013). Zahnleiter et al. (2013) found both CNV deletions and duplications in individuals 
with extremely short stature, while Dauber et al. (2011) reported CNV deletions were 
associated with short stature in children presenting with neurodevelopmental disorders. 
Dauber et al. (2011) performed a genome-wide CNV burden analysis, and showed 
children with short stature had higher combined CNV burden, with both longer lengths 
and higher counts of CNVs. They did not find any association between CNVs and tall 
stature. Specific associations between other growth abnormalities, e.g. obesity, have also 
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been found in some CNV regions (Jarick et al., 2011). Genome-wide CNV burden may 
be one of the genetic factors contributing to genetic variation not only in stature, but also 
in other modalities of physical growth.  
 
Some studies have reported specific CNV regions to be associated with growth 
abnormalities and ASD, most commonly macrocephaly (Klein et al., 2013).  Associations 
with novel CNVs located at 6q23.2 and 10q24.32 have been observed with macrocephaly 
(Conti et al., 2012). A phenomenon described as ‘mirror phenotypes’ has also been 
described for CNVs at regions 16p11.2 and 1q21.1, where the growth phenotype 
observed (abnormally small or abnormally large) depends on whether the CNV is a 
deletion or duplication. CNVs at location 16p11.2 show opposite effects on BMI and 
head circumference based on the variant present: CNV deletions were associated with 
ASD, obesity and macrocephaly while duplications were associated with ASD, 
schizophrenia, underweight and microcephaly (Shinawi et al., 2010; Jacquemont et al., 
2011; Qureshi et al., 2014; Stein, 2015).  The 1q21.1 CNV deletion presents with 
microcephaly, while the duplication CNVs showed association with macrocephaly 
(Rosenfeld et al., 2012; Bernier et al., 2016). It has been suggested that gene dosage leads 
to differential gene expression may be the biological mechanism by which CNVs can 
potentially affect phenotypes in opposite directions (McCarroll et al., 2006; Di Gregorio 
et al., 2017). 
 
In this study, we examined CNV burden over all autosomes comparing children with 
abnormalities in head circumference, height, weight and BMI. Characterization of CNV 
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burden for specific growth patterns, and assessment of this signal in ASD children versus 
typically developing children may support the co-occurrence of abnormal growth and 






Materials and Methods 
Study Population 
 
The Study to Explore Early Development (SEED), phase I, is a national multi-site case 
control study funded by the CDC. Children between ages 2-5 years old were recruited 
and evaluated at one of six states: California, Colorado, Georgia, Maryland, North 
Carolina and Pennsylvania. Potential cases, born between 2003 and 2006 were recruited 
through partnerships with developmental disability service providers, including 
healthcare and educational systems. A population-based sample of control children born 
in the same years from the same catchment areas was recruited through vital statistics.  
After phone-based screening and in-person evaluations, children were classified as ASD, 
other non-ASD developmental disabilities, and children without developmental 
disabilities from the general population (POP) (Schendel et al., 2012). Eligibility included 
birth in the study catchment area during the period 9/1/2003-8/31/2006, current residence 
in the area at the time of first contact, and child living with a knowledgeable caregiver 
who was able to communicate orally in English or Spanish competently and gave 
informed consent for participation. The enrolled children also were between the ages of 




SEED participants underwent anthropometric measurements and had standardized 
photographs taken of specific regions of the body. The specific growth measures of 
interest here were collected using a standardized procedure by trained clinic staff using 
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standardized supplies including a tape measure for head circumference, the stadiometer 
and the weighing scale. For head circumference, a non-stretchable, plasticized measuring 
tape was used to measure the head circumference for maximum circumference of the 
head. The tape was placed just above the eyebrows, above the ears and around the most 
protuberant part of the back of the head (occiput), pulled snugly to compress hair and 
read to the nearest 0.1cm, after which the measurement was recorded on the 
Dysmorphology Review Form (DRF) form and repeated, until repeated measurements 
were within 0.2cm. For height measurement, an accurate and appropriate stadiometer was 
used: a vertical board with an attached metric rule and a horizontal headpiece that could 
be brought into direct contact with the most superior (top) part of the head, and read to 
the closest 0.1cm. Height measurement was performed for all children with hair 
accessories removed and without shoes. The child was measured standing with heels, 
buttocks, shoulders and head touching a flat upright surface. The arms were held on the 
side, with shoulders relaxed and legs straight, and heels close together. The child was 
asked to look straight ahead and the perpendicular headpiece lowered to the crown of the 
head snugly with compression of the hair. The measurer’s eyes were parallel with the 
headpiece. The measurement was repeated, with agreement to within 1cm, and recorded 
on a growth chart appropriate for the child’s age and sex. The raw measurement and 
percentile growth from the percentile chart was then transferred to the DRF form. The 
stadiometer position was standardized, so there were no attachments to the wall and no 
underlying carpet. The stadiometer was also calibrated monthly. For the measurement of 
weight, a safe and accurate scale with a wide enough platform to support the child being 
weighed was used. The scale was required to be calibrated with standard weights, and 
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could be zeroed, and not be positioned on a carpeted surface. The child stood on the 
weighing platform without assistance and wearing only light undergarments or gown. 
The reading was recorded, and repeated until agreement within 0.1kg.  
 
For this analysis, raw values of head circumference, height, and weight were converted to 
z-scores and percentiles using the 2000 CDC Head Circumference-for-Age Growth 
Charts for girls and boys ages 2–20, Stature for-Age Growth Charts for girls and boys 
ages 2–20, Weight-for-Age Growth Charts for girls and boys ages 2–20 and BMI- for-
Age Growth Charts for girls and boys ages 2–20.  
 
Children were categorized as abnormal if they were beyond the upper and lower 10
th
 
percentiles for any growth feature: above 90% designated macrocephaly, tall stature, 
overweight, or high BMI; and below 10% designated microcephaly, short stature, 









For all eligible children, a brief screening interview, the Social Communication 
Questionnaire (SCQ; Rutter et al. (2003)), was administered to the primary caregiver to 
identify children who required clinical diagnostic assessment to determine final ASD 
status. For SEED, a positive screen was defined as an SCQ score ≥11.  Tools for ASD 
assessment included the Autism Diagnostic Observation Schedule (ADOS) and Autism 
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Diagnostic Interview-Revised (ADI-R) (Falkmer et al., 2013; Lord et al., 2000). Final 
classification was assigned using a SEED-specific research algorithm based on ADOS, 
ADI-R and clinical judgment (Wiggins et al., 2015). Regardless of ascertainment source, 
any eligible children with a previous ASD diagnosis, who were receiving special 
education services, and who had a positive screen, were assigned to the ASD workflow. 
This determined which instruments were administered and the type of diagnostic 
evaluation the child received during data collection. Based on previous diagnosis and 
SCQ screening, DD and POP children with negative SCQ screens were assigned to the 
DD or POP workflow, respectively. If a clinician suspects ASD during the clinical 
evaluation of a child in the DD or POP workflow, the child would be moved into the 
ASD workflow (Schendel et al., 2012; DiGiuseppe et al., 2016).  
 
Copy Number Variants (CNVs)  
 
Blood and buccal samples were collected by trained local staff and shipped to the SEED 
Biosample Repository at Johns Hopkins Bloomberg School of Public Health. These were 
used to isolate DNA via the QIAsymphony DNA Investigator and QIAsymphony DNA 
Midi kits (Qiagen) for buccal and blood, respectively. A total of 1,132 SEED 1 cases and 
controls were genotyped at 1 million single nucleotide polymorphisms (SNPs) on 
Illumina Human Omni1-Quad array. Genotyping and initial data cleaning was carried out 
at the Johns Hopkins University SNP Center. Quality control measures at the SNP and 
sample levels were performed. Samples were excluded if <98% of all markers were 
called successfully, if estimated identity by descent (IBD) sharing suggested cryptic 
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relatedness between subjects, if there were sex discrepancies, or if there was excess 
heterozygosity/homozygosity. SNPs were excluded for call rates <0.95, minor allele 
frequency (MAF) <0.01 and if there was evidence of deviation from expected genotype 
frequencies predicted by Hardy-Weinberg equilibrium (p<1.0x10
-8 
in controls).  
 
CNVs were called using a hidden Markov model implemented in PennCNV (Wang et al., 
2007). Hidden copy number state along each chromosome was estimated using total 
signal intensity, allelic intensity ratio, SNP allele frequency, distance between 
neighboring SNPs, and genomic GC content (Diskin et al., 2008). Quality control (QC) 
filters were applied at both the CNV and sample levels. CNVs were filtered out if they 
contained < 10 SNPs, were < 30 kb, or were in centromere and telomere regions; samples 
were excluded if the standard deviation of the log R ratio (LRR) >0.3, the B-allele 
frequency (BAF) >0.01, or absolute value of a ‘wave’ factor (due to high GC content 
over the region) >0.05.  The overall data quality pipeline is shown in Figure 2.  
 
Burden Metrics. We considered both CNV counts across all autosomes, as well as their 
summed lengths. CNV count was based on the total number of unique CNV sites for each 
individual; length was determined by summing the length of these unique CNVs in 
kilobases (kb) per individual.  Overall count and length burden metrics included both 
duplications and deletions, and CNVs occurring anywhere in an autosome. Measures 
were also calculated separately for duplications and deletions, and for only large 
(>400kb) CNVs. Finally, subsets of autosomal CNVs were considered: only CNVs 
overlapping known genes, using hg19 gene boundaries (categorized as “genic CNVs”), 
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and only CNVs overlapping genes associated with ASD, using the Simons Foundation 
Autism Research Initiative gene list (categorized as “SFARI CNVs”). The UCSC genome 
database using “TxDb.Hsapiens.UCSC.hg19.knownGene”, “annotate”, and 
“org.Hs.eg.db” Bioconductor packages (Goldstein et al., 2016; Carlson, 2016) were used 
to establish known genes and their boundaries.  For the “SFARI CNVs”, SFARI gene 
2.0_ENREF_22 was consulted, and a list of 757 autosomal candidate genes for ASD was 
used.  
 
CNV Candidate Regions. Malhotra and Sebat (2012) reviewed specific CNV regions 
associated with ASD, and identified the precise boundaries for each region compared to 
the catalog on CNVs available from SFARI (Malhotra & Sebat, 2012; 
https://gene.sfari.org). The largest interval between start and end of any CNV was used to 
best define the affected chromosomal region. We focused on 10 ASD-associated CNVs 
for regional analysis: chromosomes 1q21.1, 3q29, 7q11.23, 15q11.2, 15q11.2.13.1, 
15q13.3, 16p11.2, 16p13.11, 17q12 and 22q11.21.  
 
Statistical Analysis  
 
CNV burden analyses were carried out for eight growth abnormalities: macrocephaly, 
microcephaly, tall and short stature, overweight and underweight plus high and low BMI, 
comparing children with each abnormality to children with typical growth in that domain.  
CNV burden was assessed for both CNV counts and CNV lengths, with effect sizes 
estimated as the ratio of each measure between the children with abnormal growth feature 
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(e.g. macrocephaly) to those with normal growth. Mean counts or cumulative lengths 
were compared between growth groups using t-tests. These analyses were carried out 
overall, for deletions and duplications separately, and then restricting to: CNVs >400 kb 
(large CNVs), CNVs overlapping with genes (Genic CNVs), and CNVs overlapping with 
ASD-associated genes (SFARI Genic CNVs).  Analyses were also stratified by sex. 
Finally, sensitivity analyses were performed to assess the effect of excluding or including 
children with chromosomal abnormalities and recognized genetic syndromes, and 
excluding and including children diagnosed with developmental delay. We used STATA 
(MP12.1) graphics to compare effect size between the whole analytic population and 
Non-Hispanic White children only using scatter plots for each growth abnormality. For 
candidate region analyses, CNV counts between abnormal and typical growth phenotypes 
for each growth feature were compared via Fisher’s exact tests for CNVs over all 
autosomes and for deletion and duplication CNVs, as well as for large CNVs. Sex-
stratified analyses were also performed. All computational analyses were performed 




Characteristics of the Study Sample 
 
There were 3,899 children recruited into the SEED 1 study. Of these, genotyping was 
performed on 1,132, and of these 1,016 had complete data on growth. Our analyses 
included all SEED 1 children, except 147 children with non-ASD developmental delay 
and 29 with known chromosomal abnormalities and non-genetic syndromes, resulting in 
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840 samples, 341 (38.8%) children with ASD and possible ASD, and 499 (59.4%) 
typically developing children. The study flow chart describing how the final study 
population was obtained, and frequencies of each growth abnormality is shown in Figure 
1.  The growth abnormality with the largest number of individuals and highest proportion 
was microcephaly, with 165 (19.6%) children in the study categorized with 
microcephaly. The growth abnormality with the fewest individual and lowest percentage 
was macrocephaly, with 52 (6.2%) children. For growth abnormalities on the lower end 
of the spectrum, with growth measures < the 10
th
 percentile for growth, growth 
abnormalities range from 7.5% to 9% (underweight and low BMI respectively) of the 
whole sample for each growth abnormality, and for growth abnormalities on the upper 
end of the spectrum, with growth measures at or above the 90
th
 percentile of growth, 
growth abnormalities range between 12.6% to 14% (overweight and high BMI 
respectively) of the total sample. 
 
The sex, race, and ASD status frequencies among each type of growth abnormality are 
shown in Table 1.  There was a greater preponderance of males, with 549 (65.4%) males 
and 291 (34.6%) females in the whole sample. The majority (60.4%) of the children were 
Non-Hispanic White, with 17.8% Non-Hispanic Black and 21.8% Hispanic. Children 
with macrocephaly and children with high BMI had a higher proportion of ASD cases 
than children with normal head circumference. Children with high BMI were also more 
frequently Hispanic than normal-BMI children. 
 





CNV burden is reported as the ratio of counts or cumulative CNV lengths per child 
among each abnormal growth group compared to control children with normal growth for 
that feature.  Complete results for each growth abnormality as well as results stratified by 
sex are reported in Supplementary Tables I through XVI. For the study sample, there 
were a total of 18,226 individual CNVs calculated, with a mean CNV count of 21.69 per 
person. The summary of the effect sizes and t-test results for CNV burden by count and 
lengths for each of the eight growth abnormalities considered are shown in Table 2.  The 
burden ratio for tall versus normal stature children was <1 for both counts and lengths 
(Tall/Norm counts = 0.909, p = 0.029; Tall/Norm length = 0.833, p = 0.033), although 
this was not statistically significant after Bonferroni correction for multiple tests.   
 
Effect sizes and nominal p-values for each type of CNV test performed (CNVs overall, 
by deletions and duplications, and restricting to large CNVs, all genic CNVs and SFARI 
CNVs), across all eight growth abnormalities, are shown in Table 3, to allow comparison 
across both growth and CNV types. Across all growth abnormalities, the ratio of mean 
CNV length for those with a growth abnormality to those without for overall CNVs range 
from 0.83 (in tall stature vs. normal stature) to 1.62 (in macrocephaly vs. normal head 
size). Consistent with the overall CNV length differences between tall children and 
normal height children described in Table 2, similar patterns were observed when 
restricting to genic and SFARI genic CNVs (T/Ngenic = 0.83, p=0.06; T/NSFARI = 0.79, 
p=0.044), and among deletions overlapping SFARI genes (T/NSFARI = 0.63, p=0.005) 
(Table 3). For CNVs overall, children with normal stature had a 1.10-fold increase in 
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total CNV count per individual, compared to children with tall stature (Supplementary 
Table V).   
 
Some signals were seen for short stature, with less of the genome affected by deletion 
CNVs (S/N=0.78, p=0.008) and large deletion CNVs (S/N=0.23, p=0.001), when 
restricted to genic regions. For head circumference, children with macrocephaly had less 
of the genome affected when considering CNVs overlappin SFARI regions: large SFARI 
CNVs (Mac/N=0.21, p=0.032), duplication SFARI CNVs (Mac/N=0.58, p=0.049) and 
large duplication SFARI CNVs (Mac/N=0.01, p=0.008). Compared to children with 
normal BMI, children with high BMI had less of their genome affected by large 
duplication SFARI CNVs (highBMI/N=0.21, p=0.049). In tall and short stature, the CNV 
subtype involved were deletion CNVs, while in macrocephaly and high BMI, the CNV 
subtypes were duplication CNVs. For the main analysis, there were no significant 
findings for CNV burden comparing overweight or underweight children with normal 
weight children, for both CNV counts and lengths. None of these nominally significant 
differences met Bonferroni criteria for multiple testing (set at α<0.0005). 
 
Results for the same analyses, stratified by sex, are shown in Tables 4 and 5. In males, 
burden among macrocephaly and microcephaly boys appeared to be lower than typical 
boys, although results were not statistically significant. Similar results to non-stratified 
analyses were observed for tall stature. In particular, male children with tall stature had 
fewer SFARI-overlapping CNVs, and SFARI-overlapping deletion CNVs, cumulative 
lengths (T/N=0.74, p=0.047; T/Ndel=0.57, p=0.012). Other effect sizes were similar, but 
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did not reach nominal statistical significance.  Males with short stature also showed less 
CNV length burden across overall and subtype analyses. The strongest statistical 
significance was for deletion CNVs in genes, large deletion CNVs in genes, and large 
duplication CNVs in genes (S/N delgenic = 0.72, p = 0.0002; S/Nlargedelgenic = 0.13, p 
= 0.0002; S/Nlargedupgenic = 0.48, p = 0.04). After correcting for multiple testing at 
p<0.0005, the only findings still significant were the association between CNV burden 
and short stature in males, for deletion CNVs in known genes and large deletion CNVs in 
genes. 
 
Among females, macrocephaly and microcephaly had burden ratio estimates >1 for most 
analyses, although none were statistically significant. This was in the opposite direction 
from male results, although in both strata, these estimates were not significant.  Results 
for tall stature among girls were similar to unstratified analyses, with burden ratios < 1. 
Deletions, and genic deletions, showed nominally statistically significant differences 
(T/Sdel = 0.76, p = 0.010; T/Sdelgenic = 0.78, p = 0.037).  Girls also showed some 
evidence for decreased CNV burden among overweight children, particularly for deletion 
CNVs.  This corresponded with a smaller deletion burden among girls with high BMI 
(H/N ranged from 0.1 to 0.86 among deletion analyses, with corresponding p-values 
ranging from 0.001 to 0.18). However, none of the significant results survived correction 




Considering Tables 3 – 5 together, there are consistent associations across sex, such as 
decreased burden among tall stature, and sex-specific associations, particularly decreased 
burden among overweight and high BMI among girls.  
 
ASD Candidate CNV Regions 
 
To test for a potentially shared genetic risk for growth abnormalities and ASD, we tested 
for association between each of the eight growth abnormalities and CNVs in regions 
previously associated with ASD.  Counts of all CNVs, deletion and duplication CNVs 
and large CNVs for CNV regions reported to be associated with growth abnormalities are 
shown in Supplementary Tables XVII-XXIV. Tables 6 and 7 summarize results for any 
comparisons with nominal p<0.05 in overall, and sex-stratified analyses, respectively.  
Region 1q21.1 showed increased numbers of CNVs among children with macrocephaly, 
particularly duplication CNVs, but this appears to be specific to girls (Table 7). Region 
15q11.2 and 15q11.2.13.1 showed decreased numbers of CNVs among children with 
microcephaly, and 15q11.2 had increased counts among children with short stature. 
Decreased frequencies among the microcephaly group were observed among both boys 
and girls, but only achieved nominal statistical significance among boys. The increased 
counts at 15q11.2 related to short stature appear to be driven by girls (Table 7). None of 
these remain significant after correction for multiple testing. No other regions or growth 








We explored the use of observed growth abnormalities as sub-phenotype of ASD for 
genetic association studies, in hopes that shared genetic association between growth 
abnormalities and ASD could reveal possible shared mechanisms for ASD and growth. In 
our sample of young children from the Study to Explore Early Development, Phase 1 
(SEED 1), a national case-control study of autism, we observed nominally significant 
decreased CNV burden among children with tall stature. This pattern was consistent 
across boys and girls. However, we also observed marked differences between sexes for 
overweight and high BMI, where only girls showed evidence for differential (decreased) 
CNV burden. Macrocephaly may also be associated with decreased CNV burden in these 
samples, although effect estimates were in the same direction for boys, but in opposing 
direction among girls.  Notably, CNV subset analysis restricting to consideration of only 
those overlapping candidate genes for ASD (SFARI – genic) were generally implicated in 
the burden associations, showing decreased burden among children with particular 
growth abnormalities. Consistent with this specificity to ASD-associated regions, CNV 
associations in 10 specific regions previously identified as ASD candidate regions were 
also significant, but also showed sex-specific results. None of these nominally significant 
associations survive correction for multiple testing. 
 
The most striking finding across our nominally significant results is the reduced, rather 
than increased, genome CNV burden among children with abnormal growth. This is 
surprising, as previous studies of CNV burden and growth, or neurodevelopmental 
conditions, have reported increased CNV burden. One possible reason is our exclusion of 
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children with known chromosomal abnormalities, recognized genetic syndromes and 
non-ASD developmental delay. This was intentional, and should allow clearer 
understanding of risk of ASD in a generally idiopathic group, but excluding the cases 
with chromosomal abnormalities, recognized genetic syndromes and non-ASD 
developmental delay likely excluded children with more severe ASD phenotypes. 
Previous studies showing excess burden did not exclude these types of children (Dauber 
et al., 2011).  As a sensitivity analysis, we ran the same analyses including the 147 non-
ASD developmental delay (DD) children who were also genotyped in SEED and had 
growth data. The decreased burden signal goes away when DD children are included, and 
in some cases, increased burden was observed (Figure 3).  As an example, with DD 
children in the analysis, there was increased genome burden with short stature. This is 
more consistent with Dauber et al.’s (2011) findings of increased CNV burden in children 
presenting with clinical indications. Our design, nested within an ASD case-control 
study, with a high proportion of ASD children, may have also influenced our results.  The 
expected direction, assuming some genetic overlap between ASD and growth 
abnormalities, and previous findings of increased CNV burden among ASD cases, would 
be opposite of our observation of smaller CNV burden in ASD males.  Decreased burden 
has occasionally been observed for neurodevelopmental disorders. Martin et al. (2014) 
found a negative association between CNV burden for total rare duplication CNVs and 
positive symptoms of schizophrenia. They hypothesized this represented CNV 
duplication burden may have a small protective effect against positive symptoms of 
schizophrenia. As far as we are aware, no studies on CNV burden and growth have 




Previous research on CNV burden and growth abnormalities has focused on single 
features of growth, such as short stature (Dauber et al., 2011) or obesity (Jarick et al., 
2011), rather than considering multiple features simultaneously as done here.  We set out 
to examine how CNV burden as a genetic risk factor, may be associated with each growth 
abnormality, while also being able to look across abnormalities in the same children. This 
helped us identify potential patterns of CNV subtype associations across growth 
abnormalities, like duplications versus deletions, and restrictions related to genic and 
ASD genic regions versus general. Both deletions and duplications were found to be 
associated with abnormal growth in our sample. Height abnormalities tended to be 
associated with deletions, while in macrocephaly and BMI were associated with 
duplications. Previous studies have reported pathogenic CNVs are often deletions (Serra-
Juhe et al., 2017). However, it has been discovered that CNV duplications can also lead 
to aberrant gene expression; an example of this is the shift of reading frame that encodes 
a stop codon leading to null mutation seen in SRGAP3 gene duplication in childhood 
schizophrenia (Wilson et al., 2011).  
 
Our burden and candidate region analyses showed different effects between males and 
females. Tall stature has been previously reported in ASD, particularly in boys (Curtin et 
al., 2005; van Daalen et al., 2007; Chawarska et al., 2011), and potentially the decreased 
CNV burden in our sample may contribute to this genetic risk. For females, less of the 
genome was affected by CNVs with macrocephaly, tall stature, overweight, underweight 
and high BMI. These CNVs were primarily deletions, and often showed stronger 
 
 179 
evidence with restricted to SFARI genes, which are canidates for ASD. Macrocephaly 
and high BMI have both been described in ASD children, including in girls with ASD 
(Courchesne et al., 2003; Hazlett et al., 2005; Fukumoto et al., 2008; Mraz et al., 2007; 
Ahearn et al., 2001; Evans et al., 2012; Chen et al., 2009; Curtin et al., 2010), and CNVs 
may be a potential genetic risk factor.   
 
When considering specific ASD candidate regions, CNV associations further appeared to 
be sex-specific. Females may be driving the association between duplication CNVs in the 
15q11.2 region with short stature, and association for CNVs in region 1q21.1 with 
macrocephaly. In both cases, there were greater CNV counts in the abnormal growth girls 
compared to normal girls, but not as strongly differential in boys. The association 
between CNV region 15q11.2 and short stature in females has not described in published 
literature. The region encompasses TUBGCP5, CYFIP1, NIPA2, and NIPA1 genes, which 
have been implicated in axonal growth and neural connectivity, with duplication carriers 
having variable phenotype (Burnside et al., 2011; Picinelli et al., 2016). We also observed 
significant overlap between ASD-associated CNVs in regions 15q11.2 and 15q11.2.13.1 
with microcephaly, but only in males. The association was in the negative direction, with 
less CNV counts seen among microcephalic boys. 
 
These findings generally support a hypothesis of differential genetic risks in males and 
females for both ASD and growth. Sex dimorphism in growth abnormalities has been 
described in ASD (Wells et al., 2007; Suren et al., 2013; Werling & Geschwind, 2013; 
Campbell et al., 2014; Lai et al., 2015; Lai, Baron-Cohen & Buxbaum, 2015; Werling, 
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2016) and these CNV burden findings suggest the mechanism underlying these 
observations may be differ by sex.  
 
Our cross-sectional analysis sample was drawn from a case-control study of ASD, with 
over-representation in the ASD case group compared to the population. This may have 
influenced our results, particularly those showing burden specific to CNVs that overlap 
ASD-associated genes.  However, most associations suggest decreased burden among 
cases, which is not intuitively consistent with ASD sample enrichment for boys.  Thus, 
other explanations, such as excluding ASD cases with reported genetic anomalies, are the 
most likely clue to interpretation.  One advantage of our design is the ability to test for 
the association between CNVs influencing risk to ASD and growth abnormalities. For 
example, complementary growth phenotypes have been seen for CNVs at 16p11.2, a 
region with recognized CNVs for ASD. Individuals with 16p11.2 deletions are more 
likely to have ASD, be overweight and have macrocephaly and those with 16p11.2 
duplications have increased risk of ASD and schizophrenia, underweight and 
microcephaly (Shinawi et al., 2010; Jacquemont et al., 2011; Qureshi et al., 2014; 
Maillard et al., 2014; Stein, 2015). Other regions such as 7q11.23 and 1q21.1 have been 
implicated with ASD and abnormal head size (Merla et al., 2010; Sanders et al., 2011). In 
our study, we did not observe any significant growth associations for CNVs on 16p11.2.  
 
We did observe a 12-fold increase in CNV deletions on 1q21.1 among children with 
microcephaly. CNVs may influence gene expression not only through coding sequence 
disruption, but also through gene dosage effects (either loss or gain of genes in the 
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region) (McCarroll et al., 2006). The opposite head size phenotypes associated with 
different CNVs on 1q21.1 was previously reported by Rosenfeld et al. (2012). Potential 
biological mechanisms for abnormalities in head circumference resulting from CNVs 
have also been reported. Brunetti-Perri et al. (2008) postulated the HYDIN gene might 
play a causal role because it has been implicated in regulating the cerebral cortex size, 
while Rosenfeld et al. (2012) suggested that PIAS3, a regulator of hematopoietic growth 
factor signaling and LIX1L, which has been associated with limb development, might be 
part of the biological pathway leading to abnormal head size. Sequences in the 1q21.1 
region encoding DUF1220 protein domains with variable gene dosage in the NBPF gene 
have been implicated with brain size (Davis et al., 2014). This group further suggested a 
potential biologic mechanism underlying abnormal brain size results from variation in 
DUF1220 domain could lead to disruption of mitotic cell regulation and neuronal 
migration. 
 
We also found significant association between ASD-associated genes in 15q11.2 and 
15q11.2.13.1 regions with microcephaly, and the 15q11.2 region and short stature. The 
region 15q11.2 has been linked with specific learning disabilities and abnormalities of 
brain region size, and reported to have complementary phenotype effects based on pattern 
of CNV loss or gain (Ulfarsson et al., 2017). The association between region 15q11.2 and 
head circumference (as well as stature) suggest possible pleiotropy in this CNV region, 
which could influence multiple traits, like ASD and different growth abnormalities. 




Study Limitations and Strengths 
 
Our cross-sectional design, drawn from a national case-control study may not be fully 
representative of the United States in terms of racial/ethnic make-up (Schendel et al., 
2012). Although the study recruitment included a population-based approach, 
ascertainment bias for selection into the study is still possible. In terms of limitations 
associated with the growth abnormality outcome, the young age of the children limits 
generalizability, as growth trajectories are still in process. This is further limited by the 
cross-sectional nature of our measurement. To truly understand physical growth, repeated 
measurement over time is preferred.   
 
Despite being one of the largest autism case-control samples in the US, after restricting to 
complete cases analyses, our sample size, particularly the number of children categorized 
with each growth abnormality, was modest. The smallest subsample with growth 
abnormalities was for macrocephaly, with only 52 children. This limits power and the 
ability to adjust for a large number of potential confounders. In addition, the study 
population size was too small to consider more extreme thresholds for defining growth 
abnormality. For example, the SEED dysmorphology assessment for each growth feature, 
define children with height at or greater than 3 s.d. from the mean as ‘tall’, which would 
have resulted in even smaller numbers.  
 
An important limitation already discussed is that there may have been undiagnosed 
chromosomal abnormalities and recognized genetic syndromes in our sample. The 
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information we did have on such conditions was based on parental report, not direct 
genetic evaluation. Thus, it is likely additional chromosomal abnormalities or genetic 
syndromes were present and may have influenced our analyses.  
 
We were also not able to stratify analyses on de novo versus inherited CNVs, yet de novo 
CNVs have been directly implicated in previous literature on growth abnormalities 
(Dauber et al., 2011; Zahnleiter et al., 2013). Unfortunately, we did not have parental 
genotyping information and could not determine the impact of de novo CNVs. In 
addition, rare CNVs have also been associated with congenital malformations (Serra-Juhe 
et al., 2012). Although the SEED Study is one of the largest population-based samples of 
ASD in the US, for the purpose of studying growth abnormalities, we only had a subset 
of the full SEED 1 sample, and were underpowered.  
 
This study also has several strengths. The SEED Study is one of the largest ASD studies 
with population-based ascertainment. Previous studies have used clinic-based samples, 
and had smaller sample sizes. The SEED Study involves a varied geographical location 
across the United States, to best represent the diverse experiences in different regions.  A 
major strength is the uniform developmental assessment of all study participants 
including research-reliable ASD classification and rigorous, standardized anthropometric 
measures across multiple domains of growth. 
 
In summary, we found overall CNV burden is lower among children with a variety of 
growth abnormalities in SEED, but there differences by sex. Although the results were 
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not as we originally anticipated, and none of the nomially significant associations survive 
correction for multiple testing, we think these observations are worthy of further 
investigation. Growth abnormalities affect a substantial number of children, and 
understanding their etiology is an important component of understanding the health of 
children.  Growth abnormalities may also represent a distinct sub-phenotype for ASD, 
which currently affects 1 in 68 children in the United States (CDC, 2016). Elucidating 
ASD phenotypes and sub-phenotypes (including growth abnormalities) may aid toward 
greater understanding of the multiple facets of ASD and a deeper understanding of the 
biology causing ASD. Greater appreciation of the association between ASD and 
abnormal growth, and its genetic influences, may also have clinical applications by 
leading to improved detection of ASD in children with growth abnormalities and 
allowing for earlier intervention, as well as recognition of growth abnormalities in ASD 
that could then be better addressed and managed. 
 
Due to the relatively small sample sizes, these results must be considered preliminary, 
and future work replicating these findings need further evaluation for genotype-
phenotype associations in ASD.  
 
The IRB Committee of Johns Hopkins School of Public Health approved this study. 
Informed consent was obtained from all caregivers before clinical assessment as part of 
the SEED Study protocol. Diagnoses and assessments were performed at the six SEED 





Abrahams, B. S., Arking, D. E., Campbell, D. B., Mefford, H. C., Morrow, E. M., Weiss, 
L. a, … Packer, A. (2013). SFARI Gene 2.0: a community-driven knowledgebase for 
the autism spectrum disorders (ASDs). Molecular Autism, 4, 36.  
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental 
Disorders (5th ed.). Arlington, VA: American Psychiatric Publishing. 
Bailey, A., Le Couteur, A., Gottesman, I., Bolton, P., Simonoff, E., Yuzda, E., & Rutter, 
M. (1995). Autism as a strongly genetic disorder: evidence from a British twin study. 
Psychological Medicine, 25, 63–77.  
Bakkaloglu, B., O’Roak, B. J., Louvi, A., Gupta, A. R., Abelson, J. F., Morgan, T. M., … 
State, M. W. (2008). Molecular Cytogenetic Analysis and Resequencing of 
Contactin Associated Protein-Like 2 in Autism Spectrum Disorders. American 
Journal of Human Genetics, 82(1), 165–173.  
Bernier, R., Steinman, K. J., Reilly, B., Wallace, A. S., Sherr, E. H., Pojman, N., … 
Chung, W. K. (2015). Clinical phenotype of the recurrent 1q21.1 copy-number 
variant. Genetics in Medicine, 18(April), 1–9.  
Broder-Fingert, S., Brazauskas, K., Lindgren, K., Iannuzzi, D., & Van Cleave, J. (2014). 
Prevalence of overweight and obesity in a large clinical sample of children with 
autism. Academic Pediatrics, 14(4), 408–414.  
Brunetti-Pierri, N., Berg, J. S., Scaglia, F., Belmont, J., Bacino, C. A., Sahoo, T., … 
Sally, S. (2008). Recurrent reciprocal 1q21.1 deletions and duplications associated 
with microcephaly or macrocephaly and developmental and behavioral 
abnormalities. Nat. Genet. 40(12), 1466–1471.  
Bucan, M., Abrahams, B. S., Wang, K., Glessner, J. T., Herman, E. I., Sonnenblick, L. I., 
… Hakonarson, H. (2009). Genome-wide analyses of exonic copy number variants 
in a family-based study point to novel autism susceptibility genes. PLoS Genetics, 
5(6).  
Buescher, A. V. S., Cidav, Z., Knapp, M., & Mandell, D. S. (2014). Costs of Autism 
Spectrum Disorders in the United Kingdom and the United States. JAMA Pediatrics, 
168(8), 721.  
Burnside, R. D., Pasion, R., Mikhail, F. M., Carroll, A. J., Robin, N. H., Youngs, E. L., 
… Butler, M. G. (2011). Microdeletion/microduplication of proximal 15q11.2 
between BP1 and BP2: A susceptibility region for neurological dysfunction 
including developmental and language delay. Human Genetics, 130(4), 517–528.  
 
 186 
Canton, A. P. M., Costa, S. S., Rodrigues, T. C., Bertola, D. R., Malaquias, A. C., Correa, 
F. A., … Jorge, A. A. L. (2014). Genome-wide screening of copy number variants in 
children born small for gestational age reveals several candidate genes involved in 
growth pathways. European Journal of Endocrinology, 171(2), 253–262.  
Carlson, M.R., Pagès, H., Arora, S., Obenchain, V., Morgan, M. (2016). Genomic 
Annotation Resources in R/Bioconductor. Methods Mol Biol.. 1418:67-90.  
Campbell, D. J., Chang, J., & Chawarska, K. (2014). Early generalized overgrowth in 
autism spectrum disorder: Prevalence rates, gender effects, and clinical outcomes. 
Journal of the American Acad of Child and Adol Psych, 53(10), 1063–1073.  
The Centers for Disease Control and Prevention (CDC). Prevalence and Characteristics 
of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and 
Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. 
Surveillance Summaries. (2016) 65(3); 1–23 
http://www.cdc.gov/mmwr/volumes/65/ss/ss6503a1.htm 
Chakrabarti, S., Fombonne , E. (2001). Pervasive Developmental Disorder in Preschool 
Children, Journal of American Medical Association, 285(24), 3093–3099. 
Chawarska, K., Campbell, D., Chen, L., Shic, F., Klin, a., & Chang, J. (2011). Early 
Generalized Overgrowth in Boys With Autism. Archives of Gen Psychiatry, 68(10), 
1021–1031.  
Chen, A.Y., Kim, S.E., Houtrow, A.J., Newacheck, P.W. (2010) Prevalence of obesity 
among children with chronic conditions. Obesity (Silver Spring).18(1):210-3.  
Colvert, E., Tick, B., McEwen, F., Stewart, C., Curran, S. R., Woodhouse, E., … Bolton, 
P. (2015). Heritability of Autism Spectrum Disorder in a UK Population-Based Twin 
Sample. JAMA Psychiatry, 1–9.  
Conti, S., Condò, M., Posar, A., Mari, F., Resta, N., Renieri, A., Neri, I., Patrizi, A., 
Parmeggiani, A. (2012). Phosphatase and tensin homolog (PTEN) gene mutations 
and autism: literature review and a case report of a patient with Cowden syndrome, 
autistic disorder, and epilepsy. J Child Neurol. 27(3):392-7.  
Courchesne, E., Karns, C. M., Davis, H. R., Ziccardi, R., Carper, R. A., Tigue, Z. D., … 
Courchesne, R. Y. (2001). Unusual brain growth patterns in early life in patients 
with autistic disorder: An MRI study . Neurology, 57(2), 245–254.  
Courchesne, E., Carper, R., & Akshoomoff, N. (2003). Evidence of brain overgrowth in 
the first year of life in autism. JAMA, 290(3), 337–44.  
 
 187 
Curtin, C., Bandini, L.G., Perrin, E.C., Tybor, D.J., Must, A. (2005). Prevalence of 
overweight in children and adolescents with attention deficit hyperactivity disorder 
and autism spectrum disorders: a chart review. BMC Pediatr., 5:48.  
Curtin, C., Anderson, S. E., Must, A., & Bandini, L. G. (2010). The prevalence of obesity 
in children with autism: a secondary data analysis using nationally representative data 
from the National Survey of Children’s Health. BMC Pediatr., 10, 11.  
Dauber, A., Yu, Y., Turchin, M. C., Chiang, C. W., Meng, Y. A., Demerath, E. W., … 
Hirschhorn, J. N. (2011). Genome-wide association of copy-number variation 
reveals an association between short stature and the presence of low-frequency 
genomic deletions. American Journal of Human Genetics, 89(6), 751–759.  
Davis, J. M., Searles, V. B., Anderson, N., Keeney, J., Dumas, L., & Sikela, J. M. (2014). 
DUF1220 Dosage Is Linearly Associated with Increasing Severity of the Three 
Primary Symptoms of Autism. PLoS Genetics, 10(3), 1–5.  
Dementieva, Y.A., Vance, D.D., Donnelly, S.L., Elston, L.A., Wolpert, C.M., Ravan, 
S.A., DeLong, G.R., Abramson, R.K., Wright, H.H., Cuccaro, M.L. (2005). 
Accelerated head growth in early development of individuals with autism. Pediatr 
Neurol.,32(2):102-8 
Di Gregorio, E., Riberi, E., Belligni, E. F., Biamino, E., Spielmann, M., Ala, U., … 
Ferrero, G. B. (2017). CNVs analysis in a cohort of isolated and syndromic DD/ID 
reveals novel genomic disorders, position effects and candidate disease genes. 
Clinical Genetics, (February), 1–8.  
Diskin, S. J., Li, M., Hou, C., Yang, S., Glessner, J., Hakonarson, H., … Wang, K. 
(2008). Adjustment of genomic waves in signal intensities from whole-genome SNP 
genotyping platforms. Nucleic Acids Research, 36(19), 1–12.  
Evans, E. W., Must, A., Anderson, S. E., Curtin, C., Scampini, R., Maslin, M., & 
Bandini, L. (2012). Dietary patterns and body mass index in children with autism 
and typically developing children. Research in Autism Spectrum Disorders, 6(1), 
399–405.  
Feuk, L., Marshall, C. R., Wintle, R. F., & Scherer, S. W. (2006). Structural variants: 
changing the landscape of chromosomes and design of disease studies. Human 
Molecular Genetics, 15 Spec No 1(1), 57–66.  
Folstein, S., Rutter, M. (1977). Infantile autism: a genetic study of 21 twin pairs. J Child 
Psychol Psychiatry,18(4):297-321. 
Fombonne, E., Rogé, B., Claverie, J., Courty, S., Frémolle, J. (1999). Microcephaly and 
macrocephaly in autism. J Autism Dev Disord. 29(2):113-9. 
 
 188 
Fukumoto, A., Hashimoto, T., Ito, H., Nishimura, M., Tsuda, Y., Miyazaki, M., … 
Kagami, S. (2008). Growth of head circumference in autistic infants during the first 
year of life. Journal of Autism and Developmental Disorders, 38(3), 411–418.  
Geschwind, D. H. (2011). Genetics of autism spectrum disorders. Trends in Cognitive 
Sciences.  
Goldstein, L. D., Cao, Y., Pau, G., Lawrence, M., Wu, T. D., Seshagiri, S., & Gentleman, 
R. (2016). Prediction and quantification of splice events from RNA-seq data. PLoS 
ONE, 11(5), 1–18.  
Grayton, H.M., Fernandes, C., Rujescu, D., Collier, D.A.(2012). Copy number variations 
in neurodevelopmental disorders. Prog Neurobiol. 99(1):81-91. 
Hallmayer, J., Cleveland, S., Torres, A., Phillips, J., Cohen, B., Torigoe, T., Miller, J., 
Fedele, A., Collins, J., Smith, K., Lotspeich, L., Croen, L.A., Ozonoff, S., 
Lajonchere, C., Grether, J.K., Risch, N. Genetic heritability and shared 
environmental factors among twin pairs with autism. Arch Gen Psychiatry 
68(11):1095-102 (2011). 
Hazlett, H., Poe, M., Gerig, G., & al, et. (2005). Magnetic resonance imaging and head 
circumference study of brain size in autism: Birth through age 2 years. Archives of 
Gen Psyciatry, 62(12), 1366–1376.  
Hemani, G., Yang, J., Vinkhuyzen, A., Powell, J. E., Willemsen, G., Hottenga, J. J., … 
Visscher, P. M. (2013). Inference of the genetic architecture underlying bmi and 
height with the use of 20,240 sibling pairs. American Journal of Human Genetics, 
93(5), 865–875.  
Hirschhorn, J. N., & Lettre, G. (2009). Progress in genome-wide association studies of 
human height. Hormone Research, 71(SUPPL. 2), 5–13.  
Hochstenbach, R., Buizer-Voskamp, J. E., Vorstman, J. A. S., & Ophoff, R. A. (2011). 
Genome arrays for the detection of copy number variations in idiopathic mental 
retardation, idiopathic generalized epilepsy and neuropsychiatric disorders: Lessons 
for diagnostic workflow and research. Cytogenetic and Genome Research, 135(3–4), 
174–202.  
Jacquemont, S., Reymond, A., Zufferey, F., Harewood, L., Walters, R. G., Kutalik, Z., … 
Froguel, P. (2011). Mirror extreme BMI phenotypes associated with gene dosage at 
the chromosome 16p11.2 locus. Nature, 478(7367), 97–102.  
Jarick, I., Vogel, C. I. G., Scherag, S., Schäfer, H., Hebebrand, J., Hinney, A., & Scherag, 
A. (2011). Novel common copy number variation for early onset extreme obesity on 
chromosome 11q11 identified by a genome-wide analysis. Human Molecular 
Genetics, 20(4), 840–852.  
 
 189 
Iossifov, I., O'Roak, B. J., Sanders, S. J., Ronemus, M., Krumm, N., Levy, D., et al.  
(2014). The contribution of de novo coding mutations to autism spectrum 
disorder. Nature, 515(7526), 216-221. 
Kang, S. J., Chiang, C. W. K., Palmer, C. D., Tayo, B. O., Lettre, G., Butler, J. L., … 
Hirschhorn, J. N. (2010). Genome-wide association of anthropometric traits in 
African- and African-derived populations. Human Molecular Genetics, 19(13), 
2725–2738.  
Klein, S., Sharifi-Hannauer, P., & Martinez-Agosto, J. (2013). Macrocephaly as a clinical 
indicator of genetic subtypes in autism. Autism Research, 6(January), 51–56.  
Kuczmarski, R.J., Ogden, C.L., Guo, S.S., et al. (2002). 2000 CDC growth charts for the 
United States: methods and development. Vital Health Stat 11. 246:1  
Lai, M.-C., Baron-Cohen, S., & Buxbaum, J. D. (2015). Understanding autism in the light 
of sex/gender. Molecular Autism, 6(1), 24.  
Lai, M. -C., Lombardo, M. V., Auyeung, B., Chakrabarti, B., & Baron-Cohen, S. (2015). 
Sex/Gender Differences and Autism: Setting the Scene for Future Research. J Am 
Acad Child Adolesc Psychiatry, 54(1), 11–24.  
Lainhart, J.E., Piven, J., Wzorek, M., Landa, R., Santangelo, S.L., Coon, H., Folstein, 
S.E.(1997). Macrocephaly in children and adults with autism. J Am Acad Child 
Adolesc Psychiatry. 36(2):282-90.  
Lainhart, J. E., Bigler, E. D., Bocian, M., Coon, H., Dinh, E., Dawson, G., Deutsch, C. 
K., Dunn, M., Estes, A., Tager-Flusberg, H., Folstein, S., Hepburn, S., Hyman, S., 
McMahon, W., Minshew, N., Munson, J., Osann, K., Ozonoff, S., Rodier, P., 
Rogers, S., Sigman, M., Spence, M. A., Stodgell, C. J. and Volkmar, F. (2006), 
Head circumference and height in autism: A study by the collaborative program of 
excellence in autism. Am. J. Med. Genet., 140A: 2257–2274.  
Lango Allen, H., Estrada, K., Lettre, G., Berndt, S. I., Weedon, M. N., Rivadeneira, F., 
… Hirschhorn, J. N. (2010). Hundreds of variants clustered in genomic loci and 
biological pathways affect human height. Nature, 467(7317), 832–838. 0 
Lavelle, T.A., Weinstein, M.C., Newhouse, J.P., Munir, K., Kuhlthau, K.A., Prosser, 
L.A. Economic Burden of Childhood Autism Spectrum Disorders. Pediatrics 
133(3):e520-9 (2014) 
Lauritsen, M. B., Pedersen, C. B., & Mortensen, P. B. (2005). Effects of familial risk 
factors and place of birth on the risk of autism: A nationwide register-based study. 
Journal of Child Psychology and Psychiatry and Allied Disciplines, 46, 963–971.  
 
 190 
Lyall, K., Croen, L., Daniels, J., Fallin, M. D., Ladd-Acosta, C., Lee, B. K., … 
Newschaffer, C. (2017). The Changing Epidemiology of Autism Spectrum 
Disorders. Annual Review of Public Health, 38(1), 81–102.  
Li, X., Tan, L., Liu, X., Lei, S., Yang, T., Chen, X., … Deng Hongwen, H. (2010). A 
genome wide association study between copy number variation (CNV) and human 
height in Chinese population. Journal of Genetics and Genomics, 37(12), 779–785.  
Lettre, G. (2009). Genetic regulation of adult stature. 
http://doi.org/10.1097/MOP.0b013e32832c6dce 
Luo, R., Sanders, S. J., Tian, Y., Voineagu, I., Huang, N., Chu, S. H., … Geschwind, D. 
H. (2012). Genome-wide transcriptome profiling reveals the functional impact of 
rare de novo and recurrent CNVs in autism spectrum disorders. American Journal of 
Human Genetics, 91, 38–55.  
Maillard, A. M., Hippolyte, L., Rodriguez-Herreros, B., Chawner, S. J. R. A., Dremmel, 
D., Agüera, Z., … Jacquemont, S. (2015). 16P11.2 Locus Modulates Response To 
Satiety Before the Onset of Obesity. International Journal of Obesity (2005), 
(August), 1–7.  
Malhotra, D., Sebat J. (2012). CNVs: harbingers of a rare variant revolution in  
psychiatric genetics. Cell. 148(6):1223-41.  
Marouli, E., Graff, M., Medina-Gomez, C., Lo, K. S., Wood, A. R., Kjaer, T. R., … 
Lettre, G. (2017). Rare and low-frequency coding variants alter human adult height. 
Nature, 542(7640), 186–190.  
Martin, A. K., Robinson, G., Reutens, D., & Mowry, B. (2015). Clinical and parental age 
characteristics of rare copy number variant burden in patients with schizophrenia. 
American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, 168(5), 
374–382.  
McCarroll, S.,Hadnott, T., Perry, G., Sabeti, P., Zody, M., Barrett, J., Dallaire, S., 
Gabriel, B., Lee, C., Daly, M., D. Altshuler. (2006). Common deletion 
polymorphisms in the human genome. Nat. Genet., 38: 86–92 
Merla, G., Brunetti-Pierri, N., Micale, L., & Fusco, C. (2010). Copy number variants at 
Williams-Beuren syndrome 7q11.23 region. Human Genetics, 128(1), 3–26.  
Miles, J. H., & Hillman, R. E. (2000). Value of a clinical morphology examination in 
autism. American Journal of Medical Genetics, 91(January 1999), 245–253.  




Moreno-De-Luca, D., Mulle, J. G., Kaminsky, E. B., Sanders, S. J., Myers, S. M., Adam, 
M. P., … Ledbetter, D. H. (2010). Deletion 17q12 is a recurrent copy number 
variant that confers high risk of autism and schizophrenia. American Journal of 
Human Genetics, 87(5), 618–630.  
Mraz, K. D., Green, J., Dumont-mathieu, T., Makin, S., & Fein, D. (2007). Correlates of 
Head Circumference Growth, 7–9.  
Must, A., Eliasziw, M., Phillips, S. M., Curtin, C., Kral, T. V. E., Segal, M., … Bandini, 
L. G. (2016). The Effect of Age on the Prevalence of Obesity among US Youth with 
Autism Spectrum Disorder. Childhood Obesity (Print), X(X), 1–11.  
Ogden, C. L., Carroll, M. D., & Flegal, K. M. (2010). Prevalence of high body mass 
index in U.S. children and adolescents. Journal of the American Medical 
Association, 303(3), 242–249. 
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014). Prevalence of 
Childhood and Adult Obesity in the United States, 2011-2012. Jama, 311(8), 806.  
Ozonoff, S., Young, G. S., Carter, a., Messinger, D., Yirmiya, N., Zwaigenbaum, L., 
Stone, W. L. (2011). Recurrence Risk for Autism Spectrum Disorders: A Baby 
Siblings Research Consortium Study. Pediatrics.  
Picinelli, C., Lintas, C., Piras, I. S., Gabriele, S., Sacco, R., Brogna, C., & Persico, A. M. 
(2016). Recurrent 15q11.2 BP1-BP2 microdeletions and microduplications in the 
etiology of neurodevelopmental disorders. American Journal of Medical Genetics, 
Part B: Neuropsychiatric Genetics, 171(8), 1088–1098.  
Pinto, D., Pagnamenta, A. T., Klei, L., Anney, R., Merico, D., Regan, R., … Betancur, C. 
(2010). Functional impact of global rare copy number variation in autism spectrum 
disorders. Nature, 466(7304), 368–372.  
Pinto D., Darvishi K., Shi X.H., Rajan D., Rigler D., Fitzgerald T., Lionel A.C., 
Thiruvahindrapuram B., MacDonald J.R., Mills R., et al. Comprehensive assessment 
of array-based platforms and calling algorithms for detection of copy number 
variants. Nat. Biotechnol., 2011;29:512–520.  
Qureshi, A. Y., Mueller, S., Snyder, A. Z., Mukherjee, P., Berman, J. I., Roberts, T. P. L., 
… Buckner, R. L. (2014). Opposing Brain Differences in 16p11.2 Deletion and 
Duplication Carriers. Journal of Neuroscience, 34(34), 11199–11211.  
Rimmer, J.H., Yamaki, K., Lowry, B.M., Wang, E., Vogel, L.C. (2010). Obesity and 
obesity-related secondary conditions in adolescents with intellectual/developmental 
disabilities. J Intellect Disabil Res., 54(9):787-94.  
 
 192 
Redcay, E., Courchesne, E. (2005). When Is the Brain Enlarged in Autism? A Meta-
Analysis of All Brain Size Reports. Biological Psychiatry , Volume 58 , Issue 1 , 1 – 
9 
Robinson, E. B., Neale, B. M., & Hyman, S. E. (2015). Genetic research in autism 
spectrum disorders. Current Opinion in Pediatrics, 27(6), 685–91.  
Roohi, J., Montagna, C., Tegay, D. H., Palmer, L. E., DeVincent, C., Pomeroy, J. C., … 
Hatchwell, E. (2009). Disruption of contactin 4 in three subjects with autism 
spectrum disorder. Journal of Medical Genetics, 46(3), 176–82.  
Rosenberg, R. E., Law, J. K., Yenokyan, G., McGready, J., Kaufmann, W. E., & Law, P. 
a. (2009). Characteristics and concordance of autism spectrum disorders among 277 
twin pairs. Archives of Pediatrics & Adolescent Medicine, 163(10), 907–914.  
Rosenfeld, J. A., Traylor, R. N., Schaefer, G. B., McPherson, E. W., Ballif, B. C., 
Klopocki, E., Aylsworth, A. S. (2012). Proximal microdeletions and 
microduplications of 1q21.1 contribute to variable abnormal phenotypes. European 
Journal of Human Genetics : EJHG, 20(7), 754–61.  
Sanders, S., Ercan-sencicek, a G., Hus, V., Luo, R., Murtha, M. T., Moreno-De-Luca, D., 
& State, M. (2011). Multiple recurrent de novo copy number variations (CNVs), 
including duplications of the 7q11.23 Williams-Beuren syndrome region, are 
strongly associated with autism. Neuron, 70(5), 863–885.  
Sandin, S., Lichtenstein, P., Kuja-Halkola, R., Hultman, C., Larsson, H., Reichenberg, A. 
(2017). The Heritability of Autism Spectrum Disorder. Research Letter, JAMA 
Network. 318(12):1182-1184.  
Serra-Juhé, C., Martos-Moreno, G., Bou de Pieri, F., Flores, R., González, J. R., 
Rodríguez-Santiago, B., … Pérez-Jurado, L. A. (2017). Novel genes involved in 
severe early-onset obesity revealed by rare copy number and sequence variants. 
PLoS Genetics, 13(5), 1–19.  
Schendel, D. E., Diguiseppi, C., Croen, L. a, Fallin, M. D., Reed, P. L., Schieve, L. a, … 
Yeargin-Allsopp, M. (2012). The Study to Explore Early Development (SEED): a 
multisite epidemiologic study of autism by the Centers for Autism and 
Developmental Disabilities Research and Epidemiology (CADDRE) network. 
Journal of Autism and Developmental Disorders, 42(10), 2121–40.  
Schüle, B., Albalwi, M., Northrop, E., Francis, D. I., Rowell, M., Slater, H. R., … 
Francke, U. (2005). Molecular breakpoint cloning and gene expression studies of a 
novel translocation t(4;15)(q27;q11.2) associated with Prader-Willi syndrome. BMC 
Medical Genetics, 6(1), 18.  
SFARI Gene Database. 32. https://gene.sfari.org/autdb/CNVHome.do 
 
 193 
Shapira, K., Tian, L., Aylsworth, A., Elias, E., Hoover-Fong, J., Meeks, N., Souders, M.,  
 Tsai, C., Alexander, A., Schieve, L. (2014). Development of a Novel Protocol for  
 Characterizing Dysmorphology to Enhance the Phenotypic Classification of  
 Autism Spectrum Disorders, presented at International Meeting for Autism  
 Research, Atlanta, 2014. Georgia: INSAR. 
Shapira, S.K., Lin, H. T., Aylsworth A.S., Elias, E.R., Hoover-Fong, J.E., Meeks, N.J.L., 
Souders, M.C., Tsai, A.C.H., Zackai, A.H., Alexander, A.A., Yeargin-Allsopp, 
M.H., Schieve, L.A. (personal communication, SEED Dysmorphology Workgroup 
unpublished manuscript). A Novel Protocol for Characterizing Dysmorphology to 
Enhance the Phenotypic Classification of Autism Spectrum Disorder in the Study to 
Explore Early Development.  
Sheppard, B., Benke, K.S., Croen, L., Daniels, J., Newschaffer, C., Reynolds, A., 
Schendel, D., Schieve, L., Ladd-Acosta, C., Fallin, D. (2015). Polygene –by–
Prenatal Environment Interaction in Autism Spectrum Disorder using Copy Number 
Variant Burden, presenred at IGES, Baltimore, 2015. Maryland: IGES. 
Shinawi, M., Liu, P., Kang, S.-H. L., Shen, J., Belmont, J. W., Scott, D. A., Lupski, J. R. 
(2010). Recurrent reciprocal 16p11.2 rearrangements associated with global 
developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal 
head size. Journal of Medical Genetics, 47(5), 332–341.  
Shishido, E., Aleksic, B., & Ozaki, N. (2014). Copy-number variation in the pathogenesis 
of autism spectrum disorder. Psychiatry and Clinical Neurosciences. 68(2):85-95.  
Shoukier, M., Klein, N., Auber, B., Wickert, J., Schroeder, J., Zoll, B., Zirn, B. (2013). 
Array CGH in patients with developmental delay or intellectual disability: Are there 
phenotypic clues to pathogenic copy number variants? Clinical Genetics, 83(1), 53–
65.  
Stein, J. L. (2015). Copy number variation and brain structure: lessons learned from 
chromosome 16p11.2. Genome Medicine, 7(1), 13.  
Suren, P., Stoltenberg, C., Bresnahan, M., Hirtz, D., Lie, K. K., Lipkin, W. I., … Hornig, 
M. (2013). Early growth patterns in children with autism. Epidemiology 
(Cambridge, Mass.), 24(5), 660–670.  
Ulfarsson, M. O., Walters, G. B., Gustafsson, O., Steinberg, S., Silva, A., Doyle, O. M., 
… Stefansson, K. (2017). 15q11.2 CNV affects cognitive, structural and functional 
correlates of dyslexia and dyscalculia. Translational Psychiatry, 7(4), e1109.  
van Daalen, E., Swinkels, S. H. N., Dietz, C., van Engeland, H., & Buitelaar, J. K. 
(2007). Body Length and Head Growth in the First Year of Life in Autism. Pediatric 
Neurology, 37(5), 324–330.  
 
 194 
van Duyvenvoorde, H. A., Lui, J. C., Kant, S. G., Oostdijk, W., Gijsbers, A. C. J., Hoffer, 
M. J. V, Wit, J. M. (2014). Copy number variants in patients with short stature. 
European Journal of Human Genetics : EJHG, 22(5), 602–9.  
Vulto-van Silfhout, A. T., Hehir-Kwa, J. Y., van Bon, B. W. M., Schuurs-Hoeijmakers, J. 
H. M., Meader, S., Hellebrekers, C. J. M., … de Vries, B. B. a. (2013). Clinical 
Significance of De Novo and Inherited Copy-Number Variation. Human Mutation, 
34, 1679–1687.  
Wells, J. (2007). Sexual dimorphism of body composition. Best Practice & Research 
Clinical Endocrinology & Metabolism. 21(3), 415-430. 
Werling, D. M. (2016). The role of sex-differential biology in risk for autism spectrum 
disorder. Biology of Sex Differences, 7, 58. 
Werling, D. M., & Geschwind, D. H. (2013). Sex differences in autism spectrum 
disorders. Current Opinion in Neurology, 26(2), 146–153.  
WHO Multicentre Growth Reference Study Group (2006a). Assessment of differences in 
linear growth among populations in the WHO Multicentre Growth Reference Study. 
Acta Paediatrica, Suppl 450:57–66.  
Wilson, N. K. a, Lee, Y., Long, R., Hermetz, K., Rudd, M. K., Miller, R., … Addington, 
A. M. (2011). A Novel Microduplication in the Neurodevelopmental Gene SRGAP3 
That Segregates with Psychotic Illness in the Family of a COS Proband. Case 
Reports in Genetics, 2011, 585893.  
Winchester L., Yau C., Ragoussis J. Comparing CNV detection methods for SNP 
arrays. Brief. Funct. Genomic Proteomic. 2009;8:353–366.  
Xiong, N., Ji, C., Li, Y., He, Z., Bo, H., & Zhao, Y. (2009). The physical status of 
children with autism in China. Research in Developmental Disabilities, 30(1), 70–76.  
Zahnleiter, D., Uebe, S., Ekici, A. B., Hoyer, J., Wiesener, A., Wieczorek, D., … Thiel, 
C. T. (2013). Rare Copy Number Variants Are a Common Cause of Short Stature. 
PLoS Genetics, 9(3), 1–11.  
Zhang, X., Du, R., Li, S., Zhang, F., Jin, L., & Wang, H. (2014). Evaluation of copy 
number variation detection for a SNP array platform. BMC Bioinformatics, 15(1), 
50.  







Table 1: Characteristics of Children With Growth Abnormalities In the SEED 1 Study 
N=840 




























Diagnosis ASD 37.1% 51.9% 0.032 
 
41.2% 0.38 
 P. Case 1.4% 3.8% 2.4% 
POP 61.5% 44.2% 56.4% 
Sex Male 66.6% 55.8% 0.113 
 
63.6% 0.473 
 Female 33.4% 44.2% 36.4% 
Race NHW 63% 62.1% 0.148 
 
48.8% 0.058 
 NHB 15.7% 27.6% 23.2% 
Hisp 21.3% 10.3% 28.0% 
STATURE N=656 Tall, N=116  Short, N=68  
Diagnosis ASD 38.0% 40.5% 0.686 44.1% 0.461 
 P. Case 1.8% 0.9% 2.9% 
POP 60.2% 58.6% 52.9% 
Sex Male 67.2% 58.6% 0.071 
 
58.8% 0.162 
 Female 32.8% 41.4% 41.2% 
Race NHW 60% 59.4% 0.782 65.7% 0.776 
 NHB 18.3% 16.6% 17.1% 
Hisp 21.7% 25% 17.1% 
WEIGHT N=671 Overwt,N=106  Underwt,N=63  
Diagnosis ASD 38.2% 44.3% 0.198 36.5% 0.789  
 P. Case 1.9% 0 3.2% 
POP 59.9% 55.7% 60.3% 
Sex Male 65.3% 66% 0.880 
 
65.1% 0.97 
 Female 34.7% 34% 34.9% 
Race NHW 62.2% 52.9% 0.355  55.2% 0.75 
NHB 17.1% 20.6% 20.7% 
Hisp 20.7% 26.5% 24.1% 
BODY MASS INDEX N=647 High, N=118  Low, N=75  
Diagnosis ASD 36.9% 51.7% 0.005 34.7% 0.876 
 P. Case 2.0% 0 2.7% 
POP 61.1% 48.3% 62.7% 
Sex Male 64.8% 67.8% 0.524 66.7% 0.743 
Female 35.2% 32.2% 33.3% 
Race NHW 61.7% 48.7% 0.040 75.9% 0.182 
 NHB 17.9% 17.9% 17.2% 
Hisp 20.5% 33.3% 6.9% 
*Compared to normal growth children 
ASD=Autism Spectrum Disorder P. Case=Possible Case Bolded: p<0.05 




Table 2: Association Analyses of Overall Genome-wide CNV Burden in Growth 
Abnormalities  
Macrocephaly and Microcephaly 











CNV Rate 21.79 23.96 1.099 0.459 20.63 0.946 0.224 
Average Length (kb) 2,581 4,183 1.620 0.227 2,491 0.965 0.741 
 
Tall and Short Stature 
CNV Burden Normal 
Height 
Tall Tall/ N  
ratio 
p-value Short Short/N 
ratio 
p-value 
CNV Rate 22.14 20.14 0.909 0.029 20.07 0.906 0.089 
Average Length (kb) 2,718 2,264 0.833 0.033 2,803 1.031 0.879 
 
Overweight and Underweight 













CNV Rate 21.56 23.30 1.080 0.366 20.38 0.945 0.413 
Average Length (kb) 2,624 2,811 1.071 0.621 2,819 1.074 0.740 
 
High BMI and Low BMI 













CNV Rate 21.65 22.56 1.042 0.589 20.73 0.957 0.446 
Average Length (kb) 2,704 2,629 0.972 0.831 2,357 0.871 0.219 
CNV rate: CNV count per individual 
Average Length: Average CNV length per individual in kilobase pairs (kb) 
N: Normal growth 














































1.62 0.22 0.96 0.74 0.83 0.03 1.03 0.87 1.07 0.62 1.07 0.74 0.97 0.83 0.87 0.22 
OG 1.81 0.20 0.92 0.47 0.83 0.06 0.95 0.82 1.08 0.59 1.03 0.87 0.99 0.84 0.86 0.25 
OS 





2.68 0.22 1.03 0.90 0.69 0.09 1.24 0.67 0.99 0.99 1.27 0.67 0.79 0.40 0.64 0.11 
LG 
2.89 0.21 0.93 0.80 0.69 0.09 1.01 0.97 1.04 0.87 1.17 0.74 0.84 0.53 0.72 0.24 
LS 




1.03 0.84 0.97 0.76 0.86 0.05 0.89 0.23 1.12 0.45 0.96 0.75 1.03 0.78 0.94 0.54 
DeG 
0.97 0.90 0.91 0.29 0.87 0.11 0.78 .008 1.10 0.46 0.89 0.31 1.00 0.97 0.93 0.51 
DeS 
0.72 0.23 1.07 0.74 0.63 .005 0.77 0.15 1.01 0.97 1.09 0.65 1.06 0.84 1.19 0.51 
Del. 
Large 
LDe 0.74 0.48 1.22 0.61 0.87 0.76 0.75 0.57 0.93 0.88 0.52 0.06 0.73 0.42 1.17 0.81 
LDeG 
0.65 0.35 0.95 0.89 0.71 0.37 0.23 .001 0.84 0.67 0.68 0.33 0.75 0.46 1.24 0.70 
LDeS 
0.94 0.95 0.79 0.25 0.90 0.93 0.49 0.52 0.76 0.77 0 0.08 1.36 0.76 9.23 0.37 
Dup. 
Du 1.98 0.21 0.95 0.79 0.81 0.09 1.11 0.72 1.04 0.81 1.13 0.68 0.93 0.68 0.83 0.22 
DuG 
2.35 0.18 0.92 0.65 0.80 0.14 1.05 0.86 1.07 0.73 1.11 0.74 0.95 0.81 0.83 0.28 
DuS 






2.98 0.21 1.01 0.97 0.67 0.10 1.31 0.63 1.00 0.98 1.38 0.60 0.80 0.47 0.57 0.05 
LDuG 
3.32 0.19 0.93 0.82 0.69 0.14 1.15 0.78 1.07 0.73 1.25 0.68 0.85 0.61 0.64 0.13 
LDuS 
0.01 .008 1.93 0.45 0.77 0.72 3.51 0.36 1.21 0.26 2.80 0.50 0.21 0.04 0.29 0.08 
O=Overall CNVs OG= Overall Genic CNVs  OS=Overall SFARI CNVs 
L=Large CNVs  LG=Large Genic CNVs   LS=Large SFARI CNVs 
De=Deletion CNVs DeG=Deletion Genic CNVs  DeS=Deletion SFARI CNVs 
Du=Duplication CNVs DuG=Duplication Genic CNVs  DuS=Duplication SFARI 
P: p-value for t-tests comparing growth abnormality to normal growth 












































0.99 0.97 0.88 0.20 0.84 0.09 0.81 0.13 1.13 0.52 0.94 0.62 1.02 0.87 0.93 0.60 
OG 1.02 0.93 0.83 0.08 0.83 0.12 0.70 0.02 1.16 0.44 0.92 0.57 1.03 0.84 0.96 0.77 
OS 





0.84 0.65 0.79 0.30 0.77 0.29 0.60 0.08 1.14 0.70 0.71 0.23 0.96 0.91 0.67 0.19 
LG 
0.86 0.68 0.74 0.19 0.72 0.18 0.43 0.01 1.24 0.54 0.72 0.25 1.02 0.95 0.82 0.52 
LS 




1.10 0.74 0.91 0.33 0.92 0.49 0.83 0.11 1.28 0.25 1.01 0.91 1.12 0.55 0.91 0.33 
DeG 





1.28 0.19 0.96 0.78 1.09 0.62 0.91 0.37 
DeS 
0.89 0.73 0.93 0.79 0.57 0.01 0.77 0.27 1.23 0.66 1.15 0.72 1.34 0.49 1.30 0.44 
Del. 
Large 
LDe 0.57 0.33 0.80 0.57 1.21 0.73 0.67 0.57 1.38 0.55 0.72 0.46 0.94 0.91 0.59 0.24 
LDeG 





1.36 0.52 0.94 0.91 1.06 0.89 0.89 0.82 
LDeS 
1.80 0.67 0 -- 4.51 0.44 0 -- 3.12 0.41 0 -- 2.61 0.46 0 -- 
Dup. 
Du 0.92 0.75 0.87 0.31 0.79 0.10 0.80 0.25 1.04 0.86 0.89 0.50 0.97 0.89 0.94 0.75 
DuG 
1.02 0.92 0.81 0.20 0.77 0.12 0.70 0.11 1.10 0.71 0.90 0.58 1.00 0.98 0.98 0.94 
DuS 






0.88 0.74 0.79 0.36 0.71 0.21 0.59 0.10 1.10 0.79 0.70 0.27 0.96 0.92 0.68 0.28 
LDuG 
0.94 0.89 0.75 0.27 0.68 0.17 0.48 0.04 1.22 0.62 0.68 0.24 1.01 0.97 0.81 0.55 
LDuS 
0 -- 0.86 0.86 0.76 0.75 0 -- 0.80 0.80 0.17 0.07 0.32 0.20 0.45 0.31 
 
O=Overall CNVs OG= Overall Genic CNVs OS=Overall SFARI CNVs 
L=Large CNVs  LG=Large Genic CNVs  LS=Large SFARI CNVs 
De=Deletion  DeG=Deletion Genic CNVs DeS=Deletion SFARI CNVs 
Du=Duplication DuG=Duplication Genic CNVs DuS=Duplication SFARI 
P: p-value for t-tests comparing growth abnormality to no growth abnormality 
Blue-colored cell and bolded effect size: p< 0.05 













































2.55 0.20 1.13 0.61 0.81 0.20 1.33 0.48 0.96 0.82 1.31 0.59 0.87 0.42 0.76 0.18 
OG 2.98 0.20 1.11 0.65 0.82 0.30 1.28 0.52 0.93 0.74 1.22 0.69 0.86 0.46 0.71 0.16 
OS 





6.32 0.19 1.68 0.47 0.59 0.22 2.13 0.40 0.73 0.47 2.25 0.47 0.53 0.14 0.59 0.35 
LG 
6.81 0.18 1.43 0.57 0.66 0.34 1.79 0.46 0.71 0.43 1.91 0.50 0.56 0.18 0.56 0.32 
LS 




0.96 0.80 1.09 0.56 0.76 0.01 0.97 0.89 0.82 0.11 0.86 0.19 0.86 0.18 0.99 0.96 
DeG 
0.95 0.79 1.03 0.83 0.78 0.03 0.88 0.47 0.78 0.04 0.78 0.08 0.82 0.08 0.95 0.87 
DeS 
0.52 0.13 1.33 0.46 0.71 0.15 0.78 0.37 0.61 0.05 0.99 0.97 0.57 0.02 1.01 0.97 
Del. 
Large 
LDe 1.10 0.88 2.28 0.31 0.43 0.19 0.84 0.81 0.21 0.01 0.19 0.01 0.23 .003 2.44 0.52 
LDeG 
1.10 0.90 1.51 0.58 0.39 0.13 0.36 0.15 0 -- 0.28 0.06 0.10 .001 1.94 0.58 
LDeS 
0 0.31 10.0 0.33 0 0.19 0.51 0.59 0 -- 0 -- 0 -- 19.4 0.35 
Dup. 
Du 3.62 0.18 1.15 0.58 0.84 0.46 1.54 0.46 1.04 0.86 1.58 0.53 0.87 0.58 0.64 0.07 
DuG 
4.29 0.18 1.16 0.68 0.83 0.53 1.50 0.46 1.02 0.94 1.45 0.59 0.88 0.66 0.59 0.08 
DuS 






7.15 0.19 1.59 0.58 0.61 0.31 2.33 0.39 0.82 0.67 2.59 0.43 0.56 0.22 0.39 0.08 
LDuG 
8.00 0.18 1.42 0.64 0.70 0.48 2.05 0.40 0.84 0.72 2.21 0.45 0.31 0.97 0.38 0.09 
LDuS 
0.07 0.10 6.11 0.33 1.23 0.87 23.0 0.22 0 -- 12.0 0 -- 0.20 0 -- 
O=Overall CNVs OG= Overall Genic CNVs OS=Overall SFARI CNVs 
L=Large CNVs  LG=Large Genic CNVs  LS=Large SFARI CNVs 
De=Deletion CNVs DeG=Deletion Genic CNVs DeS=Deletion SFARI CNVs 
Du=Duplication CNVs DuG=Duplication Genic CNVs DuS=Duplication SFARI 
P: p-value for t-tests comparing growth abnormality to no growth abnormality 
Red-colored cell and bolded effect size: p< 0.05 




Table 6: Summary of Associations (nominal P<0.05) between CNVs in ASD-associated 
regions and Growth Abnormalities 
 




























1q21.1 All CNVs 
1q21.1 Large CNVs 
1q21.1 Dup 





















1q21.1 Del 0.015 2 (1.2) 1 (0.1) 12.00 
15q11.2 All CNVs 0.023 12 (7.2) 86 (13.8) 0.52 
15q11.2.13.1 All CNVs  














15q11.2 Large Dup 0.046 2 (2.9) 2 (0.3) 9.67 
Overweight - None < 0.05    
Underweight - None < 0.05    
High BMI - None < 0.05    
Low BMI - None < 0.05    
 
 201 
Table 7: Summary of Associations between CNVs in ASD-associated Regions and 
Growth Abnormalities Stratified by Sex 
 
L. Dup=Large Duplication 































































































1q21.1 Del 0.363 1(0.9) 1(0.2) 4.5 -- 1(0.5) 0(0) -- 










































































































Figure 2: CNV SEED Quality Control Pipeline (Sheppard et al., 2015) 
 
CNV= Copy Number Variants 
SNP= Single Nucleotide Polymorphism 
QC= Quality Control 
LRR= Log R Ratio 
BAF= B Allele Frequency 

























Figure 3. CNV Burden Results Comparison With and Without DD 






DD= Developmental Delay 
Values in cells: Effect Size (ratio of mean CNV in growth abnormality to 
mean CNV in normal growth) 
Green cells: significant p-values for t-test comparing means for CNV length in 
analysis excluding children with developmental delay  
Orange cells: significant p-values for t-test comparing means for CNV length 
















M/NM I/NI T/NT S/NS O/NO U/NU 
Overall 
Overall 1.62 0.96 0.83 1.03 1.07 1.07 
Overall Genic 1.81 0.92 0.83 0.95 1.08 1.03 
Overall  SFARI 0.67 0.97 0.79 0.91 1.08 1.14 
Large 
(>400kb) 
Large 2.68 1.03 0.69 1.24 0.99 1.27 
Large Genic 2.89 0.93 0.69 1.01 1.04 1.17 
Large SFARI 0.20 2.38 0.81 2.55 0.67 1.92 
Deletion 
All Del. 1.03 0.97 0.86 0.89 1.12 0.96 
Del. Genic 0.97 0.91 0.87 0.78 1.10 0.89 
Del. SFARI 0.72 1.07 0.63 0.77 1.01 1.09 
Duplicati
on 
All Dup. 1.98 0.95 0.81 1.11 1.04 1.13 
Dup. Genic 2.35 0.92 0.80 1.05 1.07 1.11 















M/NM I/NI T/NT S/NS O/NO U/NU 
Overall 
Overall 1.43 1.35 0.82 1.81 1.08 1.48 
Overall Genic 1.57 1.30 0.83 1.75 1.09 1.47 
Overall SFARI 0.64 1.12 0.78 1.19 1.04 1.29 
Large 
(>400kb) 
Large 2.19 2.26 0.66 3.56 1.08 2.41 
Large Genic 2.34 1.92 0.69 2.93 1.10 2.20 
Large SFARI 0.14 4.63 0.91 7.58 0.96 3.66 
Deletion 
All Del. 0.93 1.02 0.83 1.28 1.06 1.41 
Del. Genic 0.90 0.98 0.85 1.27 1.04 1.41 
Del. SFARI 0.64 1.04 0.64 0.79 0.93 1.18 
Duplica-
tion 
All Dup. 1.77 1.57 0.81 2.13 1.09 1.53 
Dup. Genic 2.02 1.51 0.81 2.03 1.04 1.51 





S. Table 1: CNV Burden for Counts and Lengths Comparing Children With 







N (Macrocephaly): 52 









All CNVs Overall 1.099 0.458 1.620 0.227 
Overall Genic  1.129 0.376 1.812 0.209 
Overall SFARI 0.922 0.702 0.675 0.070 
All Large CNVs Overall large 1.635 0.269 2.686 0.227 
Overall large 
Genic  
1.554 0.327 2.890 0.214 
Overall large 
SFARI 
1.497 0.661 0.209 0.032 
Deletions Overall 
Deletion 
1.045 0.763 1.036 0.843 
Deletion Genic  1.025 0.840 0.979 0.906 
Deletion SFARI 1.037 0.891 0.729 0.238 
Deletions Large Deletion Large 1.012 0.979 0.739 0.483 
Deletion Large 
Genic  
0.773 0.568 0.649 0.350 
Deletion Large 
SFARI 
4.792 0.434 0.940 0.956 
Duplications Dup. Overall 1.165 0.294 1.985 0.212 
Dup. Genic  1.257 0.246 2.357 0.186 
Dup. SFARI 0.755 0.179 0.586 0.049 
Duplications Large Dup. Large 
Overall 
1.759 0.240 2.981 0.216 
Dup. Large 
Genic  
1.711 0.274 3.321 0.197 
Dup. Large 
SFARI 
0.630 0.587 0.017 0.008 
Bolded: significant at p<0.05. No statistically significant result after multiple testing 
corrections. 
Mac= Macrocephaly N=Normal Head Circumference HC=Head Circumference 
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S. Table II: CNV Burden for Lengths in Macrocephaly Stratified by Sex 
MACROCEPHALY  
Stratified by Sex 
 
Average CNV 




















All CNVs Overall 
 








































































Deletions Overall Deletion 
 





















































































































































Total and group totals 
Bolded: significant p<0.05 
Mac=Macrocephaly 














S. Table III: CNV Burden for Counts and Lengths Comparing Children With 







N (Microcephaly): 165 









All CNVs Overall 0.946 0.224 0.965 0.741 
Overall Genic  0.929 0.117 0.922 0.474 
Overall SFARI 0.898 0.249 0.970 0.849 
All Large CNVs Overall large 0.817 0.126 1.038 0.901 
Overall large 
Genic  
0.775 0.067 0.934 0.803 
Overall large 
SFARI 
1.416 0.488 2.387 0.271 
Deletions Overall 
Deletion 
0.957 0.531 0.974 0.760 
Deletion Genic  0.933 0.262 0.914 0.299 
Deletion SFARI 0.966 0.799 1.074 0.741 
Deletions Large Deletion Large 0.957 0.867 1.224 0.614 
Deletion Large 
Genic  
0.852 0.562 0.954 0.897 
Deletion Large 
SFARI 
1.510 0.658 4.134 0.415 
Duplications Dup. Overall 0.933 0.172 0.959 0.798 
Dup. Genic  0.925 0.229 0.927 0.657 
Dup. SFARI 0.800 0.084 0.798 0.253 
Duplications Large Dup. Large 
Overall 
0.789 0.116 1.009 0.977 
Dup. Large 
Genic  
0.760 0.082 0.931 0.819 
Dup. Large 
SFARI 
1.391 0.576 1.929 0.454 
Bolded: significant at p<0.05. No statistically significant result after multiple testing 
corrections. 




S. Table IV: CNV Burden for Lengths in Microcephaly Stratified by Sex 
MICROCEPHALY  
Stratified by Sex 
 
Average CNV 




















All CNVs Overall 
 
















































Deletions Overall Deletion 
 





































































































Total and group totals 
Bolded: significant p<0.05 
Mic=Macrocephaly 














S. Table V: CNV Burden for Counts and Lengths Comparing Children With Tall Stature 







N (Tall Stature): 116 









All CNVs Overall 0.909 0.029 0.832 0.033 
Overall Genic  0.937 0.195 0.831 0.069 
Overall SFARI 0.798 0.012 0.792 0.044 
All Large CNVs Overall large 0.751 0.070 0.699 0.095 
Overall large 
Genic  
0.778 0.121 0.699 0.099 
Overall large 
SFARI 
0.837 0.728 0.819 0.744 
Deletions Overall 
Deletion 
0.878 0.020 0.861 0.054 
Deletion Genic  0.932 0.198 0.875 0.119 
Deletion SFARI 0.685 0.004 0.631 0.005 
Deletions Large Deletion Large 0.545 0.056 0.877 0.759 
Deletion Large 
Genic  
0.646 0.202 0.710 0.374 
Deletion Large 
SFARI 
0.807 0.833 0.907 0.932 
Duplications Dup. Overall 0.948 0.389 0.815 0.099 
Dup. Genic  0.942 0.463 0.806 0.148 
Dup. SFARI 0.977 0.862 1.109 0.529 
Duplications Large Dup. Large 
Overall 
0.795 0.195 0.674 0.100 
Dup. Large 
Genic  
0.805 0.241 0.697 0.145 
Dup. Large 
SFARI 
0.848 0.781 0.778 0.728 
Bolded: significant at p<0.05. No statistically significant result after multiple testing 
corrections. 




S. Table VI: CNV Burden for Lengths in Tall Stature Stratified by Sex 
TALL STATURE 
Stratified by Sex 
Average CNV 






















All CNVs Overall 0.832 0.033 0.845 0.091 0.813 0.203 
Overall Genic  0.831 0.069 0.834 0.123 0.819 0.308 
Overall SFARI 0.792 0.044 0.745 0.047 0.861 0.410 
All Large 
CNVs 
Overall large 0.699 0.095 0.775 0.294 0.589 0.228 
Overall large 
Genic  
0.699 0.099 0.721 0.182 0.661 0.343 
Overall large 
SFARI 
0.819 0.744 1.176 0.831 0.313 0.317 
Deletions Overall 
Deletion 
0.861 0.054 0.928 0.492 0.766 0.010 
Deletion Genic  0.875 0.119 0.939 0.598 0.786 0.037 
Deletion 
SFARI 
0.631 0.005 0.573 0.012 0.711 0.158 
Deletions 
Large 
Deletion Large 0.877 0.759 1.211 0.738 0.431 0.191 
Deletion Large 
Genic  
0.710 0.374 0.936 0.896 0.399 0.132 
Deletion Large 
SFARI 
0.907 0.932 4.514 0.442 0 -- 
Duplications Duplic. 
Overall 
0.815 0.099 0.794 0.100 0.840 0.465 
Duplic. Genic  0.806 0.148 0.773 0.124 0.837 0.532 





0.674 0.100 0.716 0.211 0.613 0.316 
Duplic. Large 
Genic  
0.697 0.145 0.683 0.172 0.708 0.482 
Duplic. Large 
SFARI 
0.778 0.728 0.768 0.757 1.238 0.870 
Total and group totals 
Bolded: significant p<0.05 
*: significant at p<0.0005 














S. Table VII: CNV Burden for Counts and Lengths Comparing Children Short Stature 







N (Short Stature): 
68 








All CNVs Overall 0.906 0.089 1.031 0.879 
Overall Genic  0.931 0.313 0.956 0.829 
Overall SFARI 0.886 0.332 0.914 0.636 
All Large CNVs Overall large 0.773 0.159 1.248 0.670 
Overall large 
Genic  
0.734 0.117 1.015 0.973 
Overall large 
SFARI 
1.786 0.411 2.552 0.413 
Deletions Overall Deletion 0.917 0.229 0.896 0.236 
Deletion Genic  0.950 0.496 0.785 0.008 
Deletion SFARI 0.911 0.540 0.778 0.159 
Deletions Large Deletion Large 0.465 0.036 0.756 0.574 
Deletion Large 
Genic  
0.275 0.001 0.233 0.001 
Deletion Large 
SFARI 
1.378 0.794 0.494 0.520 
Duplications Duplic. Overall 0.894 0.175 1.112 0.725 
Duplic. Genic  0.909 0.388 1.054 0.863 
Duplic. SFARI 0.847 0.386 1.180 0.645 
Duplications Large Duplic. Large 
Overall 
0.838 0.395 1.317 0.633 
Duplic. Large 
Genic  
0.830 0.399 1.155 0.779 
Duplic. Large 
SFARI 
1.929 0.438 3.511 0.364 
Bolded: significant at p<0.05. No statistically significant result after multiple testing 
corrections. 
SS= Short Stature    N= Normal Height 
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S. Table VIII: CNV Burden for Lengths in Short Stature Stratified by Sex 
TALL STATURE 
Stratified by Sex 
Average CNV 






















All CNVs Overall 1.031 0.879 0.814 0.129 1.332 0.479 
Overall Genic  0.956 0.829 0.708 0.024 1.288 0.523 
Overall SFARI 0.914 0.636 0.808 0.264 1.069 0.851 
All Large 
CNVs 
Overall large 1.248 0.670 0.600 0.083 2.138 0.406 
Overall large 
Genic  
1.015 0.973 0.433 0.008 1.799 0.459 
Overall large 
SFARI 
2.552 0.413 0 -- 6.199 0.259 
Deletions Overall 
Deletion 
0.896 0.236 0.838 0.112 0.978 0.891 





0.778 0.159 0.775 0.273 0.782 0.375 
Deletions 
Large 










0.494 0.520 0 -- 0.511 0.599 
Duplications Duplic. Overall 1.112 0.725 0.800 0.255 1.539 0.459 
Duplic. Genic  1.054 0.863 0.700 0.118 1.506 0.461 





1.317 0.633 0.590 0.105 2.331 0.398 
Duplic. Large 
Genic  
1.155 0.779 0.485 0.038 2.057 0.407 
Duplic. Large 
SFARI 
3.511 0.364 0 -- 22.99 0.225 
Total and group totals 
Bolded: significant p<0.05 
*: significant at p<0.0005 






















N (Overweight): 106 









All CNVs Overall 1.080 0.366 1.071 0.621 
Overall Genic  1.088 0.308 1.083 0.594 
Overall SFARI 1.096 0.571 1.083 0.729 
All Large CNVs Overall large 1.103 0.667 0.997 0.994 
Overall large 
Genic  
1.146 0.591 1.045 0.874 
Overall large 
SFARI 
1.130 0.835 0.673 0.515 
Deletions Overall 
Deletion 
1.087 0.510 1.120 0.458 
Deletion Genic  1.074 0.500 1.105 0.466 
Deletion SFARI 1.063 0.801 1.011 0.973 
Deletions Large Deletion Large 0.712 0.302 0.937 0.880 
Deletion Large 
Genic  
0.661 0.265 0.842 0.673 
Deletion Large 
SFARI 
1.808 0.548 0.761 0.777 
Duplications Dup. Overall 1.072 0.356 1.042 0.813 
Dup. Genic  1.104 0.317 1.070 0.731 
Dup. SFARI 1.147 0.322 1.214 0.267 
Duplications Large Dup. Large 
Overall 
1.185 0.509 1.007 0.981 
Dup. Large 
Genic  
1.246 0.436 1.081 0.801 
Dup. Large 
SFARI 
0.904 0.893 0.632 0.558 
Bolded: significant at p<0.05. No statistically significant result after multiple testing 
corrections. 




S. Table X: CNV Burden for Lengths in Overweight Stratified by Sex 
OVERWEIGHT              
Stratified by Sex 
Average CNV 






















All CNVs Overall 1.071 0.621 1.130 0.519 0.961 0.822 
Overall Genic  1.083 0.594 1.167 0.442 0.935 0.740 
Overall SFARI 1.083 0.729 1.216 0.548 0.840 0.360 
All Large 
CNVs 
Overall large 0.997 0.994 1.142 0.707 0.736 0.473 
Overall large 
Genic  
1.045 0.874 1.241 0.546 0.712 0.434 
Overall large 
SFARI 
0.673 0.515 1.090 0.904 0 -- 
Deletions Overall 
Deletion 
1.120 0.458 1.279 0.251 0.827 0.116 
Deletion Genic  1.105 0.466 1.279 0.192 0.780 0.040 
Deletion 
SFARI 
1.011 0.973 1.236 0.665 0.615 0.052 
Deletions 
Large 
Deletion Large 0.937 0.880 1.387 0.551 0.213 0.008 
Deletion Large 
Genic  
0.842 0.673 1.368 0.527 0 -- 
Deletion Large 
SFARI 
0.761 0.777 3.124 0.415 0 -- 
Duplications Duplic. Overall 1.042 0.813 1.043 0.859 1.041 0.866 
Duplic. Genic  1.070 0.731 1.101 0.716 1.019 0.946 





1.007 0.981 1.108 0.797 0.821 0.674 
Duplic. Large 
Genic  
1.081 0.801 1.219 0.622 0.844 0.719 
Duplic. Large 
SFARI 
0.632 0.558 0.802 0.801 0 -- 
Total and group totals 
Bolded: significant p<0.05 
*: significant at p<0.0005 





















N (Underweight): 63 









All CNVs Overall 0.945 0.413 1.074 0.740 
Overall Genic  0.943 0.408 1.034 0.876 
Overall SFARI 1.006 0.964 1.148 0.488 
All Large CNVs Overall large 0.835 0.297 1.275 0.672 
Overall large 
Genic  
0.842 0.356 1.171 0.747 
Overall large 
SFARI 
1.141 0.871 1.924 0.620 
Deletions Overall 
Deletion 
0.974 0.802 0.964 0.751 
Deletion Genic  0.944 0.507 0.899 0.313 
Deletion SFARI 1.112 0.589 1.093 0.657 
Deletions Large Deletion Large 0.798 0.546 0.520 0.066 
Deletion Large 
Genic  
0.953 0.906 0.687 0.335 
Deletion Large 
SFARI 
0 -- 0 -- 
Duplications Dup. Overall 0.910 0.258 1.139 0.686 
Dup. Genic  0.941 0.566 1.111 0.742 
Dup. SFARI 0.844 0.414 1.249 0.554 
Duplications Large Dup. Large 
Overall 
0.843 0.372 1.387 0.604 
Dup. Large 
Genic  
0.819 0.345 1.257 0.680 
Dup. Large 
SFARI 
1.521 0.652 2.805 0.505 
Bolded: significant at p<0.05. No statistically significant result after multiple testing 
correction. 




S. Table XII: CNV Burden for Lengths in Underweight Stratified by Sex 
UNDERWEIGHT              
Stratified by Sex 
Average CNV 






















All CNVs Overall 1.074 0.740 0.939 0.619 1.315 0.596 
Overall Genic  1.034 0.876 0.924 0.569 1.222 0.693 
Overall SFARI 1.148 0.488 1.099 0.629 1.234 0.623 
All Large 
CNVs 
Overall large 1.275 0.672 0.711 0.229 2.257 0.474 
Overall large 
Genic  
1.171 0.747 0.722 0.253 1.909 0.506 
Overall large 
SFARI 
1.924 0.620 0.149 0.039 4.678 0.442 
Deletions Overall 
Deletion 
0.964 0.751 1.018 0.911 0.866 0.191 
Deletion Genic  0.899 0.313 0.962 0.788 0.786 0.080 
Deletion 
SFARI 
1.093 0.657 1.153 0.594 0.990 0.973 
Deletions 
Large 
Deletion Large 0.520 0.066 0.727 0.465 0.199 0.014 
Deletion Large 
Genic  
0.687 0.335 0.948 0.913 0.284 0.060 
Deletion Large 
SFARI 
0 -- 0 -- 0 -- 
Duplications Duplic. Overall 1.139 0.686 0.891 0.506 1.583 0.532 
Duplic. Genic  1.111 0.742 0.901 0.581 1.458 0.596 





1.387 0.604 0.708 0.278 2.592 0.437 
Duplic. Large 
Genic  
1.257 0.680 0.683 0.242 2.211 0.456 
Duplic. Large 
SFARI 
2.805 0.505 0.171 0.072 12.05 0.369 
Total and group totals 
Bolded: significant p<0.05 
*: significant at p<0.0005  














S. Table XIII: CNV Burden for Counts and Lengths Comparing Children With High BMI 







N (High BMI): 118 









All CNVs Overall 1.041 0.589 0.972 0.831 
Overall Genic  1.025 0.740 0.997 0.847 
Overall SFARI 1.040 0.787 0.972 0.831 
All Large CNVs Overall large 0.984 0.943 0.799 0.407 
Overall large 
Genic  
1.013 0.954 0.844 0.533 
Overall large 
SFARI 
0.548 0.231 0.382 0.109 
Deletions Overall 
Deletion 
1.031 0.778 1.038 0.786 
Deletion Genic  1.035 0.714 1.003 0.976 
Deletion SFARI 1.025 0.906 1.066 0.841 
Deletions Large Deletion Large 0.541 0.035 0.731 0.424 
Deletion Large 
Genic  
0.572 0.081 0.757 0.463 
Deletion Large 
SFARI 
1.827 0.546 1.365 0.764 
Duplications Dup. Overall 1.054 0.460 0.934 0.686 
Dup. Genic  1.013 0.888 0.955 0.810 
Dup. SFARI 1.063 0.648 1.157 0.453 
Duplications Large Dup. Large 
Overall 
1.081 0.746 0.808 0.476 
Dup. Large 
Genic  
1.107 0.702 0.858 0.611 
Dup. Large 
SFARI 
0.228 0.018 0.211 0.049 
Bolded: significant at p<0.05. No statistically significant result after multiple testing 
corrections. 




S. Table XIV: CNV Burden for Lengths in High BMI Stratified by Sex 
HIGH BMI 
Stratified by Sex 
Average CNV 






















All CNVs Overall 1.099 0.660 1.028 0.875 0.872 0.420 
Overall Genic  0.997 0.847 1.037 0.845 0.864 0.459 
Overall SFARI 0.972 0.831 1.276 0.403 0.772 0.227 
All Large 
CNVs 
Overall large 0.799 0.407 0.963 0.912 0.529 0.148 
Overall large 
Genic  
0.844 0.533 1.022 0.949 0.564 0.188 
Overall large 
SFARI 
0.382 0.109 0.599 0.454 0 -- 
Deletions Overall 
Deletion 
1.038 0.786 1.120 0.551 0.866 0.182 
Deletion Genic  1.003 0.976 1.089 0.621 0.821 0.085 
Deletion 
SFARI 
1.066 0.841 1.339 0.496 0.575 0.024 
Deletions 
Large 
Deletion Large 0.731 0.424 0.947 0.911 0.229 0.003 
Deletion Large 
Genic  
0.757 0.463 1.064 0.890 0.102 0.001 
Deletion Large 
SFARI 
1.365 0.764 2.615 0.465 0 -- 
Duplications Duplic. Overall 0.934 0.686 0.972 0.898 0.875 0.584 
Duplic. Genic  0.955 0.810 1.006 0.979 0.885 0.662 





0.808 0.476 0.965 0.926 0.561 0.225 
Duplic. Large 
Genic  
0.858 0.611 1.014 0.970 0.626 0.316 
Duplic. Large 
SFARI 
0.211 0.049 0.321 0.201 0 -- 
Total and group totals 
Bolded: significant p<0.05 
*: significant at p<0.0005 













S. Table XV: CNV Burden for Counts and Lengths Comparing Children With Low BMI 







N (Low BMI): 75 









All CNVs Overall 0.957 0.446 0.871 0.219 
Overall Genic  0.944 0.358 0.867 0.253 
Overall SFARI 1.054 0.638 1.142 0.485 
All Large CNVs Overall large 0.822 0.363 0.641 0.118 
Overall large 
Genic  
0.876 0.556 0.723 0.242 
Overall large 
SFARI 
0.862 0.797 1.616 0.663 
Deletions Overall 
Deletion 
0.896 0.096 0.939 0.543 
Deletion Genic  0.922 0.184 0.930 0.515 
Deletion SFARI 0.987 0.938 1.197 0.513 
Deletions Large Deletion Large 0.639 0.193 1.175 0.813 
Deletion Large 
Genic  
0.772 0.490 1.241 0.706 
Deletion Large 
SFARI 
1.437 0.773 9.233 0.376 
Duplications Dup. Overall 1.031 0.680 0.833 0.220 
Dup. Genic  0.971 0.766 0.832 0.282 
Dup. SFARI 1.158 0.425 1.043 0.841 
Duplications Large Dup. Large 
Overall 
0.862 0.544 0.571 0.055 
Dup. Large 
Genic  
0.898 0.671 0.641 0.133 
Dup. Large 
SFARI 
0.718 0.614 0.291 0.082 
Bolded: significant at p<0.05. No statistically significant result after multiple testing 
corrections. 




S. Table XVI: CNV Burden for Lengths in Low BMI Stratified by Sex 
LOW BMI 
Stratified by Sex 
Average CNV 






















All CNVs Overall 0.871 0.219 0.932 0.601 0.764 0.188 
Overall Genic  0.867 0.253 0.960 0.773 0.710 0.164 
Overall SFARI 1.142 0.485 1.195 0.460 1.052 0.871 
All Large 
CNVs 
Overall large 0.641 0.118 0.676 0.199 0.591 0.358 
Overall large 
Genic  
0.723 0.242 0.826 0.523 0.568 0.324 
Overall large 
SFARI 
1.616 0.663 0.395 0.213 3.708 0.475 
Deletions Overall 
Deletion 
0.939 0.543 0.913 0.334 0.989 0.965 
Deletion Genic  0.930 0.515 0.916 0.369 0.957 0.874 
Deletion 
SFARI 
1.197 0.513 1.307 0.443 1.015 0.974 
Deletions 
Large 
Deletion Large 1.175 0.813 0.590 0.240 2.439 0.526 
Deletion Large 
Genic  
1.241 0.706 0.893 0.824 1.944 0.579 
Deletion Large 
SFARI 
9.233 0.376 0 -- 19.47 0.352 
Duplications Duplic. Overall 0.833 0.220 0.944 0.755 0.644 0.078 
Duplic. Genic  0.832 0.282 0.986 0.946 0.589 0.084 





0.571 0.055 0.688 0.280 0.391 0.083 
Duplic. Large 
Genic  
0.641 0.133 0.815 0.554 0.385 0.094 
Duplic. Large 
SFARI 
0.291 0.082 0.450 0.313 0 -- 
Total and group totals 
Bolded: significant p<0.05  
*: significant at p<0.0005 













S. Table XVII: Association between CNVs in ASD-associated regions and Macrocephaly 
 
Region All and All large CNVs Deletion and Deletion 
large CNVs 
Duplication and 


















1q21.1A 4(7.7%) 12(1.9%) 0.028 0(0%) 1(0.1%) 1 4(7.7%) 11(1.7%) 0.022 
1q21.1L 3(5.7%) 4(0.6%) 0.012 0(0%) 0(0%) -- 3(5.7%) 4(0.6%) 0.012 
3q29A 1(1.9%) 5(0.8%) 0.383 0(0%) 0(0%) -- 1(1.9%) 5(0.8%) 0.383 
3q29L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
7q11.23A 0(0%) 6(0.9%) 1 0(0%) 0(0%) -- 0(0%) 6(0.9%) 1 
7q11.23L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
15q11.2A 6(11.5%) 86(13.8%) 0.833 5(9.6%) 51(8.1%) 0.608 1(1.9%) 35(5.6%) 0.513 
15q11.2L 0(0%) 2(0.3%) 1 0(0%) 0(0%) -- 0(0%) 2(0.3%) 1 
15q11.2.13.1A 6(11.5%) 85(13.6%) 0.833 5(9.6%) 51(8.1%) 0.608 1(1.9%) 34(5.4%) 0.509 
15q11.2.13.1L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
15q13.3A 0(0%) 11(1.7%) 1 0(0%) 0(0%) -- 0(0%) 11(1.7%) 1 
15q13.3L 0(0%) 8(1.2%) 1 0(0%) 0(0%) -- 0(0%) 8(1.2%) 1 
16p11.2A 0(0%) 3(0.5%) 1 0(0%) 1(0.1%) 1 0(0%) 2(0.3%) 1 
16p11.2L 0(0%) 2(0.3%) 1 0(0%) 1(0.1%) 1 0(0%) 1(0.1%) 1 
16p13.11A 6(11.5%) 73(11.7%) 1 1(1.9%) 13(2%) 1 5(9.6%) 60(9.6%) 1 
16p13.11L 0(0%) 3(0.5%) 1 0(0%) 1(0.1%) 1 0(0%) 2(0.3%) 1 
17q12A 4(7.7%) 107(17.1%) 0.081 0(0%) 7(1.1%) 1 4(7.7%) 100(16%) 0.158 
17q12L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
22q11.21A 1(1.9%) 29(4.6%) 0.721 0(0%) 5(0.8%) 1 1(1.9%) 24 0.712 
22q11.21L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 























S. Table XVIII: Association between CNVs in ASD-associated regions and 
Microcephaly 
 
Region All and All large CNVs Deletion and Deletion 
large CNVs 
Duplication and 



















1q21.1A 2(1.2%) 12(1.9%) 0.745 2(1.2%) 1(0.1%) 0.015 0(0%) 11 (1.7%) 0.132 
1q21.1L 0(0%) 4(0.6%) 0.585 0(0%) 0(0%) -- 0(0%) 4(0.6%) 0.585 
3q29A 0(0%) 5(0.8%) 0.589 0(0%) 0(0%) -- 0(0%) 5(0.8%) 0.589 
3q29L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
7q11.23A 5(3.0%) 6(0.9%) 0.058 2(1.2%) 0(0%) 0.043 3(1.8%) 6(0.9%) 0.405 
7q11.23L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
15q11.2A 12(7.2%) 86 (13.8%) 0.023 7(4.2%) 51(8.1%) 0.094 5(3.0%) 35(5.6%) 0.231 
15q11.2L 3(1.8%) 2(0.3%) 0.064 1(0.6%) 0(0%) 0.209 2(1.2%) 2(0.3%) 0.195 
15q11.2.13.1A 9(5.4%) 85(13.6%) 0.002 6(3.6%) 51(8.1%) 0.043 3(1.8%) 34(5.4%) 0.060 
15q11.2.13.1L 1(0.6%) 0(0%) 0.209 1(0.6%) 0(0%) 0.209 0(0%) 0(0%) -- 
15q13.3A 3(1.8%) 11(1.7%) 1 0(0%) 0(0%) -- 3(1.8%) 11(1.7%) 1 
15q13.3L 1(0.6%) 8(1.2%) 0.693 0(0%) 0(0%) -- 1(0.6%) 8(1.2%) 0.693 
16p11.2A 1(0.6%) 3(0.5%) 1 0(0%) 1(0.1%) 1 1(0.6%) 2(0.3%) 0.506 
16p11.2L 0(0%) 2(0.3%) 1 0(0%) 1(0.1%) 1 0(0%) 1(0.1%) 1 
16p13.11A 17(10.3%) 73(11.7%) 0.681 4(2.4%) 13(2%) 0.765 13(7.8%) 60(9.6%) 0.548 
16p13.11L 0(0%) 3(0.5%) 1 0(0%) 1(0.1%) 1 0(0%) 2(0.3%) 1 
17q12A 24(14.5%) 107(17.1%) 0.481 0(0%) 7(1.1%) 0.355 24(14.5%) 100(16%) 0.718 
17q12L 2(1.2%) 0(0%) 0.043 0(0%) 0(0%) -- 2(1.2%) 0(0%) 0.043 
22q11.21A 9(5.4%) 29(4.6%) 0.683 0(0%) 5(0.8%) 0.589 9(5.4%) 24 0.381 
22q11.21L 2(1.2%) 0(0%) 0.043 0(0%) 0(0%) -- 2(1.2%) 0(0%) 0.043 























S. Table XIX: Association between CNVs in ASD-associated regions and Tall Stature 
 
Region All and All large CNVs Deletion and Deletion 
large CNVs 
Duplication and 



















1q21.1A 1(0.8%) 16(2.4%) 0.492 1(0.8%) 2(0.3%) 0.386 0(0%) 14(2.1%) 0.245 
1q21.1L 0(0%) 7(1.0%) 0.602 0(0%) 0(0%) -- 0(0%) 7(1.0%) 0.602 
3q29A 1(0.8%) 4(0.6%) 0.558 0(0%) 0(0%) -- 1(0.8%) 4(0.6%) 0.558 
3q29L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
7q11.23A 3(2.5%) 8(1.2%) 0.221 0(0%) 2(0.3%) 1 3(2.5%) 6(0.9%) 0.140 
7q11.23L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
15q11.2A 17(14.6%) 78(11.9%) 0.442 11(9.5%) 47(7.1%) 0.443 6(5.1%) 31(4.7%) 0.814 
15q11.2L 0(0%) 3(0.4%) 1 0(0%) 1(0.1%) 1 0(0%) 2(0.3%) 1 
15q11.2.13.1A 16(12.7%) 78(11.9%) 0.540 11(9.5%) 47(7.1%) 0.443 5(3.9%) 31(4.7%) 1 
15q11.2.13.1L 0(0%) 1(0.1%) 1 0(0%) 1(0.1%) 1 0(0%) 0(0%) -- 
15q13.3A 2(1.7%) 10(1.5%) 0.698 0(0%) 0(0%) -- 2(1.7%) 10(1.5%) 0.698 
15q13.3L 2(1.7%) 6(0.9%) 0.343 0(0%) 0(0%) -- 2(1.7%) 6(0.9%) 0.343 
16p11.2A 0(0%) 4(0.6%) 1 0(0%) 1(0.1%) 1 0(0%) 3(0.4%) 1 
16p11.2L 0(0%) 2(0.3%) 1 0(0%) 1(0.1%) 1 0(0%) 1(0.1%) 1 
16p13.11A 10(8.6%) 79(12.0%) 0.345 3(2.5%) 15(2.2%) 1 7(6.0%) 64(9.7%) 0.226 
16p13.11L 0(0%) 3(0.4%) 1 0(0%) 1(0.1%) 1 0(0%) 2(0.3%) 1 
17q12A 20(17.2%) 103(15.7%)  0.680 1(0.8%) 4(0.6%) 0.558 19(16.3%) 99(15.1%) 0.779 
17q12L 0(0%) 2(0.3%) 1 0(0%) 0(0%) -- 0(0%) 2(0.3%) 1 
22q11.21A 7(6.0%) 32 0.644 1(0.8%) 4(0.6%) 0.558 6(5.1%) 28(4.2%) 0.625 
22q11.21L 0(0%) 2(0.3%) 1 0(0%) 0(0%) -- 0(0%) 2(0.3%) 1 


























S. Table XX: Association between CNVs in ASD-associated regions and Short Stature 
 
Region All and All large CNVs Deletion and Deletion 
large CNVs 
Duplication and 
Duplication large CNVs 


















1q21.1A 1(1.4%) 16(2.4%) 1 0(0%) 2(0.3%) 1 1(1.4%) 14 (2.1%) 1 
1q21.1L 0(0%) 7(1.0%) 1 0(0%) 0(0%) -- 0(0%) 7(1.0%) 1 
3q29A 1(1.4%) 4(0.6%) 0.390 0(0%) 0(0%) -- 1(1.4%) 4(0.6%) 0.390 
3q29L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
7q11.23A 0(0%) 8(1.2%) 1 0(0%) 2(0.3%) 1 0(0%) 6(0.9%) 1 
7q11.23L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
15q11.2A 9(13.2%) 78(11.9%) 0.697 5(7.3%) 47(7.1%) 1 4(5.8%) 31(4.7%) 0.561 
15q11.2L 2(2.9%) 3(0.4%) 0.072 0(0%) 1(0.1%) 1 2(2.9%) 2(0.3%) 0.046 
15q11.2.13.1A 6(8.8%) 78(11.9%) 0.553 4(5.8%) 47(7.1%) 1 2(2.9%) 31(4.7%) 0.760 
15q11.2.13.1L 0(0%) 1(0.1%) 1 0(0%) 1(0.1%) 1 0(0%) 0(0%) -- 
15q13.3A 2(2.9%) 10(1.5%) 0.313 0(0%) 0(0%) -- 2(2.9%) 10(1.5%) 0.313 
15q13.3L 1(1.4%) 6(0.9%) 0.500 0(0%) 0(0%) -- 1(1.4%) 6(0.9%) 0.500 
16p11.2A 0(0%) 4(0.6%) 1 0(0%) 1(0.1%) 1 0(0%) 3(0.4%) 1 
16p11.2L 0(0%) 2(0.3%) 1 0(0%) 1(0.1%) 1 0(0%) 1(0.1%) 1 
16p13.11A 7(10.3%) 79(12.0%) 0.843 0(0%) 15(2.2%) 0.383 7 (10.3%) 64(9.7%) 0.828 
16p13.11L 0(0%) 3(0.4%) 1 0(0%) 1(0.1%) 1 0(0%) 2(0.3%) 1 
17q12A 12(17.6%) 103(15.7%)  0.727 2(2.9%) 4(0.6%) 0.101 10(14.7%) 99(15.1%) 1 
17q12L 0(0%) 2(0.3%) 1 0(0%) 0(0%) -- 0(0%) 2(0.3%) 1 
22q11.21A 0(0%) 32 0.063 0(0%) 4(0.6%) 1 0(0%) 28(4.2%) 0.099 
22q11.21L 0(0%) 2(0.3%) 1 0(0%) 0(0%) -- 0(0%) 2(0.3%) 1 



















S. Table XXI: Association between CNVs in ASD-associated regions and Overweight 
 
Region All and All large CNVs Deletion and Deletion 
large CNVs 
Duplication and 



















1q21.1A 1(0.9%) 17(2.5%) 0.492 0(0%) 3(0.4%) 1 1(0.9%) 14(2.1%) 0.707 
1q21.1L 1(0.9%) 6(0.9%) 1 0(0%) 0(0%) -- 1(0.9%) 6(0.9%) 1 
3q29A 1(0.9%) 5(0.7%) 0.586 0(0%) 0(0%) -- 1(0.9%) 5(0.7%) 0.586 
3q29L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
7q11.23A 2(1.9%) 8(1.2%) 0.634 0(0%) 2(0.3%) 1 2(1.9%) 6(0.9%) 0.299 
7q11.23L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
15q11.2A 11(10.3%) 84(12.5%) 0.633 6(5.6%) 52(7.7%) 0.553 5(4.7%) 32(4.7%) 1 
15q11.2L 1(0.9%) 3(0.4%) 0.444 0(0%) 1(0.1%) 1 1(0.9%) 2(0.3%) 0.356 
15q11.2.13.1A 10 (9.4%) 83(12.3%) 0.518 6(5.6%) 52(7.7%) 0.553 4(3.7%) 31(4.6%) 1 
15q11.2.13.1L 0(0%) 1(0.1%) 1 0(0%) 1(0.1%) 1 0(0%) 0(0%) -- 
15q13.3A 1(0.9%) 12(1.7%) 1 0(0%) 0(0%) -- 1(0.9%) 12(1.7%) 1 
15q13.3L 1(0.9%) 8(1.2%) 1 0(0%) 0(0%) -- 1(0.9%) 8(1.2%) 1 
16p11.2A 1(0.9%) 2(0.3%) 0.356 1(0.9%) 0(0%) 0.136 0(0%) 2(0.3%) 1 
16p11.2L 1(0.9%) 0(0%) 0.136 1(0.9%) 0(0%) 0.136 0(0%) 0(0%) -- 
16p13.11A 11(10.3%) 0(0%) 0.746 0(0%) 17(2.5%) 0.149 11(10.3%) 62(9.2%) 0.720 
16p13.11L 1(0.9%) 2(0.3%) 0.356 0(0%) 1(0.1%) 1 1(0.9%) 1(0.1%) 0.254 
17q12A 23(21.7%) 102(15.2%) 0.116 2(1.9%) 5(0.7%) 0.245 21(19.8%) 97(14.4%) 0.188 
17q12L 0(0%) 1(0.1%) 1 0(0%) 0(0%) -- 0(0%) 1(0.1%) 1 
22q11.21A 4(3.7%) 35(5.2%) 0.639 1(0.9%) 4(0.6%) 0.520 3(2.8%) 31(4.6%) 0.608 
22q11.21L 0(0%) 1(0.1%) 1 0(0%) 0(0%) -- 0(0%) 1(0.1%) 1 




















S. Table XXII: Association between CNVs in ASD-associated regions and Underweight 
 
Region All and All large CNVs Deletion and Deletion 
large CNVs 
Duplication and 
Duplication large CNVs 


















1q21.1A 0(0%) 17(2.5%) 0.386 0(0%) 3(0.4%) 1 0(0%) 14(2.1%) 0.623 
1q21.1L 0(0%) 6(0.9%) 1 0(0%) 0(0%) -- 0(0%) 6(0.9%) 1 
3q29A 0(0%) 5(0.7%) 1 0(0%) 0(0%) -- 0(0%) 5(0.7%) 1 
3q29L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
7q11.23A 1(1.5%) 8(1.2%) 0.556 0(0%) 2(0.3%) 1 1(1.5%) 6(0.9%) 0.468 
7q11.23L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
15q11.2A 9(14.2%) 84(12.5%) 0.691 5(7.9%) 52(7.7%) 1 4(6.3%) 32(4.7%) 0.539 
15q11.2L 1(1.5%) 3(0.4%) 0.302 0(0%) 1(0.1%) 1 1(1.5%) 2(0.3%) 0.236 
15q11.2.13.1A 7(11.1%) 83(12.3%) 1 4(6.3%) 52(7.7%) 1 3(4.7%) 31(4.6%) 1 
15q11.2.13.1L 0(0%) 1(0.1%) 1 0(0%) 1(0.1%) 1 0(0%) 0(0%) -- 
15q13.3A 1(1.5%) 12(1.7%) 1 0(0%) 0(0%) -- 1(1.5%) 12(1.7%)  1 
15q13.3L 0(0%) 8(1.2%) 1 0(0%) 0(0%) -- 0(0%) 8(1.2%) 1 
16p11.2A 1(1.5%) 2(0.3%) 0.236 0(0%) 0(0%) -- 1(1.5%) 2(0.3%) 0.236 
16p11.2L 1(1.5%) 0(0%) 0.085 0(0%) 0(0%) -- 1(1.5%) 0(0%) 0.085 
16p13.11A 6(9.5%) 0(0%) 1 1(1.5%) 17(2.5%) 1 5(7.9%) 62(9.2%) 1 
16p13.11L 0(0%) 2(0.3%) 1 0(0%) 1(0.1%) 1 0(0%) 1(0.1%) 1 
17q12A 10(15.8%) 102(15.2%) 0.855 0(0%) 5(0.7%) 1 10(15.8%) 97(14.4%) 0.711 
17q12L 1(1.5%) 1(0.1%) 0.164 0(0%) 0(0%) -- 1(1.5%) 1(0.1%) 0.164 
22q11.21A 0(0%) 35(5.2%) 0.063 0(0%) 4(0.6%) 1 0(0%) 31(4.6%) 0.100 
22q11.21L 0(0%) 1(0.1%) 1 0(0%) 0(0%) -- 0(0%) 1(0.1%) 1 





















S. Table XXIII: Association between CNVs in ASD-associated regions and High BMI 
 
Region All and All large CNVs Deletion and Deletion 
large CNVs 
Duplication and 



















1q21.1A 1(0.8%) 16(2.4%) 0.494 0(0%) 3(0.4%) 1 1(0.8%) 13 (2.0%) 0.707 
1q21.1L 1(0.8%) 6(0.9%) 1 0(0%) 0(0%) -- 1(0.8%) 6(0.9%) 1 
3q29A 1(0.8%) 5(0.7%) 1 0(0%) 0(0%) -- 1(0.8%) 5(0.7%) 1 
3q29L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
7q11.23A 3(2.5%) 8(1.2%) 0.389 0(0%) 2(0.3%) 1 3(2.5%) 6(0.9%) 0.149 
7q11.23L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
15q11.2A 14(11.8%) 82(12.6%) 0.881 9(7.6%) 47(7.2%) 0.848 5(4.2%) 35(5.4%) 0.821 
15q11.2L 1(0.8%) 3(0.4%) 0.489 0(0%) 0(0%) -- 1(0.8%) 3(0.4%) 0.489 
15q11.2.13.1A 14(11.8%) 79(12.2%) 1 10(8.4%)  46(7.1%) 0.567 4(3.3%) 33(5.1%) 0.639 
15q11.2.13.1L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
15q13.3A 0(0%) 11(1.7%) 0.230 0(0%) 0(0%) -- 0(0%) 11(1.7%) 0.230 
15q13.3L 0(0%) 8(1.2%) 0.616 0(0%) 0(0%) -- 0(0%) 8(1.2%) 0.616 
16p11.2A 1(0.8%) 2(0.3%) 0.395 1(0.8%) 0(0%) 0.154 0(0%) 2(0.3%) 1 
16p11.2L 1(0.8%) 0(0%) 0.154 1(0.8%) 0(0%) 0.154 0(0%) 0(0%) -- 
16p13.11A 10(8.4%) 75(11.6%) 0.425 0(0%) 16(2.5%) 0.151 10(8.4%) 59(9.1%) 1 
16p13.11L 0(0%) 3(0.4%) 1 0(0%) 1(0.1%) 1 0(0%) 2(0.3%) 1 
17q12A 24(20.3%) 97(14.9%) 0.169 1(0.8%) 6(0.9%) 1 23(19.5%) 91(14.0%) 0.158 
17q12L 0(0%) 1(0.1%) 1 0(0%) 0(0%) -- 0(0%) 1(0.1%) 1 
22q11.21A 7(5.9%) 29(4.4%) 0.479 1(0.8%) 4(0.6%) 0.568 6(5.1%) 25(3.8%) 0.609 
22q11.21L 0(0%) 1(0.1%) 1 0(0%) 0(0%) -- 0(0%) 1(0.1%) 1 



























S. Table XXIV: Association between CNVs in ASD-associated regions and Low BMI 
 
Region All and All large CNVs Deletion and Deletion 
large CNVs 
Duplication and 



















1q21.1A 1(1.3%) 16(2.4%) 1 0(0%) 3(0.4%) 1 1(1.3%) 13 (2.0%) 1 
1q21.1L 0(0%) 6(0.9%) 1 0(0%) 0(0%) -- 0(0%) 6(0.9%) 1 
3q29A 0(0%) 5(0.7%) 1 0(0%) 0(0%) -- 0(0%) 5(0.7%) 1 
3q29L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
7q11.23A 0(0%) 8(1.2%) 1 0(0%) 2(0.3%) 1 0(0%) 6(0.9%) 1 
7q11.23L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
15q11.2A 8 (10.6%) 82 (12.6%) 0.714 7(9.3%) 47(7.2%) 0.488 1(1.3%) 35(5.4%) 0.163 
15q11.2L 1(1.3%) 3(0.4%) 0.355 1(1.3%) 0(0%) 0.104 0(0%) 3(0.4%) 1 
15q11.2.13.1A 7(9.3%) 79(12.2%) 0.574 6(8.0%) 46(7.1%) 0.812 1(1.3%) 33(5.1%) 0.243 
15q11.2.13.1L 1(1.3%) 0(0%) 0.104 1(1.3%) 0(0%) 0.104 0(0%) 0(0%) -- 
15q13.3A 3(4.0%) 11(1.7%) 0.170 1(1.3%) 0(0%) 0.104 3(4.0%) 11(1.7%) 0.170 
15q13.3L 1(1.3%) 8(1.2%) 1 0(0%) 0(0%) -- 1(1.3%) 8(1.2%) 1 
16p11.2A 1(1.3%) 2(0.3%) 0.280 0(0%) 0(0%) -- 1(1.3%) 2(0.3%) 0.280 
16p11.2L 1(1.3%) 0(0%) 0.104 0(0%) 0(0%) -- 1(1.3%) 0(0%) 0.104 
16p13.11A 11(14.6%) 75(11.6%) 0.450 2(2.6%) 16 (2.5%) 0.709 9(12%) 59(9.1%) 0.404 
16p13.11L 0(0%) 3(0.4%) 1 0(0%) 1(0.1%) 1 0(0%) 2(0.3%) 1 
17q12A 14(18.6%) 97(14.9%) 0.399 1(1.3%) 6(0.9%) 0.537 14(18.6%) 91(14.0%) 0.299 
17q12L 1(1.3%) 1(0.1%) 0.197 0(0%) 0(0%) -- 1(1.3%) 1(0.1%) 0.197 
22q11.21A 3(4.0%) 29(4.4%) 1 0(0%) 4(0.6%) 1 3(4.0%) 25(3.8%) 1 
22q11.21L 0(0%) 1(0.1%) 1 0(0%) 0(0%) -- 0(0%) 1(0.1%) 1 














S. Table XXV: Summary of Overall Association Between ASD-associated CNVs and 












Total overlapping CNV 
counts across growth 





Fisher’s exact p 




























All Del Dup All Large All  Large All Large 










3q29 5 0(0%) 5(100%)       
7q11.23 14 2(7%) 12(93%)   Micro-
cephaly 
   
15q11.2 86 55(64%) 31(36%) Micro-
cephaly 
    Short 
Stature 




   
15q13.3 12 1(8%) 11(92%)       
16p11.2 5 2(40%) 3(60%)       
16p13.11 78 11(14%) 67(86%)       
17q12 131 7(5%) 124(95%)  Micro-
cephaly 
   Micro-
cephaly 
22q11.21 
31 3(10%) 28(90%)  Micro-
cephaly 




S. Table XXVI: Summary of Overall Association Between ASD-associated CNVs and 
Growth Abnormalities by Growth Abnormality Stratified by Sex 
Region All and All large CNVs Deletion and Deletion 
large CNVs 
Duplication and 
Duplication large CNVs 
Growth Abnormal Normal p-value Abnormal Normal p-
value 
Abnormal Normal p-value 
Macrocephaly 
ALL, N 52 623  52 623  52 623  
1q21.1A 4(7.7%) 12(1.9%) 0.028 0(0%) 1(0.1%) 1 4(7.7%) 11(1.7%) 0.022 
1q21.1L 3(5.7%) 4(0.6%) 0.012 0(0%) 0(0%) -- 3(5.7%) 4(0.6%) 0.012 
MALE, N 29 415        
1q21.1A 1(3%) 11(1.7%) 0.560 0(0%) 1(0.1%) 1 1(3.4%) 10(2.4%) 0.528 
1q21.1L 1(3%) 4(0.6%) 0.287 0(0%) 0(0%) -- 1(3.4%0 4(0.9%) 0.287 
FEMALE, N 24 208        
1q21.1A 3(12.5%) 1(0.5%) 0.003 0(0%) 0(0%) -- 3(12.5%) 1(0.5%) 0.003 
1q21.1L 2(8.3%) 0(0%) 0.010 0(0%) 0(0%) -- 2(8.3%) 0(0%) 0.010 
Microcephaly 
ALL 165 623  165 623  165 623  
1q21.1A 2(1.2%) 12(1.9%) 0.745 2(1.2%) 1(0.1%) 0.015 0(0%) 11(1.7%) 0.132 
1q21.1L 0(0%) 4(0.6%) 0.585 0(0%) 0(0%) -- 0(0%) 4(0.6%) 0.585 
MALE, N 105 415  105 415  105 415  
1q21.1A 1(0.9%) 11(2.6%) 0.474 1(0.9%) 1(0.2%) 0.363 0(0%) 10(2.4%) 0.224 
1q21.1L 0(0%) 4(0.9%) 0.587 0(0%) 0(0%) -- 0(0%) 4(0.9%) 0.587 
FEMALE, N 60 208  60 208  60 208  
1q21.1A 1(1.6%) 1(0.5%) 0.398 1(%) 0(0%) 0.224 0(0%) 1(0.5%) 1 
1q21.1L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
ALL 165 623  165 623  165 623  
15q11.2A 12(7.2%) 86(13.8%) 0.023 7(4.2%) 51(8.1%) 0.094 5(3.0%) 35(5.6%) 0.231 
15q11.2L 3(1.8%) 2(0.3%) 0.064 1(0.6%) 0(0%) 0.209 2(1.2%) 2(0.3%) 0.195 
MALE, N 105 415  105 415  105 415  
15q11.2A 6(5.7%) 55(13.2%) 0.040 4(3.8%) 30(7.2%) 0.270 2(1.9%) 25(6%) 0.136 
15q11.2L 0(0%) 2(0.5%) 1 0(0%) 0(0%) -- 0(0%) 2(0.5%) 1 
FEMALE, N 60 208  60 208  60 208  
15q11.2A 6(10%) 29(13.9%) 0.518 3(5%) 19(9.1%) 0.426 3(5%) 10(4.8%) 1 
15q11.2L 3(5%) 0(0%) 0.010 1(1.6%) 0(0%) 0.224 2(3.3%) 0(0%) 0.049 
ALL 165 623  165 623  165 623  
15q11.2.13.1A 9(5.4%) 85(13.6%) 0.002 6(3.6%) 51(8.1%) 0.043 3(1.8%) 34(5.4%) 0.060 
15q11.2.13.1L 1(0.6%) 0(0%) 0.209 1(0.6%) 0(0%) 0.209 0(0%) 0(0%) -- 
MALE, N 105 415  105 415  105 415  
15q11.2.13.1A 5(4.7%) 55(13.2%) 0.015 2(1.9%) 30(7.2%) 0.063 3(2.8%) 25(6.0%) 0.235 
15q11.2.13.1L 0(0%) 0(0%) -- 0(0%) 0(0%) -- 0(0%) 0(0%) -- 
FEMALE, N 60 208  60 208  60 208  
15q11.2.13.1A 4(6.6%) 28(13.4%) 0.180 3(5%) 21(10.1%) 0.307 1(1.6%) 9(4.3%) 0.465 
15q11.2.13.1L 1(1.6%) 0(0%) 0.224 1(1.6%) 0(0%) 0.224 0(0%) 0(0%) -- 
Short Stature 
ALL 68 656  68 656  68 656  
15q11.2A 9(13.2%) 78(11.9%) 0.697 5(7.3%) 47(7.1%) 1 4(5.8%) 31(4.7%) 0.561 
15q11.2L 2(2.9%) 3(0.4%) 0.072 0(0%) 1(0.1%) 1 2(2.9%) 2(0.3%) 0.046 
MALE, N 40 441  40 441  40 441  
15q11.2A 1(2.5%) 51(11.5%) 0.106 1(2.5%) 29(6.5%) 0.497 0(0%) 22(4.9%) 0.241 
15q11.2L 0(0%) 2(0.4%) 1 0(0%) 0(0%) -- 0(0%) 2(0.4%) 1 
FEMALE, N 28 215  28 215  28 215  
15q11.2A 8(28.5%) 25(11.6%) 0.034 4(14.2%) 16(7.4%) 0.262 4(14.2%) 9(4.1%) 0.048 





S. Figure I: Scatter Plots of Effect Size in All vs. White for Growth Abnormalities 
 
We created scatter plots of effect size for CNV burden lengths comparing results from the 
whole analytic sample to results among Non-Hispanic Whites only (S. Figure 1 below). 
Macrocephaly is the only growth abnormality that shows strong correlation between 
overall and Non-Hispanic White results. This suggests that Non-Hispanic Whites 
contribute significantly to the association between CNV burden and macrocephaly. For 
the other growth abnormalities we assessed, it appears that Non-Hispanic Whites do not 
drive the association between CNV burden and abnormal growth. Studies assessing 
genome-wide CNV analyses in different races have shown that there are ethnic 
differences of CNVs for anthropometric measurements including height and BMI in 
African and Asian ancestry populations compared to populations with European ancestry 
(Kang et al., 2010; Li et al., 2010). The potential confounding effect of race needs to be 
considered in evaluating CNV burden associations for growth abnormalities, although the 





S. Figure I: Scatter Plots of Effect Size in All vs. White for Growth Abnormalities 
 
Macrocephaly    Microcephaly 
 
% of NHW with Macrocephaly: 62.1% % of NHW with Microcephaly: 48.8% 
% of NHW with No Macrocephaly: 63% % of NHW with No Microcephaly: 63% 
 
Tall Stature     Short Stature 
 
% of NHW with Tall Stature: 54.0%  % of NHW with Short Stature: 64.3% 
% of NHW with No Tall Stature: 58% % of NHW with No Short Stature: 58% 
 
High BMI     Low BMI 
 
% of NHW with High BMI: 48.2%  % of NHW with Low BMI: 66.7% 
% of NHW with No High BMI: 59.4% % of NHW with No Low BMI: 59.4% 
 
Further description of S.Figure I provided in the text for appendices on pages that follow.  
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Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder that can 
manifest with varying degrees of severity. In addition, ASD often co-occurs with 
medical, behavioral, or other psychiatric disorders, and characterization of ASD by 
subgroups as defined by these co-occuring conditions is increasingly recognized (Levy et 
al., 2010; Muskens, Velders, & Staal, 2017). As ASD may well have multiple etiologies, 
classifying ASD into one homogenous category could easily limit our ability to identify 
true causal factors, while also precluding development of tailored approaches to 
prognostic and therapeutic strategies. Characterizing co-occurring phenotype as ASD 
sub-groups or sub-phenotypes could improve our understanding of the nuances of autism 
biology, and potentially unveil associations with risk factors related to distinct etiologies.  
 
In this dissertation, the phenotypes of dysmorphology and specifically abnormal growth 
as potential ASD sub-phenotypes were examined to help with etiologic research, 
particularly in genetic subgrouping.  Previous work in the SEED 1 study revealed 
association between ASD and dysmorphism (Shapira et al., 2014). Our assessment of 
growth abnormalities, a specific subset of dysmorphologic features, in this sample 
showed females with ASD had short stature and a combination of short stature, 
microcephaly and normal weight compared to typically developing females. When 
considering genetic risk via two cumulative measures of CNV burden, we found 
cumulatie CNV burden was negatively associated with dysmorphism among SEED 1 
cases and controls. We also observed decreased CNV burden among those CNVs 
encompassed previously reported candidate genes for ASD among children with tall 
stature and macrocephaly. Importantly, these associations also varied by sex. When 
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considering specific CNVs already known to be associated with ASD, we observed 
association between ASD and short stature at CNV region 15p11.2 that varied by sex, 
with significant association only observed in females.  
 
Our results not only highlight the potential utility of dysmorphism co-occurring with 
ASD, they also highlight the importance of sex differences in ASD phenotypes. Although 
the high male:female sex ratio in ASD is well established, it was only more recently 
recognized that ASD can present differently in females compared to males (Rutter et al., 
2003; Lai et al., 2015; Ecker et al., 2017). Females with ASD tend to present with more 
severe phenotypes, and higher likelihood of co-existing conditions such as intellectual 
disability (Werling & Geschwind, 2013). The ‘Female Protective Effect’ in ASD was put 
forth to explain the phenomenon, whereby females can tolerate the presence of more 
autism risk variants than boys, and would need a larger genetic burden or possibly 
environmental risk factors before presenting as affected with ASD (Sanders et al., 2011). 
Research in ASD genetic risk factors has found a higher overall burden, specifically of de 
novo CNV mutations, in females with ASD (Iossifov et al., 2014; Sanders et al., 2011; 
Sanders et al., 2015; De Rubeis et al., 2014). Given these findings, we decided to further 
explore sex differences in ASD by stratifying genotype-phenotype associations by sex.   
 
We chose to utilize specific ASD phenotypes and genotypes in our study to explore areas 
these relative new areas in ASD research. Dymorphism in ASD is not yet fully 
understood, and there is no specific pathognomic dysmorphic feature associated with 
ASD. Unpublished work from the SEED population showed a higher likelihood of 
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dysmorphism in ASD children compared to typically developing children. In addition, 
there are indications emerging of specific dysmorphic features that are more likely to be 
associated with ASD, for example short stature and high BMI. Prior to this, research on 
genotype-phenotype associations for dysmorphology was not performed specifically for 
dysmorphism, but instead used dysmorphism as an additional condition to intellectual 
impairment or ASD itself. In addition, unlike in most previous studies, we were able to 
exclude children with developmental delay and chromosomal abnormalities and 
recognized genetic syndromes, enabling us to examine dysmophism more specifically. 
This work should thus allow for a more precise genotype-phenotype association between 
CNV and dysmorphology to be evaluated. Using various growth abnormalities as 
phenotypes, we checked across three growth modalities to examine differences in 
genotype-phenotype associations. Previous research in this field has generally tended to 
assess only individual modalities of growth. 
 
Review of Specific Aims 
 
In Specific Aim 1, we characterized growth abnormalities in a sample of ASD children 
compared to typically developing children from Phase 1 of the SEED Study. In addition, 
we assessed the combination of height, weight and head circumference simultaneously, 
which we term trivariate growth phenotype, to examine differences in growth symmetry 
in children with ASD compared to typically developing children. We found sex-specific 
differences in growth abnormalities among young children with ASD regardless of 
abnormality definition used. ASD girls had greater odds of short stature compared to 
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typically developing girls which achieved statistical signifcance, and a higher prevalence 
of the combined growth phenotype involving microcephaly and short stature, but normal 
weight.  
 
In Specific Aim 2, we investigated the genotype-phenotype association between CNVs 
and dysmorphology by estimating the CNV burden measures (both combined counts and 
cumulative length of CNVs on all autosomes) comparing dysmorphic to non-dysmorphic 
children and the association between ASD candidate CNV regions and dysmorphism. We 
found genome-wide CNV burden was negatively associated with dysmorphology, even 
among ASD cases, and these associations varied by sex. Decreased CNV burden in 
dysmorphic SEED 1 children were observed for large duplication CNVs and those 
restricted to genic regions. None of the CNVs in ASD candidate genes revealed 
statistically significant associations with dysmorphism, but these CNVs observed were 
quite rare and, in the current study sample, these analyses were underpowered. 
 
In Specific Aim 3, we assessed the genotype-phenotype association between CNVs and 
growth abnormalities by estimating the CNV burden comparing children with growth 
abnormality to normal children, and testing for association between ASD candidate CNV 
regions and abnormal growth. We observed decreased CNV burden associated with each 
growth modality, and found CNV burden was restricted to ASD candidate genes which 
were negatively associated with tall stature and macrocephaly, and again these 
associations varied by sex. Associations with specific CNVs in ASD candidate regions 
showed sex-specific results. We found there is potential shared genetic risk for ASD and 
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short stature at CNV region 15p11.2 that varied by sex, as the association was only 
significant in females. 
 
 
These findings demonstrate the importance of taking into consideration the influence of 
sex in characterizing the ASD sub-phenotypes of growth abnormalities and 
dysmorphology, as well as the variability of genetic risk factors for ASD. To improve 
discovery of genotype-phenotype associations in ASD, it is imperative to include females 
in all ASD research. We found a negative association between genome-wide CNV 
burden and dysmorphology in the SEED 1 Study, an unexpected finding that may be due 
to: (1) the exclusion of children with chromosomal abnormalities and recognized genetic 
syndromes, (2) undetected single-gene insults among control samples, or (3) actual 
protective effects especially among females. We also found genome-wide CNV burden 
restricted to ASD candidate genes appear to be associated with specific growth 
abnormalities that vary by sex, suggesting a potential common pathway involving CNVs 
for ASD and short stature only in females. This potential shared genetic risk factor for 
ASD and growth abnormality may lead to possible future clinical application in the 








Study Limitations  
 
One key limitation is our reliance on a cross-sectional design; children were only 
assessed at one point in time close to study recruitment. This is of particular importance 
for Aims 1 and 3, where categorized growth abnormalities were used. In this study, 
children were only assessed once between the ages of 2 and 5 years. This likely does not 
impact the dysmorphology classification, which is expected to remain fairly consistent in 
early childhood. However, for specific growth abnormality determination, this is a 
notable limitation. Growth in children is a developmental process with sensitive periods 
and changing trajectories of growth based on age. To truly understand physical growth, 
sequential measurements over time is preferable, as a single reading may not be 
representative of the child’s growth and cannot establish the child’s growth trajectory. In 
ASD children in particular, growth trajectories and deviations from this is time-sensitive, 
with abnormal growth changes usually occurring from 6 months of life onwards and 
starting to decline in severity after approximately 2 years of age.  
 
Thus, the age at which growth measurement was performed is integral to not just the 
results but also their interpretation. The absence of overgrowth in autistic boys may be 
associated with this limitation in our study design. We utilized growth measurements 





The relatively small sizes of subsamples for both dysmorphism and abnormal growth 
limited our ability to adjust for potential confounders beyond race/ethnic group and sex. 
The sample size was too small to use the criteria for growth abnormality defined by 
clinically-informed algorithm implemented in the SEED study (Dysmorphology Review 
Form) for CNV analyses, as this would have resulted in even smaller numbers of 
individuals categorized with growth abnormalities.  We were also unable to distinguish 
between inherited and de novo CNVs. Published literature has shown the importance of 
de novo CNVs in children with dysmorphism (Vulto-van Silfhout et al., 2013) and 
growth abnormalities (Canton et al., 2014; Zahnleiter et al., 2013; van Duyvenvoorde et 
al., 2014). Rare CNVs have also been associated with congenital malformations (Serra-
Juhe et al., 2012) and growth abnormalities (Dauber et al., 2011; Zahnleiter et al., 2013). 
Unfortunately, we did not have parental genotyping information and hence were not able 
to identify de novo CNVs. In addition, although the SEED Study itself is one of the 
largest population-based samples of ASD in the US, for the purpose of dysmorphology 
and growth abnormalities, this study is still underpowered to detect rare variants. 
Although the CNV burden measures used in this study reflect both common and rare 
CNVs, the limited analytic size likely hampered our ability to detect associations for rare 
variants. Finally, the size of the analytic sample also influenced our ability to obtain 
statistically significant results after correction for multiple testing. Although a large 
proportion of the results did not survive correction for multiple testing, these results may 
still point towards potential factors could be of clinical significance, and may eventually 




Working within an ASD case-control study presented challenges as well. We had a large 
percentage of children with ASD in the sample (approximately 40-55%), yet we were 
examining relationships between CNV burden and dysmorphism or growth phenotypes, 
not just ASD. The interpretation of CNV burden for both dysmorphism and growth 
abnormalities were made within this context. In addition, the analytic sample obtained 
from SEED 1 had a multi-ethnic composition but is not fully representative of the United 
States in terms of racial make-up, as it oversampled certain minority ethnic groups 
(Schendel et al., 2012). 
 
Another potential imitation is our use of a single CNV calling algorithm, the PennCNV 
algorithm. Comparisons of various CNV detection algorithms for using SNP data have 
shown that there is no gold standard for detection of CNVs (Winchester, Yau & 
Ragoussis, 2009). Previous studies recommend using more than one calling algorithm to 
improve specificity, as different CNV calling tools may lead to inconsistent results (Pinto 
et al., 2011; Winchester, Yau & Ragoussis, 2009). However, some researchers support 
the use of the PennCNV algorithm even on its own as this program has been observed to 
outperform other packages in sensitivity and specificity of CNV calling (Zhang et al., 
2014).  
 
We must also consider the limits of our dysmorphology evaluation, particularly the 
process of determining dysmorphic features using clinical photographs of children’s body 
parts where there are missing data. This occurred despite various rigorous quality control 
measures to maintain the photographic quality of the photographs used for 
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dysmorphology assessment. However, unpublished sensitivity analyses and multiple 
imputations from the same analytic sample showed missing data had no significant effect 
on the observed results (Shapira, personal communication, SEED Dysmorphology Group 
unpublished manuscript). We also attempted to account for the high proportion of 
children with ASD in the analytic population (55%) by stratifying the results by ASD 
diagnosis, and found ASD diagnosis contributed to the association observed for the 




This study nonetheless has several important strengths. The first is the SEED Study itself.  
SEED 1 is the largest ASD case-control study with population-based ascertainment in the 
United States (Schendel et al., 2012). Multiple studies on dysmorphology and growth 
abnormalities have been on clinic-based samples without population-based controls. This 
was especially useful for Aim 1, when we evaluated growth abnormalities in children 
with ASD and had local controls in the analytic sample. The SEED Study also includes 
children from varied geographical locations and race/ethnic groups across the United 
States, representing diverse experiences in different regions and accounting for 
geographical factors that might affect the associations assessed.  
 
Inclusion of ASD children with typically developing children in the SEED Study enriches 
the analytic sample with children who are likely to have a higher genetic burden, 
especially for ASD-related genes, and improve the likelihood of finding genetic 
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associations between our phenotypes of growth abnormalities and dysmorphology with 
ASD. Using the phenotypes of dysmorphology and growth abnormalities, which have 
both been linked with underlying genetic defects, also increases the likelihood of finding 
associations with genetic risk factors. Morphological abnormalities should reflect genetic 
abnormalities, and we did find significant results for CNVs in candidate genes associated 
with ASD and dysmorphology and growth abnormalities.  
 
Another advantage of the SEED study is the number of females in the analytic sample, 
especially females with ASD. ASD is more prevalent in males, with the current ratio of 
male-to-female being 4-5 to 1 (Fombonne, 2009; Loomes et al., 2017). Several studies on 
children with ASD for growth abnormalities did not obtain adequate females with ASD 
to allow for stratification by sex, resulting in ASD females either being excluded from the 
study, or stratified analysis yielding no meaningful information on risk among females 
(Lai et al., 2017). Inclusion of autistic girls in studies on ASD is increasingly recognized 
as important, and may give insights about potential risk factors.  
 
The SEED study had the advantage of dedicated medical geneticists focused on rigorous 
research assessment of dysmorphology. They developed a new tool to quantify 
dysmorphology as part of the SEED Study that use information from cases and 
population-based controls, blinding of the raters, and standardization of growth 
measurements across sites via Standard Operating Procedures (SOPs), as well as the 
implementation of repeated measurements to improve accuracy. Use of this new tool 
allowed quantification of dysmorphic features and a more robust measure of 
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dysmorphology.  This also included multiple aspects of growth modalities. This allowed 
analysis of uni-dimensional and bi-dimensional growth abnormalities, as well as the 
trivariate growth phenotype. Previous studies often concentrated on just one aspect of 
growth abnormality, for example, macrocephaly, in children with ASD. We performed 
analyses of growth abnormalities in all modalities including BMI and the trivariate 
growth phenotype to give a comprehensive view of cross-sectional growth abnormalities 
in multiple dimensions. The trivariate growth phenotype is not an aspect of growth that 
has been considered in detail for ASD, and in fact, there is a dearth of literature 
considering growth asymmetry. Thus, we believe this is a novel way of considering 
growth in children with ASD, and may give a better perspective of overall physical 







Public Health Implications 
 
ASD is a developmental condition of major public health import. The global prevalence 
of ASD has increased by almost forty-fold in the past five decades from a prevalence of 
one in 2,500 children (Gillberg & Wing, 1999) in the 1990s to one in 68 children in a 
recent report by the CDC (CDC, 2016). It is a source of enormous emotional burden to 
the families involved, a strain on resources for local communities and a substantial 
economic burden to society. It has been estimated that the lifetime individual ASD-
related costs range between $1.5 to $2.5 million US dollars (Buescher et al., 2014). 
Addressing this condition of considerable public health significance is therefore timely 
and urgent.  
 
The positive findings from this study indicate areas where screening, service provision 
and management of children with ASD could be enhanced, if our results are replicated. 
Improved recognition of growth abnormalities in ASD children, and use of genotyping as 
a tool to increase awareness and ASD detection in children with growth abnormalities 
and dysmorphology would be of significant clinical impact. 
 
Based on our findings, establishing potential genotype-phenotype associations between 
ASD and growth abnormalities may improve risk factor identification in the subset of 
ASD individuals with abnormal growth. Recognizing the association of growth 
abnormalities with ASD could be utilized to increase awareness in providers of care for 
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ASD children to monitor growth and implement intervention for factors that could be 
ameliorated, for example dietary management.  
 
The association between dysmorphism and ASD could potentially be developed into a 
diagnostic clinical tool for early intervention through laboratory-based as well as clinical 
methods (utilizing measures of dysmorphism). Understanding dysmorphic phenotypes 
may lead to more focused and potentially earlier provision of intervention in phenotypes 
such as abnormal growth and potentially to establishing better outcomes (Dawson, 2008; 
Boyd et al., 2010).
 
 
This study shows including autistic females in research, even if it may be limited by 
smaller samples, is important to identify possible sex-specific risk factors. Sex gives a 
unique perspective to understand the underlying etiologies in autism, and should become 
as core principle in autism research to further explore the heterogeneity of this 
neurodevelopmental condition (Rutter et al., 2003; Lai et al., 2015; Ecker et al., 2017). 








Recent advances in research suggest that ASD presents differently in males and females. 
Researchers are seeking to understand the biological differences between ASD in males 
and females, as well as re-evaluating the effectiveness of diagnostic tools and treatments 
for ASD females. Our study shows outcomes that differ by sex, emphasizing the 
importance of including females in ASD research. Our finding of short stature limited to 
ASD females has rarely been reported, and thus a crucial future direction is replicating 
this finding in other studies. In addition, for assessment of ASD phenotypes, including 
ASD females would allow for stratified analysis for sex-specific risk factors. 
 
Studying these sub-phenotypes of ASD may improve our biological understanding of this 
complex and heterogeneous disorder, particularly if different risk factor constellations are 
reflected in different phenotype presentations.  This may be particularly helpful in 
parsing out different genetic risks. In addition, characterization of specific autistic 
phenotypes may aid in early diagnosis and prediction of outcomes (Walsh, 2011). For 
future work, one potential avenue for research on genotype-phenotype association is 
narrowing the phenotype from general dysmorphism to specific dysmorphic features not 
restricted to growth abnormalities, for example ear abnormalities.  
 
Longitudinal measures of growth would be more representative of true growth 
trajectories and improve accuracy of categorizing growth abnormalities. For future work, 
it would be useful to expand this study to a longitudinal analysis, to further understand 
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developmental trajectories for somatic growth. It would also be beneficial to be able to 
incorporate covariates of both paternal and maternal growth measures, even just adult 
head circumference, height and weight. Adjusting for the anthropometric measures in 
both parents may allow greater insight into the genetic factors related to abnormal growth 
in ASD.  Another avenue for future research is considering other covariates such as 
medication use (psychotropic medication) for specific ASD growth abnormality 
phenotypes such as obesity/overweight.  
 
An important limitation in this study is the possibility there may be undiagnosed 
chromosomal abnormalities and genetic syndromes among our study sample. The 
information we utilized was based on parental report, and it is probable that additional 
chromosomal abnormalities or genetic syndromes may be present, and may have 
influenced associations detected here. This is an important issue that could be addressed 
for future work in this field. Genetic analyses incorporating full genome sequencing or at 
least whole exome sequencing on these subjects would enable improved delineation of 
underlying genetic risk factors in ASD, and in the case of CNV burden analysis, allow for 
exclusion of children with chromosomal abnormalities or other causes of increased 
genetic risk detected through sequencing.  
 
Finally, the young age of the children recruited (2-5 years) for SEED restricts the 
generalizability of our results to only those in early childhood, as morphological changes 
occurring with age cannot be considered. Future work to expand the analysis on older 
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